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Vaccination is the most effective means to protect populations against infectious 
viruses by eliciting a diverse repertoire of antibodies. For influenza, a rapidly mutating 
virus posing a constant threat of a pandemic, seasonal vaccination is considered the best 
prophylactics, but it has limited efficacy and requires annual vaccination. To develop 
more effective influenza vaccine strategies, a comprehensive understanding of serum 
antibodies elicited by vaccination is essential, yet it has been confounded by the 
complexity of the antibody response. In this work, we used the high-resolution 
proteomics analysis of immunoglobulin (Ig-seq) coupled with the high-throughput 
sequencing of B cell receptor transcripts (BCR-seq) to quantitatively delineate the serum 
antibody repertoire to influenza. In Chapter 2, we analyzed the sera collected from four 
young adults before and after receiving trivalent seasonal influenza vaccine, which 
contains hemagglutinins from two influenza A virus strains (H1 and H3) and one 
influenza B strain. The serum repertoire comprised between 40-147 clonotypes specific 
to each of the three monovalent components of the vaccine, with ~60% of the vaccine 
response consisting of antibodies that were already present in serum before vaccination. 
We also observed a surprisingly high fraction of serum antibodies recognizing both the 
H1 and H3 monovalent vaccines (H1 + H3 cross-reactive antibodies). For subsequent 
 viii 
analysis, in Chapter 3, we recombinantly expressed representative serum antibodies, and 
the H1 + H3 cross-reactive antibodies displayed a broad range of binding specificities to 
hemagglutinins from historic viral strains. We identified a group of antibodies 
recognizing the same conserved epitope in the hemagglutinin head domain that is only 
exposed in its monomeric form. These antibodies protected mice in challenging with 
H1N1 and H3N2 virus strains. In Chapter 4, we performed a longitudinal analysis of an 
individual’s serological repertoire specific to pandemic A/California/04/2009 (CA09pdm) 
viral strain across 6 years. Through multiple exposures to CA09pdm from infection and 
vaccination, our analysis revealed that the immediate antibody response to CA09pdm 
differed for each instance of exposure, but the antibody repertoire returned back to the 
pre-exposure state. This observation was due to the persistent antibodies comprising 
about half of the serum antibodies, while the intermittent antibodies were elicited 
following exposures but decayed soon after. The subsequent analysis on their binding 
specificities revealed that the persistent antibodies were likely to be targeting the stem 
region of the hemagglutinin while the intermittent antibodies tended to be head-specific. 
Collectively, our data provide unprecedented insights on the serological responses to 
influenza with direct implications for engineering a future influenza vaccine endowed 
with higher and broader protective efficacy. 
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Chapter 1: Introduction 
 
The development of smallpox vaccination by Edward Jenner in 1796 remains one 
of the greatest medical achievements in recent history and has had a significant impact on 
the health of the general population. It also marked the beginning of the practice of 
deliberately mounting protective immunity against various infectious diseases. Today, 
millions of lives are saved each year as a result of vaccination, and once deadly diseases 
like smallpox, polio and tetanus are now either eradicated or well under control [1, 2]. 
However, unlike these successful examples of developed vaccination, influenza vaccines 
have been largely ineffective. Vaccination against influenza still leaves a large fraction of 
the population vulnerable, primarily failing to elicit robust and lasting protective 
responses against the virus [3]. Every year, influenza causes over 1 billion infections, 5 
million cases of severe illness, and approximately half a million deaths globally. In the 
U.S. alone, the economic burden arising from annual influenza epidemics totals over $80 
billion [4, 5]. Influenza is a persisting global threat, and the most pressing unmet need is 
to improve vaccination strategies to be more effective, with this fundamentally hinging 
on a better understanding of vaccine-mediated immunity in humans. 
 
OVERVIEW OF INFLUENZA VIRUS 
Types, Structures and Infection Cycle 
Influenza is an enveloped, single-stranded RNA virus of the Orthomyxorividae 
family. Influenza was first isolated from humans in 1933 [6], and is classified into three 
genera: A, B and C. Influenza A virus causes moderate to severe illness for humans and 
 2 
other mammals, consisting mostly of wild aquatic birds, which serves as the natural 
reservoir for the viruses. In contrast, influenza B affects almost exclusively humans with 
milder symptoms while influenza C virus is rarely reported in humans [7]. Transmission 
of the virus occurs through air with rapid replication in the human respiratory system, 
making the virus transmittable from coughing and sneezing [8]. 
On the surface of the influenza virion envelope, there are two major glycoproteins, 
hemagglutinin (HA) and neuraminidase (NA) (Figure 1.1) [9]. HA is a trimeric protein 
responsible for binding to target cell surfaces via sialic acid receptors and subsequent 
fusion with the host cell, while NA is involved in virus progeny release from infected 
cells [10, 11]. Currently, there are 18 different known influenza A virus HA subtypes (H1 
through H18), which are categorized into group 1 (which includes H1, H2, H5, H6, H8, 
H9, H11, H12, H13, H16, H17 and H18) and group 2 (which includes H3, H4, H7, H10, 
H14 and H15) based on their antigenic differences and 11 distinct known NA subtypes 
(N1 through N11) identified in nature [12]. The differences in HA and NA determine the 
subtype of viral strains. For example, the H1N1 viral strain name indicates that it contains 
the H1 subtype of HA and the N1 subtype of NA. Of all the different HAs and NAs, only 
H1, H2 and H3, and N1 and N2 are commonly found in human infections [13]. For the 
influenza B virus, strains are grouped into two lineages, Victoria and Yamagata, based on 
the antigenic properties of the surface proteins [14]. Influenza A and B viruses carry eight 
pieces of segmented viral RNA that encode for eleven proteins required for infection and 
replication of the viruses, inside of the viral envelopes [15]. As shown in Figure 1.1, 
information regarding the viral type based on the genetic materials, geographical origin, 
strain number, year of isolation and virus subtype is used to determine the specific 
nomenclature for each identified viral strain [8].  
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Figure 1.1:  Structure and nomenclature of influenza virus. Hemagglutinin and 
neuraminidase are two major surface proteins that define virus subtypes, 
while the genetic materials inside of the viral envelope determine the virus 
type. Nomenclature for each viral strain includes information about virus 
type, location of virus origin, strain number and year of isolation. 
 
In order for the virion to be infectious, HA needs to be cleaved by the host’s 
trypsin-like protease [16]. Since these proteases are mainly produced in the respiratory 
tract in humans, viral replication is generally restricted to the cells in the respiratory 
tissue. The uncleaved HA is called HA0, and the cleaving of HA0 generates two subunits, 
HA1 and HA2, which remain bound to each other. This cleavage of HA0 also generates 
the fusion peptide, which consists of amino acids at the N-terminus of HA2. This fusion 
peptide is required for the viral infectivity. As shown in Figure 1.2, the head domain of 
HA is mainly formed by HA1, and it mediates the attachments to host cells through a 
pocket known as the receptor-binding site (RBS). Underneath the head domain is the 
stem domain, where the fusion peptide is located. Following the attachment of the virion 
to the cell surface through RBS, the virus is endocytosed and placed in endosomal 
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vesicles inside of the host cell. The pH inside of the endosomal vesicle then drops, which 
causes a conformational change of the HA from pre-fusion to post-fusion structures. This 
transformation projects the fusion peptide outwards, and it is inserted into the host’s 
endosomal membrane during the infection cycle. This leads to the fusion of the viral 
envelope and the host cell’s endosomal membrane [8, 17, 18].  
 
 
Figure 1.2:  Structure of hemagglutinin. Hemagglutinin contains HA1 (blue) and HA2 
(magenta) subunits that form head and stem domains. The receptor-binding 
site (RBS) mediates the attachment to host cells while the fusion peptide is 
essential for fusion between viral and host cells’ membranes for subsequent 
infection. 
 
Upon fusion, viral RNAs, along with other viral proteins including core proteins 
and RNA-dependent RNA polymerases, are released into the host cell’s cytoplasm [15]. 
The core proteins transport the viral RNA to the cell nucleus, and the viral RNA serves as 
a template for the viral RNA-dependent RNA polymerase. Some of the newly 
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synthesized viral RNA leave the nucleus and are translated into HA and NA proteins, 
which are secreted to the cell surface. Other newly-translated viral proteins required for 
RNA replication are transported back into the nucleus. As HA and NA cluster on the 
surface of the cell and begin budding, viral RNA along with other viral proteins are 
packaged into a virion. Through the action of NA cleaving sialic acid from the surface of 
the cell, virus particles are released and the host cell then dies. The free virions then 
attach to other healthy host cells and repeat the infection cycle [8, 19]. 
 
Antigenic Drift and Shift 
Influenza virus is equipped with the ability to rapidly evolve due to the low 
fidelity of the viral RNA polymerase. The RNA polymerase incorporates roughly one 
error every 10,000 nucleotides, accumulating point mutations on the surfaces of HA and 
to a lesser extent NA [14]. Considering the entire genome of the virus is roughly 14,000 
bases long, the incorporation of mutations leads to rapid diversification of the virus, 
which aids in evading the host’s immune system. This mechanism of escape is known as 
antigenic drift [8]. It is worth noting that not every amino acid residue is equally inclined 
to mutate. This is because the resulting mutations are constrained by the necessity for the 
virus to maintain its cell-binding capability and assembly into the infective viral structure. 
Accordingly, some regions are more conserved than others; in the case of HA, the stem 
region and the RBS tend to be conserved across different strains of virus while the 
residues around the RBS diverge substantially [20]. 
Antigenic shift, on the other hand, results from the shuffling of genomic RNA 
segments between different influenza A virus strains, particularly strains infecting 
different hosts (i.e. avian, swine, and human influenza viruses). When two viral strains 
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co-infect a single host cell, viral RNAs from each virus are copied in the host cell’s 
nucleus (Figure 1.3). As the cell surface begins budding and genetic materials are 
packaged as described above, the reassortments of genetic material can occur where some 
of the RNA segments could have derived from either of the viruses. As a result, progeny 
virions carrying reassorted RNA are produced, and they are called reassortants. Unlike 
antigenic drift, which integrates limited variations, antigenic shift can result in extensive 
alterations of the virus. In contrast, because influenza B virus mainly infects humans only, 
it is difficult for influenza B viruses to undergo antigenic shift [8]. 
 
 
Figure 1.3:  Influenza virus reassortment. When two different strains of influenza A 
viruses (avian and human influenza viruses in this case) co-infect a single 
host cell, reassortments of the genetic materials can occur, resulting in the 
generation of reassorted viruses, which could become a pandemic strain. 
 7 
Significant transformation in viral properties resulting from antigenic shift can 
potently give rise to a pandemic influenza virus. The major difference in avian and 
human influenza viruses is their ability to recognize different sialic acids; most avian 
influenza viruses bind to sialic acid linked to galactose via an α-2,3 linkage, while 
human-infecting viruses have a preference for an α-2,6 linkage [21]. The majority of 
epithelial cells in the gut of birds have the α-2,3 linkage while human respiratory 
epithelial cells have the α-2,6 linkage. Due to this difference, avian influenza viruses do 
not transmit well in humans. However, in animals such as pigs, which have cells with 
both α-2,3 and α-2,6 linkages, both influenza viruses can co-infect a single cell, resulting 
a reassortant strain that is similar to avian influenza viruses but now has a capability to 
bind to the α-2,6 linkage and spread between humans. The divergent antigenic nature of 
the surface proteins of avian influenza viruses, which humans have not been exposed to 
before, could quickly lead to a pandemic especially when the reassortants are highly 
virulent. 
Such shuffling of genetic materials has led to numerous pandemics throughout the 
history. The last deadly pandemic took place back in 1918 when a strain of virus jumped 
from birds to humans and caused an estimated 50-100 million deaths [4]. A more recent 
pandemic occurred in the spring of 2009 caused by A/California/07/2009pdm (CA09pdm) 
virus strain. While the lack of mortality associated with CA09pdm infection prevented a 
large number of deaths, an estimated 43-89 million people were still infected [4]. 
CA09pdm was capable of binding to both α-2,3 and α-2,6 linked sialic acids since it was 
a reassortant from human, avian, and swine influenza viruses [22]. These past incidents 
highlight the potential danger of influenza virus the need for controlling the infection. 
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Therapeutics and Vaccines for Influenza 
There are several therapeutic options available for influenza infection. Antiviral 
therapeutics, zanamivir (Relenza) and oseltamivir (Tamiflu) are major drugs currently 
available on the market [23, 24]. These are NA-inhibiting small molecules rationally 
designed based on the structure of NA. However, because of their mode of action, which 
relies on preventing the release of progeny from infected cells, they have a limited 
window of therapeutic efficacy. If these inhibitors are not taken shortly after the onset of 
flu symptoms, they will not be sufficient to stop the infection. Moreover, there have been 
recent reports of emerging drug-resistant viral strains as well [25]. In addition to the 
antiviral drugs, several promising monoclonal antibodies (mAb) against influenza are 
currently under clinical trials [26]. These antibodies provide protection against a wide 
range of influenza virus subtypes, including the ones that have caused pandemics, mostly 
through targeting conserved regions of the HA stem. 
Alternatively, influenza vaccination offers a prophylactic means to control the 
disease. The history of influenza vaccine dates back to 1938, where a vaccine developed 
by Jonas Salk and Thomas Francis was administered monovalently against influenza A 
virus of the H1N1 subtype [27]. In 1942, a bivalent vaccine was formulated after the 
discovery of influenza B virus, and it included an influenza A H1N1 strain and an 
influenza B strain. The first trivalent vaccine containing two strains of influenza A virus 
(H1N1 and H3N2 subtypes), and a strain of influenza B was introduced in 1978, and in 
2012, a quadrivalent vaccine was approved in the United States that added another 
influenza B strain to ensure the inclusion of a strain from both the Victoria and Yamagata 
lineages [28]. 
Currently, there is one major licensed influenza vaccine available - inactivated 
influenza vaccines (IIV). Live attenuated influenza vaccine (LAIV) was once used widely, 
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but in 2016, the Centers for Disease Control and Prevention (CDC) recommended to stop 
administering it due to its inefficacy [29]. IIV is prepared mainly by propagating 
influenza viruses using an egg-based process, although there is one approved IIV made 
from a cell-based process [30]. From the virus-containing fluid, viruses are inactivated, 
and HA from viruses are isolated to produce IIVs [31]. Alternatively, recombinant 
influenza vaccine (RIV) is also available, where HA is recombinantly purified, but is not 
as widely used as IIV [32]. 
Because of the seasonal change of influenza virus in circulation resulting from 
antigenic drift and shift, flu vaccine is the only immunization that is annually updated. 
This is a critical drawback of the vaccine. In 1952, the World Health Organization (WHO) 
influenza surveillance system was established to constantly monitor influenza strains in 
nature. Each year, based on the epidemiology of influenza, WHO decides which strains 
are most likely to affect the populations and recommend them to be included in the list of 
vaccines being manufactured by commercial suppliers [8]. However, there have been 
several instances where the predictions mismatched the strains that spread in the 
population that particular year, which greatly limited the vaccine efficacy [33, 34]. 
Nonetheless, a protective antibody response elicited by vaccination holds the most 
promise for protecting the population against influenza infection, especially pandemics. 
 
HUMORAL IMMUNE SYSTEM  
The goal of influenza vaccination is to provide a lifelong protective immunity 
against a wide range of influenza virus strains. Over 200 years have passed since the first 
development of smallpox vaccines, but the current influenza vaccines work on essentially 
the same principles demonstrated by Jenner. This principle encompasses the activation of 
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humoral immunity through the administration of antigenic material derived from the 
pathogen, prompting the body to produce antibodies to mount defense against the 
infection. Humoral immunity relies on diverse repertoires of the membrane-bound form 
of antibodies, called B cell receptors (BCR) on the surface of B cells, and soluble 
immunoglobulin (Ig) molecules secreted by a subset of B cells [35]. 
 
Antibody Isotypes, Structure and Functions 
The basic structure of antibodies consists of two identical heavy chains and two 
identical light chains connected by disulfide bonds, with both heavy and light chains 
contain variable (V) and constant (C) domains [36] (Figure 1.4). In humans, there are 5 
different isotypes of antibodies (IgM, IgA, IgG, IgD and IgE), classified based on the 
different C regions of the heavy chains, with IgG and IgA being the most abundant 
isotypes in circulation and at mucosal sites, respectively. The heavy chain of IgG is 
comprised of a V region (VH), and 3 C regions (CH1, CH2 and CH3). Light chains, on the 
other hand, have two types of C domains, λ and ҡ [35], and in humans, about 65% of 
antibodies contain the ҡ C domain. VH, VL, CH1, and CL domains of an antibody molecule 
form an antigen-binding fragment (Fab), which, as its name indicates, mediates binding 
to the antibody’s target antigen. The rest of the C region of the heavy chain is known as 
the crystallizable fragment (Fc), and this Fc domain is important in mediating various 





Figure 1.4:  Diagram of an immunoglobulin G (IgG) molecule. The heavy chain 
molecule consists of variable (VH) and constant (CH1, CH2 and CH3) domains, 
and the light chain molecule is comprised of variable (VL) and constant (CL) 
domains. Red lines indicate disulfide bonds connecting two heavy chains. 
Fab, antigen-binding fragment; Fc, crystallizable fragment. 
 
The specificity of an antibody molecule toward its target antigen is mainly 
determined by the complementarity determining regions (CDRs), which are highly 
variable regions in the V domain that form loops [37, 38]. A combination of 3 CDRs 
from both the heavy and light chain (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 
and CDR-L3) forms the antigen-binding site of an antibody molecule [39]. This binding 
site is also known as a paratope, and it targets an epitope on its target antigen. In 
particular, CDR-H3 and CDR-L3 hypervariable regions contain the most diversity in 
terms of length and amino acid composition. Variations in these regions are fundamental 
to the generation of highly diverse antibody molecules that can bind to variety of 
different antigens [40-42]. 
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Soluble Ig molecules in circulation provide protection against viral infections 
through several mechanisms. First, they can prevent pathogens from infecting cells by 
blocking parts of the surface of pathogens, and this process is known as neutralization. In 
the case of influenza, antibodies that target the RBS of HA can neutralize the virus by 
inhibiting the binding of HA to sialic acid receptors. Additionally, antibodies that bind 
tightly to the fusion peptide, or other nearby regions in the stem of HA, can limit the 
conformational change of HA that is required for infection, thereby nullifying the 
infectivity of the virus. These epitopes on HA that lead to neutralization of the virus are 
called neutralizing epitopes, and antibodies targeting them are referred to as neutralizing 
antibodies [43]. 
Antibodies can also trigger other immune responses to disable pathogens. Even 
when antibodies target non-neutralizing epitopes on pathogens, they can coat the surface 
of the pathogen by binding via their Fab domains. The resulting cluster of Fc domains 
surrounding the pathogen stimulate effector functions by recruiting immune cells that 
express FcRs. Different isotypes of antibodies, IgA, IgG and IgE, have different FcRs 
specific for each. Upon binding to the Fc clustered on the surface of pathogens, effector 
cells are activated which leads to variety of mechanisms resulting in the elimination of 
pathogens [44]: phagocytosis of pathogens can occur via phagocytes, via a process 
known as antibody-dependent cell-mediated phagocytosis (ADCP); natural killer cells 
can release cytokines and cytotoxic molecules through a mechanism called antibody-
dependent cell-mediated cytotoxicity (ADCC); and mast cells and neutrophils can also 
degranulate to destroy pathogens. Because the different isotypes of antibodies have their 
own cognate FcRs, effector functions can be modulated with a great control. Furthermore, 
pathogens can be cleared through another process called the complement pathway [44]. 
In addition to binding to FcRs, the Fc domain of IgG can also bind to the first 
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complement protein in the pathway, C1q, which triggers a cascade of other complement 
protein activation. As a result, pathogens can be destroyed through opsonization via 
phagocytes, as well as lysed through a membrane-attacking complex formed by 
complement pathway components [45]. Through these different mechanisms of action, a 
conglomerate of antibodies specific to pathogens, also referred to as an antibody 
repertoire, moderates infections. 
 
B Cell Development and Antibody Diversification 
Antibody diversity is the foundation for the immune system to mount protective 
humoral immune responses against a variety of pathogens encountered during a lifetime, 
with diversification of the antibody repertoire occurring in B cells. The initial 
development of B cells takes place within the bone marrow, originating from 
hematopoietic stem cells (HSC). These cells differentiate into pro-B cells, which can 
become, among others, a pre-B cell [35].  
During these stages of the B cell development, B cells first generate diversity 
through the process of recombining gene segments, which is known as V(D)J 
recombination [46]. Genes for heavy and light chains of antibodies are encoded on three 
loci of the genome. The immunoglobulin heavy gene locus is located on chromosome 14, 
and the immunoglobulin light kappa chain and lambda chain loci are located on 
chromosomes 2 and 22, respectively [47-49]. In the heavy chain locus, there are multiple 
copies of variable (V), diversity (D), and joining (J) gene segments while each light chain 
locus contains V and J gene segments only. As illustrated in Figure 1.5, the heavy chain 
locus contains several V, D, and J gene segments, as well as multiple C genes. In HSC, 
before becoming early pro-B cells, one copy of a D gene and one copy of J gene are 
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recombined (DJ) by removing the D and J gene segments located between the two. Then 
recombination of V with DJ occurs in late pro-B cells, where effectively one copy of V, 
D, and J are recombined while the other gene segments are deleted from the genome.  
 
 
Figure 1.5:  VDJ recombination of heavy chain locus.  
 
Following the VDJ recombination of the heavy chain, pro-B cells become pre-B 
cells by expressing pre-B cell receptor (pre-BCR) consisting of the rearranged heavy 
chains with μ constant region assembled with surrogate light chains [49]. A surrogate 
light chain consists of lambda 5 and VpreB subunits, which resemble constant and 
variable regions of a light chain molecule, respectively. The purpose of the surrogate 
light chain is to check whether the rearranged heavy chains are productive. These 
surrogate light chains are replaced by light chains once they undergo VJ recombination, 
and when the assembly of productive heavy and light chains genes is achieved in B cells, 
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they become immature B cell. The junction of the recombined V(D)J gene segments 
forms CDR-3 regions, which explains the aforementioned high degree of diversity found 
in them. Combined with the junctional diversity resulting from imprecise recombinations, 
such as palindromic (P) and non-templated (N) nucleotide addition and deletion by 
terminal deoxynucleotidyl transferase (TdT) [50], and D gene’s ability to use three 
reading frames [51], a theoretical diversity of antibodies reaches over 10
12
 [52]. At this 
stage of the development, B cells are checked for auto-reactivity, and B cells expressing 
BCR that bind to self-antigens are either corrected through a process known as receptor 
editing or die through apoptosis [53]. Cells then further differentiate and express IgD on 
the surface to become what is known as mature naïve B cells and leave the bone marrow 
and enter peripheral circulation. 
Mature naïve B cells become activated upon encountering cognate antigen, but 
BCR on mature naïve B cells tend to have low affinities for its target (Figure 1.6). With 
the necessary signals, and help from T follicular helper (Tfh) cells with antigen-
presenting cells (APCs) such as dendritic cells (DCs) [54], these B cells proceed to enter 
germinal centers (GC). In the case of influenza infection, DCs that exit the respiratory 
tract upon infection with influenza virus are the main source of antigen, which then travel 
to lymph nodes or the spleen [55, 56]. In the GCs, B cells rapidly proliferate through a 
process known as B cell clonal expansion [57, 58]. At this stage of B cell development, 
the multiplicity of antibody specificity is further increased through an activation-induced 
(cytidine) deaminase (AID)-catalyzed mechanism called somatic hypermutation (SHM), 
which introduces point mutations in V regions [59]. Following clonal expansion in the 
GCs, the affinity of BCRs to the antigen will change through SHM, and B cells with 
BCRs that have increased affinities will be able to outcompete those B cells that have 
decreased antigen-binding potency or acquired autoreactivity. They survive through 
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signaling from follicular DCs (FDCs) and undergo additional expansion; this mechanism 
is called affinity maturation [60, 61]. Class switching recombination then takes place and 
BCRs of either IgG, IgA, or IgE isotype are generated [35].  
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Figure 1.6:  Development of antigen-specific B cells and antibody diversification During 
the primary response (green), with the help from T follicular helper cells (T 
cells), uptake and presentation of foreign antigen by dendritic cells leads to 
germinal center (GC) reaction for mature naïve B cells where clonal 
expansion, somatic hypermutation, affinity maturation, selection, and class 
switching occurs. Upon leaving the GC, some differentiate into memory B 
cells (mBCs) while the others differentiate into plasma cells (PCs) that 
secrete soluble antibodies. Some of these PCs become long-lived plasma 
cells. Upon repeated exposure to the antigen, a secondary response (purple) 
follows where mBCs can either re-enter the GC or differentiate into PCs. 
FDC, follicular dendritic cell. 
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Ultimately, these B cells can terminally differentiate into plasmablasts (PBs) or 
plasma cells (PCs) that secrete soluble Ig molecules, which will bind to pathogens and 
trigger the mechanisms of protection described above, or differentiate into memory B 
cells (mBCs). Upon repeated exposure to the same antigen, these mBCs serve as a 
mediator for a rapid recall response and quickly differentiate into PBs and PCs that 
generate a burst of Ig molecules [54, 62, 63]. A small fraction of PCs can also hone in the 
bone marrow and become long-lived, bone marrow plasma cells (BM-PCs) [64]. These 
BM-PCs are antibody-secreting cells responsible for maintaining antibody levels in the 
periphery. Once secreted into circulation, or in serum, IgG molecules have a half-life of 
about 3 weeks. Without the persistence of the cognate antigen to continuously activate B 
cells to secrete more antibodies, serum antibody levels begin to decay as short-lived PBs 
and PCs die. However, the BM-PCs in the bone marrow continue to secrete antibodies, 
achieving steady-state serum antibody levels [65, 66]. It is postulated that BM-PCs can 
survive in the bone marrow for a very long time, possibly throughout an entire lifetime 
[65]. Thus, immunological memory is rendered by the diverse repertoires of antibodies 
maintained by the mBCs and BM-PCs. These antibodies secreted by BM-PCs provide the 
immediate, first line of protection against pathogens before the reactivation of mBCs [64]. 
With the different compartmentalization of antibody repertoires, there is a great level of 
control mediating the humoral responses. 
 
TOOLS FOR ANALYZING ANTIBODY RESPONSES 
An indication of an effective vaccination is the generation of diversified 
antibodies that can confer protection against various pathogens. To assess the elicitation 
of such antibodies, several serologic assays relying on the bulk serum antibodies have 
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been developed. These assays use the aggregate of antibodies in serum without an 
understanding of their identities. For influenza, the gold standard of evaluating vaccine 
responses encompasses the use of total anti-influenza antibody binding, hemagglutinin-
inhibition (HAI), and neutralizing titers. These assays provide quantitative information on 
the total antibodies with binding specificity to the antigens, the level of antibodies that 
can prevent its attachment of the virus to cells, and the level of antibodies capable of 
neutralizing the infectivity of the virus, respectively. Each assay uses different dilution of 
serum, which contains circulating antibodies. Currently, HAI titers of a 1:40 dilution is 
considered to be the main correlate of protection, which stems from clinical tests 
illustrating such levels achieved following vaccination being associated with protection in 
50-70% of the cases [66-68]. Vaccine manufacturers and the U.S. Food and Drug 
Administration (FDA) also primarily use these bulk analyses for the determination of 
vaccine efficacy. However, these methods are not precise enough to understand antibody 
responses elicited by complex viruses like influenza. Such understanding requires a much 
detailed interrogation and identification of the constituent monoclonal antibodies that 
comprise the bulk antibody response and the subsequent characterization of these 
antibodies. Through the development of novel technologies enabling such studies, our 
understanding of antibody response has increased tremendously in recent years.  
 
Single Cell Analysis 
Because Ig molecules are encoded by B cells, information on the antibody 
repertoire is encoded in B cells. Thus, analyzing B cells has served as a substitute to 
dissect the humoral response. The recombinant expression of monoclonal antibodies 
comprising bulk antibody properties can be used for functional characterization as well as 
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for the identification of epitopes on antigens to better understand the mechanisms of 
protective immunity. With peripheral blood B cells being the primary source due to 
sample availability, PCs and PBs, as well as mBCs following vaccination or infection 
have been extensively analyzed through two major methods developed for the examining 
single B cells. 
The first breakthrough was the development of a technique for immortalizing B 
cells [69]. This technique relies on isolating B cell subsets of interest and immortalizing 
those B cells with Epstein Barr Virus (EBV). The EBV-immortalized B cells are then 
allowed continuously secrete Ig molecules expressed by each cell inside of individual 
well, and the culture supernatants can be directly used for binding and functional assays. 
Because single cells are immobilized in each well, the supernatants contain monoclonal 
antibodies. This technique bypasses the need for cloning and purifying each monoclonal 
antibody; instead, it enables a very rapid functional screening of antibodies being 
secreted by EBV-immobilized B cells. After isolating antibodies with interesting features, 
their sequences are determined through classical Sanger sequencing of transcripts 
encoding the antibodies. In 2011, Corti et al. combined the immortalization technique 
with influenza neutralization assays to screen for antibodies secreted by B cells that have 
neutralization capabilities against a broad range of viral strains [70]. One of their isolated 
bNAbs, called FI6, showed its remarkable ability to neutralize all of the influenza A virus 
strains through the targeting of a conserved epitope in the stem of HA. 
Another technique involves isolating single PBs, PCs, or mBCs and recovering 
antibody sequences through single-cell polymerase chain reaction (PCR) for subsequent 
cloning, expression, and functional characterization of monoclonal antibodies [71, 72]. 
After sorting single cells into individual wells, transcripts from the cells are used to 
amplify and subsequently clone the encoded antibodies. These antibodies are then 
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recombinantly purified and further characterized. A notable study by Wrammert and 
colleagues employed such technique to generate 86 recombinant mAbs from PCs isolated 
after influenza vaccination to determine that 71% of PCs at 7 days post-vaccination were 
specific to influenza [72]. A further breakdown of the specificities indicated that 20% of 
the antibodies could bind and neutralize the virus, while others only bound to HA (20%), 
other surface proteins (12%), a denatured form of the surface proteins (10%), or a non-
influenza component of the vaccine (9%). In a similar study involving sorted PBs from 
an adult one week after 2007-2008 TIV vaccination, Whittle et al. identified and 
characterized an antibody, named CH65, with CDR-H3 loop that binds to the RBS pocket 
of the HA by mimicking sialic acid [73]. This antibody garnered great interest due to its 
wide range of neutralization capability against H1 strains (31 out of 36) by targeting the 
conserved receptor-binding region. 
Additionally, single cell analysis has led to identification of numerous potent and 
broadly neutralizing antibodies against influenza virus [74-83]. Some of these antibodies 
are currently being developed as therapeutic mAbs. Characterization of mAbs from these 
studies has elucidated the neutralizing epitopes that these antibodies target which are 
conserved across multiple strains of influenza virus. These studies also helped identify 
conserved epitopes in the stem and shown how mAbs targeting the stem region have the 
potential to neutralize a wide range of strains, which led to the inception of using stem-
only HA as a universal vaccine [76, 84-86]. However, the main limitation encompassed 
by these approaches is the low-throughput nature of those analyses since such techniques 
capture only a small fraction of the antibody repertoire, making it difficult to accomplish 
a broader characterization of the antibody response. 
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High-throughput Sequencing Analysis 
More recently, the rapid advancement of next generation sequencing (NGS) 
technology with lowering cost and increasing throughput has enabled in-depth 
characterization of B cells through the sequencing of millions of B cells simultaneously 
by relying on the generation of cDNA from mRNA. Initial studies have focused on 
sequencing heavy chain sequences since previous studies have shown that heavy chains 
largely determine the antigen specificity [41]. Such development has led to the utilization 
of NGS to study the antibody responses following influenza vaccination and infection 
[87-91].  
In a study involving the new pandemic 2009 H1N1 vaccine, Li and colleagues 
determined that the vaccination with the pandemic strain elicited many antibodies that 
were cross-reactive between different H1N1 strains. They hypothesized that the influenza 
response is mainly driven by recall responses mediated by mBCs, and that the 
significantly altered HA head domain of novel H1N1 pandemic strain led to the 
stimulation of stem-specific mBCs generated from previous exposure [91]. Moreover, a 
couple of studies from Quake’s group uncovered that most of vaccine response is 
established by the recall response, through the discovery of identical sequences after two 
different annual vaccines in the same individual [88], and that the repertoire is highly 
clonal in the elderly with a high number of accumulated mutations [89]. These studies 
have shown the effect that pre-existing antibodies can have on a subsequent exposure to 
influenza virus, a notion first observed over a half-century before using aggregate 
serology [92]. 
Still, high-throughput sequencing of BCR repertoire has a limitation associated 
with expressing and characterizing monoclonal antibodies due to the lack of information 
on the endogenous light chain paired with sequenced heavy chains. The problem arises 
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from the fact that the heavy chain and light chain of an Ig molecule comes from two 
distinct mRNA molecules, and that this information is lost during the NGS of heavy 
chains. To resolve this issue, several additional technologies have been developed that 
enable high-throughput identification of native VH:VL pairing [93-95]. In all, B cell 
repertoire studies have provided us with significant insights about the immune response 
to influenza. 
 
Proteomics-based Technology for Antibody Repertoire Analysis 
Despite all the recent advancements in technology, there still is a sizable gap in 
our understanding of the monoclonal antibodies comprising the serum antibody repertoire 
in circulation at the protein level. This is because peripheral blood B cells represent only 
a very small fraction of the total antibody producing cells in the body [96]. Additionally, 
B cells and circulating Ig molecules have great difference in their temporal persistence 
(Figure 1.7). For instance, pathogen-specific B cells peak in abundance around 7 days 
after exposure but quickly decay in the periphery, while pathogen-specific Ig molecules 
peak in abundance around 3 weeks after the exposure and decay with a slower rate until a 
steady-a state level is reached. Because of this difference, it is particularly difficult to 
understand the protein-level serological abundance and temporal dynamics of the 
antibody identified through the interrogation of the B cell compartment. Due to the 
technical complexities arising from the high frequency of homologous sequences 
obscuring the direct identification of the monoclonal antibodies through proteomics, 




Figure 1.7:  Temporal dynamics of antigen-specific peripheral B cells and serum 
antibodies following vaccination. While peripheral B cells peak in 
abundance around day 7 and quickly decay, serum antibodies peak around 3 
weeks after vaccination and slowly decay until reaching a steady-state level. 
 
In recent years, the development of bottom-up proteomics technology using 
shotgun liquid chromatography tandem mass spectrometry (LC-MS/MS) have led to the 
deconvolution of the antibody repertoire at the protein-level in various studies [97-101]. 
These techniques involve using antigen-immobilized resins to isolate antigen-specific Ig 
molecules from the serum samples collected after vaccination via affinity 
chromatography. These antibodies are trypsinized, which generates CDR-H3 peptides, 
and analyzed through mass spectrometry. For peptide identification, custom databases are 
constructed for each donor by NGS of day 7 peripheral B cells. Individual databases are 
used to interpret the MS/MS spectra by searching the spectra against the given database 
of sequences. Such a method was used for antibody discovery studies where antigen-
specific antibodies from rabbits, mice, and humans were isolated [97-101]. In addition to 
antibody discovery, one of the studies applied the technology to analyze the repertoire of 
antibodies elicited by tetanus vaccine boosters from two volunteers and determined the 
temporal dynamics of serological tetanus-specific antibodies [98]. The study compared 
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between peripheral B cell repertoire and the steady-state molecular antibody repertoire, 
and showed that less than 5% of sequences from antigen-specific PCs identified at day 7 
after vaccination encoded for antibodies that were actually present at steady-state (9 
months after the booster) in serum. This finding is significant since it highlighted the 
potential misinterpretation of the antibody repertoire following influenza vaccination that 
could arise from solely relying on the analysis of transcripts from B cells. It is apparent 
that there is the need for the repertoire analysis at the protein-level to decipher which 
antibodies are actually present and involved in providing protection, in particular, for 
determining which antibodies are maintained to mediate long-term protection. 
 
SUMMARY 
The holy grail of influenza vaccine research is to develop a ‘universal’ vaccine 
that can elicit long-term protective antibodies to combat a variety of different strains, 
negating the need for annual influenza vaccination. Such development may require 
immunogen engineering [84, 86], adjuvant studies to improve immune responses [102], 
or a better understanding of how innate immunity to enhance vaccine response [103]. 
Nevertheless, a comprehensive understanding of the vaccine response is the cornerstone 
of this goal. 
Recent studies interrogating B cells have led to the discovery of therapeutically 
promising bNAbs; yet, whether the bNAbs encoded by peripheral PCs and mBCs are 
present at physiologically relevant abundances as Ig molecules in serum and can 
contribute to protection remains unanswered. Previous studies showing the apparent 
discordance between the B cell compartments and the serum antibody compartment 
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strongly argue that the determination of the serological repertoire is critical for a 
comprehensive understanding of the response to influenza vaccination or infection. 
In this dissertation, we utilize a proteomics-based analysis of the antibody 
repertoire to characterize how seasonal vaccination changes the serum antibody repertoire 
in healthy young adults, to better understand the functions and biochemical properties of 
abundant monoclonal antibodies, and to illustrate the changes in the serum response in 
one individual following 6 years of repeated exposure to the same viral strain. 
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Chapter 2: Quantitative, Molecular-Level Analysis of the Serum 
Antibody Repertoire in Young Adults Before and After Seasonal 
Influenza Vaccination 
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INTRODUCTION 
Influenza infections cause over 5 million cases of severe illness resulting in 
approximately half a million deaths globally every year and constantly pose a threat of 
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another pandemic [4, 5]. The influenza hemagglutinin (HA) surface glycoprotein is the 
main antigenic determinant of the influenza virus, and neutralizing antibodies that bind to 
HA are known to confer protective immunity [85, 104]. Influenza A and influenza B are 
mainly responsible for the infection, and they are antigenically distinct from one another. 
There are two major groups, group 1 and group 2, belonging to influenza A, and there are 
two main lineages, Victoria and Yamagata lineages, in influenza B. Seasonal trivalent 
inactivated influenza vaccine (IIV3) currently in use contains HA of virus strains from 
each group of influenza A (H1N1 and H3N2) and one of the two lineages in influenza B 
(either the Yamagata or Victoria lineage). Presently, the IIV3 is gradually being replaced 
by quadrivalent inactivated influenza vaccine (IIV4) that includes HA from both 
Yamagata and Victoria lineage strains. Whether the IIV4 offers increased protection over 
IIV3 is actively debated [105, 106]. 
Every year, epidemiologically-identified circulating virus strains constitute the 
seasonal influenza vaccine, making it the only vaccine that is continually updated through 
surveillance systems. Despite the effort, however, it has been estimated that IIV3 confers 
protection in only about 60% of young adults and efficacy can be substantially lower for 
at-risk groups such as infants and the elderly [3, 107]. For this reason, improved 
immunogen designs aimed at increasing effectiveness are at the forefront of the quest for 
the next generation influenza vaccine [84-86], and it underscores the need to have better 
understanding of the antibody response elicited by the vaccination. 
Over the past few years, cloning and characterization of antibodies and high-
throughput sequencing of transcripts encoding heavy chain variable (VH) regions from 
peripheral blood B cells has enhanced our understanding of antibody-mediated protection 
to influenza [70, 72, 73, 78, 81, 88, 108]. Nevertheless, it is antibodies circulating in 
serum, not immunoglobulin receptors on B cells, that directly mediate protection against 
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viral infection. For that reason, bulk serological metrics including ELISA and 
neutralization titers to viral strains have also been used to understand the response to 
vaccination or infection. However, neither investigation of peripheral B cells nor bulk 
serological assays provide information regarding the sequence, relative concentrations, 
temporal dynamics and functions of the individual monoclonal antibodies that comprise 
the polyclonal anti-influenza serum repertoire. In this chapter, the serum antibody 
repertoire is directly investigated at a molecular level through high-resolution liquid 
chromatography coupled to tandem mass spectrometry (LC–MS/MS) to determine the 
extent to which seasonal influenza vaccination either boosts levels of pre-existing serum 
antibodies or elicits new antibodies, how clonal diversity of the serum repertoire is 
affected by immunization and how it relates to the overall ELISA titer, the influenza-
binding breadth of the antibody response, and the differences between vaccine-boosted 




MATERIALS AND METHODS 
 
Study Volunteers, Peripheral Blood Mononuclear Cell (PBMC) Isolation and RNA 
Extraction 
All study protocols were approved by the Institutional Review Boards at Stanford 
University. Informed consent was obtained from participants. Blood was taken before 
(day 0) and after (days 7, 28 and 180) vaccination. Volunteers were four young adults 
(22–32 yrs) in generally good health and vaccinated with one dose of IIV3 (FluZone; 
Sanofi-Pasteur); 60 ml peripheral blood were taken from individuals and heparinized. 
PBMCs were extracted from 10 ml blood using a Ficoll-Gradient and frozen in 10% (v/v) 
DMSO/40% (v/v) FBS according to the Protocols of the Stanford Human Immune 
Monitoring Center (HIMC). After thawing, total RNA was extracted from 5 million 
PBMCs using the Qiagen AllPrep Kit. 
 
Library Preparation for High-throughput Sequencing of VH-encoding Genes 
500 ng of total RNA was used as input for library preparation. Reverse-
transcription was performed according to the manufacturer’s instructions using 
SuperScript III Enzyme (Life Technologies) and primers for all five isotypes containing 
eight random nucleotides and partial Illumina adapters containing Illumina barcodes. 
Second-strand synthesis was done using Phusion Polymerase (NEB), and primers 
containing eight random nucleotides and partial Illumina adaptor sequences that bind 
either framework region (FR) 1 or 3 of all variable (V) segments with a maximum of one 
mismatch (98 °C for 2 min, 52 °C for 2 min, and 72 °C for 10 min). Double-stranded 
cDNA was purified two times using Ampure XP beads at a ratio of 1:1. Double-stranded 
cDNA was amplified with Platinum Hifi Polymerase (Life Technologies) with two 
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primers completing Illumina adaptor sequences (amplification conditions: 95 °C for 2 
min; 27 cycles of 95 °C for 30 s, 65 °C for 30 s and 68 °C for 2 min; and 68 °C for 7 min). 
Final sequencing libraries were generated by purifying the PCR product using Ampure 
XP beads at a ratio of 1:1, and they were sequenced using the Illumina MiSeq platform. 
 
Reagents  
Individual IIV1s comprising the 2011–2012 FluZone IIV3 (H1N1 
A/California/07/2009 X-179A, H3N2 A/Victoria/210/2009 X-187 and 
B/Brisbane/60/2008), as well as the influenza B component of the 2012–2013 FluZone 
IIV3 (B/Texas/6/2011), were obtained from Sanofi-Pasteur. A/California/7/2009-X181 
rHA was provided by Dr. Stephen Harrison (Harvard Medical School). 
 
Purification of Total IgG from Serum and Subsequent Digestion into F(ab’)2 
For each serum sample analyzed in this study, 30 ml of diluted serum (1:2 
dilution in PBS) was passed through a 4-ml Protein G Plus agarose (Pierce) affinity 
column in gravity mode. Serum flowthrough was collected and passed through the 
column three times. The column was washed with 15 column volumes (cv) of PBS before 
elution with 5 cv of 100 mM glycine-HCl, pH 2.7. The eluate, containing total IgG from 
serum, was immediately neutralized with 2 ml of 1 M Tris-HCl, pH 8.0, and dialyzed into 
20 mM sodium acetate, pH 4.5, overnight at 4 °C. Purified IgG was digested into F(ab)2 
with 1 ml of immobilized pepsin resin (Pierce) per 40 mg of IgG in 20 mM sodium 
acetate, pH 4.5, for 4 h on an inverter at 37 °C. Pepsin resin was spun down at 2,000g to 
halt digestion and washed with PBS three times. Supernatants from the digestion 
reactions and washes were combined and pH-adjusted to 7. 
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Antigen Enrichment of F(ab’)2 and Mass Spectrometry Sample Preparation 
Respective IIV1s or rHA were immobilized on N-hydroxysuccinimide (NHS)-
activated agarose resins (Pierce) by overnight rotation at 4 °C. The coupled agarose resins 
were washed with PBS, and unreacted NHS groups were blocked with 1 M ethanolamine, 
pH 8.3, for 30 min at room temperature (RT). The beads were further washed with PBS 
and packed into a 2-ml chromatography column (Clontech). The column was prewashed 
with 5 cv of 2 M urea and equilibrated with 10 cv of PBS. The prewashing step with urea 
was to remove HA that was noncovalently bound to the resin following immobilization, 
because we initially noticed that a large amount of HAs detaching from the resins 
interfered with the subsequent analysis. Exhaustive controls with elution and flowthrough 
samples from affinity chromatography were performed to ensure that the prewashing step 
with 2 M urea does not impede complete capture of F(ab)2 molecules that recognize 
IIV1. 
For each sample, the F(ab)2 sample was divided into equal volumes, with each 
fraction being applied to the individual antigen affinity columns in gravity mode. 
Flowthrough was collected and reapplied to the column three times, and the column was 
washed with 10 cv of PBS and 10 cv of diluted PBS (1:2 in ddH2O). Antigen-enriched 
F(ab)2 was eluted with 60 mM HCl, pH 1.7, in 0.5-ml fractions and neutralized with 
NaOH/Tris. Flowthrough and elution fractions were assayed by indirect ELISA with the 
corresponding IIV1. To ensure that our enrichment steps were not biasing isolation for 
high-affinity antibodies, the depletion of ELISA signal in each flowthrough sample was 
checked. Elution fractions showing an ELISA signal were pooled and concentrated under 
vacuum to a volume of ~0.1 ml and desalted into ddH2O using a 0.5-ml Zeba spin 
column (Pierce). The desalted eluate was further concentrated to 50 μl under vacuum.  
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For each enrichment, elution and flowthrough samples were denatured in 50% 
(vol/vol) 2,2,2-trifluoroethanol (TFE), 50 mM ammonium bicarbonate and 10 mM 
dithiothreitol (DTT) at 60 °C for 1 h, then alkylated by incubation with 32 mM 
iodoacetamide (Sigma) for 1 h at RT in the dark. Alkylation was quenched by the 
addition of 20 mM DTT. Samples were diluted tenfold with 50 mM ammonium 
bicarbonate and digested with trypsin (1:30 trypsin:protein) for 16 h at 37 °C. Formic 
acid was added to 1% (vol/vol) to quench the digestion, and the sample volume was 
reduced to ~100 μl under vacuum. Peptides were then bound to a C18 Hypersep SpinTip 
(Thermo Scientific), washed three times with 0.1% formic acid and eluted with 60% 
acetonitrile, 0.1% formic acid. C18 eluate was dried under vacuum-centrifugation and 
resuspended in 50 μl in 5% acetonitrile, 0.1% formic acid. 
 
LC-MS/MS Analysis 
Samples were analyzed by liquid chromatography–tandem mass spectrometry on 
a Dionex Ultimate 3000 RSLCnano uHPLC system (Thermo Scientific) coupled to an 
LTQ Orbitrap Velos Pro mass spectrometer (Thermo Scientific). Peptides were first 
loaded onto an Acclaim PepMap RSLC NanoTrap column (Dionex; Thermo Scientific) 
before separation on a 75-μm × 15-cm Acclaim PepMap RSLC C18 column (Dionex; 
Thermo Scientific) using a 5–40% (vol/vol) acetonitrile gradient over 250 min at 300 
nl/min. Eluting peptides were injected directly into the mass spectrometer using a nano-
electrospray source. The LTQ Orbitrap Velos Pro was operated in data-dependent mode 
with parent ion scans (MS1) collected at 60,000 resolutions. Mono-isotopic precursor 
selection and charge-state screening were enabled. Ions with a charge ≥+2 were selected 
for collision-induced dissociation fragmentation spectrum acquisition (MS2) in the ion 
trap, with a maximum of 20 MS2 scans per MS1. Dynamic exclusion was active with a 
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45-s exclusion time for ions selected more than twice in a 30-s window. Each sample was 
run three times to generate technical replicate data sets. 
 
MS/MS Data Analysis 
Donor-specific protein sequence databases were constructed using the donor’s VH 
sequences with 2 reads, concatenated to a database of background proteins comprising 
non-donor-derived VL sequences (HD1) [98], a consensus human protein database 
(Ensembl 73, longest sequence per gene) and a list of common protein contaminants 
(MaxQuant). Donor-specific spectra were searched against the corresponding donor-
specific database using SEQUEST (Proteome Discoverer 1.4; Thermo Scientific). 
Searches considered fully tryptic peptides only, allowing up to two missed cleavages. A 
precursor mass tolerance of 5 p.p.m. and a fragment-mass tolerance of 0.5 Da were used. 
Modifications of carbamidomethyl cysteine (static) and oxidized methionine (dynamic) 
were selected. High-confidence peptide-spectrum matches (PSMs) were filtered at a false 
discovery rate of <1% as calculated by Percolator (q-value < 0.01, Proteome Discoverer 
1.4; Thermo Scientific). 
Isoleucine/leucine sequence variants were collapsed into single peptide groups. 
For each scan, PSMs were ranked first by posterior error probability (PEP), then q-value, 
and finally XCorr. Only unambiguous top-ranked PSMs were kept; scans with multiple 
top-ranked PSMs (equivalent PEP, q-value and XCorr) were designated ambiguous 
identifications and removed. Observed precursor masses were recalibrated according to 
the previous method [109], and the average mass deviation (AMD) for each peptide was 
calculated as described [97] using data from elutions only. Peptides with an AMD >1.5 
p.p.m. were removed. Additionally, only peptides identified in ≥2 replicate injections for 
at least one elution sample were kept as high-confidence identifications. 
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Peptide abundance was calculated from the extracted-ion chromatogram (XIC) 
peak area, as described [98], using peak area values generated by the Precursor Ions Area 
Detector node in Proteome Discoverer. For each peptide, a total XIC area was calculated 
as the sum of all unique XIC areas of associated precursor ions, and the average XIC area 
across replicate injections was calculated for each sample. For each antigen data set, the 
eluate and flowthrough abundances were compared and peptides with 10-fold higher 
signal in the elution sample were considered to be antigen specific. Similarly, peptide 
abundances in elution samples were compared across antigens; peptides with 10-fold 
higher signal for a single antigen were considered specific (i.e., H1 or H3 specific), and 
peptides with <10-fold difference for two or more antigens were considered cross-
reactive (i.e., H1 + H3 cross-reactive). In addition, in our H1 + H3 cross-reactive 
serological repertoire analysis, to avoid overestimating, we removed peptides that 
appeared in the eluates of all three IIV1 enrichments (which could potentially be binding 
to other constituents in the vaccine); on average, they accounted for <10% (by abundance) 
of the serological repertoire. 
 
Clonotype Indexing and Peptide-to-peptide Mapping 
VH-encoding sequences were grouped into clonotypes based on single-linkage 
hierarchical clustering as described [98]. Cluster membership required 90% identity 
across the CDR-H3 amino sequence as measured by edit distance. High-confidence 
peptides identified by MS/MS analysis were mapped to clonotype clusters, and peptides 
uniquely mapping to a single clonotype were considered ‘informative’. The abundance of 
each antibody clonotype was calculated by summing the XIC areas of the informative 
peptides mapping to 4 amino acids of the CDR-H3 region. 
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Quantitating Abundance of Individual Antibody Clonotypes 
For each serological repertoire, the relative abundance of a clonotype was 
calculated by dividing the XIC area for a particular clonotype by the sum of the XIC 
areas for all clonotypes. Fraction of serological repertoire refers to this relative 
abundance based on XIC. The amount for a particular clonotype was determined by 
multiplying its fraction of serological repertoire by the corresponding serum sample’s 
binding titer. To generate heat maps, we accounted for the different total binding titers 
toward each IIV1 by normalizing amount using the day 28 titer as a reference, calling this 
‘relative amount’. For example, the amount for each clonotype divided by the serum titer 
of the day 28 sample refers to relative amount. 
 
Enzyme-Linked Immunosorbent Assays (ELISAs) 
EC50 values based on ELISA were used to determine the binding titers of IIV1-
specific antibodies in the serum samples or apparent affinities of the recombinant 
monoclonal antibodies. First, costar 96-well ELISA plates (Corning) were coated 
overnight at 4 °C with 4 g/ml IIV1 or recombinant HAs, and washed and blocked with 2% 
milk in PBS for 2 h at RT. After blocking, serially diluted recombinant antibodies or 
serum samples were bound to the plates for 1 h, followed by incubation with 1:5,000-
diluted goat anti-human-IgG Fc horseradish peroxidase (HRP)-conjugated secondary 
antibodies (Jackson ImmunoResearch; 109-035-008) for 1 h. For detection, 50 l TMB-
ultra substrate (Thermo Scientific) was added before quenching with 50 l 1 M H2SO4. 
Absorbance was measured at 450 nm using a Tecan M200 plate reader. Data were 
analyzed and fitted for EC50 using a four-parameter logistic nonlinear regression model in 
the GraphPad Prism software. All ELISA assays were performed in triplicate. 
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Hemagglutination Inhibition Assay 
The HAI assay was used to assess abilities of functional antibodies specific to the 
HA to inhibit agglutination of turkey erythrocytes. The protocol was adapted from the 
CDC laboratory-based influenza surveillance manual [110]. To inactivate non-specific 
inhibitors, sera were treated with Receptor Destroying Enzyme (RDE; Denka Seiken, Co., 
Japan) prior to being tested [111]. Briefly, three parts RDE was added to one part sera 
and incubated overnight at 37 °C. RDE was inactivated by incubation at 56 °C for ~30 
min. RDE-treated sera were two-fold serially diluted in v-bottom microtiter plates. An 
equal volume of each influenza virus strains (A/California/07/2009, A/Perth/16/2009 and 
B/Brisbane/60/2008), adjusted to approximately 8 HAU/50 μl, was added to each well. 
The plates were covered and incubated at RT for 20 min followed by the addition of 1% 
turkey erythrocytes (RBC; Lampire Biologicals, Pipersville, PA, USA) in PBS. Red 
blood cells were stored at 4 °C and used within 72 h of preparation. The plates were 
mixed by agitation, covered, and the RBCs were allowed to settle for 1 hr at room 
temperature. The HAI titer was determined by the reciprocal dilution of the last well that 




Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad 
Software, Inc., San Diego, CA), unless specifically noted otherwise in the figure legends. 
All the statistical tests performed are described in the figure legends, and correlations 





Analytical Pipeline for Characterizing Influenza-specific Serological Repertoire 
We previously developed a proteomics-based pipeline for the identification and 
semi-quantitative determination of the antigen-specific antibodies in human serum [94, 
96, 98]. Utilizing this method, we delineated the composition and relative quantities of 
the antibody clonotypes comprising the serum IgG repertoire before (pre-) and after 
(post-) vaccination (days 0, 28 and 180) in four human donors who were immunized with 
the 2011–2012 IIV3 vaccine (Table 2.1 and Figure 2.1). For the analysis, serum IgG was 
digested with pepsin to generate F(ab’)2 fragments, and F(ab’)2 specific for each of the 
three vaccine strains was purified by three separate affinity chromatography columns, 
each using resins immobilized with one of the monovalent inactivated vaccine 
components (IIV1) that comprise the IIV3 (A/California/07/2009 X-179A, 
A/Victoria/210/2009 X-187 and B/Brisbane/60/2008; abbreviated as ‘H1 A/CA09’, ‘H3 
A/VI09’ and ‘Vic B/BR08’, respectively). For peptide identification, custom databases 
were constructed for each donor by high-throughput sequencing of the VH repertoires 
from day 7 peripheral B cells. 
 
Table 2.1:  Descriptions of the donors involved in the study. The vaccination and 
diagnosis history is based on self-reporting.  







1 22 Female No No No 
2 22 Male No No No 
3 28 Male No No No 





Figure 2.1:  Experimental design. For the sequencing of B cell receptor (BCR)-encoding 
transcripts (BCR-seq), we used peripheral B cells isolated 7 d after 
vaccination to sequence the VH repertoires for constructing custom 
databases of each donor for heavy-chain peptide identification. From sera of 
the donors, antibodies specific to each IIV1 were isolated through IIV1-
immobilized column purification, and the purified immunoglobulins were 
subsequently analyzed proteomically (Ig-seq). 
 
To ensure that the affinity chromatography conditions result in proper and 
complete isolation of serum antibodies that recognize IIV1, we performed several control 
experiments. First, because a pre-washing step with 2 M urea for the IIV1-immobilized 
resins was added to remove noncovalently-bound HAs shedding into the eluates which 
interfered with the subsequent LC-MS/MS analyses, we examined the effect of using 2 M 
urea. IIV1-immobilized resins were packed into two columns, and one column was 
washed with PBS and the other one with 2 M urea. After equilibrating the columns with 
PBS, F(ab’)2 was applied to each column, and the flowthrough from each column was 
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collected. Based on the ELISA signal of IIV1-specific antibodies remaining in the 
flowthrough samples, both had a negligible amount, and the amount of antibody in the 
flowthrough from the 2 M urea-washed column was indistinguishable from the 
flowthrough of the column pre-washed with PBS (Figure 2.2). We also repeated the 
control experiment and analyzed the amount of antibody in each elution fraction with and 
without the 2 M urea-washing step, and our data showed that they were indistinguishable 
(Figure 2.3). From the two control experiments, we concluded that the additional pre-
washing step with 2 M urea did not affect the integrity of the immobilized IIV1. Second, 
because of the nature of affinity chromatography, the eluate could be skewed for high 
affinity antibodies. To test, we checked for the depletion of IIV1-specific antibodies in 
flowthrough samples, and ensured that the flowthrough samples were depleted of 
antibodies capable of binding to IIV1 (Figure 2.4). These control experiments 
conclusively demonstrated that the conditions used for capturing the IIV1-specific 
antibodies resulted in thorough purification of serum antibodies with affinity toward IIV1. 
Each eluate samples enriched following the affinity chromatography conditions were 
subsequently trypsinized and analyzed by LC–MS/MS. In total, analysis of the 
serological repertoire for all of the time points and donors required 240 runs and >1,200 h 






Figure 2.2:  Analysis of IIV1-specific F(ab’)2 in flowthrough samples after the affinity 
chromatography. The amounts of IIV1-specific antibodies in the pre-
enrichment sample (pre-enrichment) as well as the flowthrough samples 
from PBS-washed column (pre-wash with PBS) and 2 M urea-washed 
column (pre-wash with 2 M urea) were analyzed by ELISA.  
 
 
Figure 2.3:  Analysis of IIV1-specific F(ab’)2 in each elution fraction from the affinity 
chromatography. The amounts of IIV1-specific antibodies in each elution 
and flowthrough fractions from PBS-washed column (pre-wash with PBS) 




Figure 2.4:  A representative experiment data showing the depletion of IIV1-specific 
antibodies in the flowthrough. ELISA signals for the samples 2-fold diluted 
are shown.  
 
The Serological Repertoire to IIV3 
Antibodies that share sequence similarity in the heavy-chain complementarity-
determining region 3 (CDR-H3) and have the same binding specificity belong to a 
particular clonotype and are likely to recognize the same epitope. For our analyses, we 
identified high-confidence CDR-H3 peptides and grouped the peptides belonging to the 
same clonotype together. The corresponding LC peak intensities were used for relative 
quantification of the antibody clonotypes [97]. An estimated >80% of the CDR-H3 
peptides within a sample are typically identified in this manner (detection limit around 
0.4 ng/ml), and quantification calibrations using isobaric peptide spike-ins showed that 
peak intensities correlate well with absolute peptide concentrations [112]. Accordingly, 
our proteomic methodology enabled us to quantify changes in the abundance of different 
antibody clonotypes among the serum repertoire of antibodies that bind to each IIV1. 
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For each time point, the antibody repertoire composition and relative quantities at 
the clonotypic level were plotted as a histogram, with each bar representing an individual 
clonotype and the y axis showing its relative abundance (Figure 2.5). We defined 
antibody clonotypes present in both the pre-vaccination repertoire (day 0) and the post-
vaccination repertoire (day 28 and/or day 180) as ‘pre-existing’, and clonotypes observed 
exclusively in the post-vaccination repertoire (not at day 0) as ‘vaccine-elicited’. The 
term ‘vaccine-elicited antibodies’ refers only to the fact that these antibodies become 
detectable in the serum after vaccination and should not be interpreted in B cell ontogeny 
terms (i.e., whether they arise from stimulated naive or memory B cells). The temporal 
dynamics of the serum repertoire to each IIV1 at days 0, 28 and 180 for individual donors 
are represented as heat maps, with color intensity reflecting relative amount of the 
respective clonotype (Figure 2.6). The comparison of pre-existing and vaccine-elicited 
antibodies revealed that in the four donors we analyzed, on average pre-existing antibody 
clonotypes comprised 61.2% and 65.4% of the HA-binding repertoire in day 28 and day 
180 sera, respectively (Figure 2.7). Thus, the post-vaccination response is dominated by 
pre-existing serum antibodies. 
 
 
Figure 2.5: Representative serological repertoire (donor 1, day 28 anti-H1 A/CA09).  
Each bar represents a unique clonotype and the y axis indicates the relative 
abundance (fraction) determined by proteomic analysis. 
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Figure 2.6 Heat maps of the relative amounts of antibody clonotypes (each column 
indicates distinct clonotype) comprising the serological repertoire to each 
IIV1 at different time points for each donor. The amount of each clonotype 
is determined by multiplying its relative abundance by the serum titer for 
that sample. Relative amounts are determined by normalizing the amounts to 
day 28 serum titers (refer to Materials and Methods). 
 
 
Figure 2.7: Predominance of pre-existing antibody clonotypes (Abs) in serum following 
vaccination. Each data point (see key, which is used throughout the chapter) 
corresponds to the fraction of pre-existing Abs in the serological repertoire 
to an IIV1 for a specific donor. Averages are calculated as mean, with error-
bars indicating s.e.m. (n = 12 for each group). 
 45 
Inspection of the serological repertoires for all of the donors also revealed several 
additional insights. First, the number of distinct antibody clonotypes specific for each 
IIV1 ranged from as low as 6 at day 0 to between 40 and 147 at day 28 (Table 2.2), 
revealing that the influenza-specific repertoire is highly restricted and oligoclonal. The 
restricted clonality of the serum repertoire observed here is in sharp contrast to the much 
more diverse repertoire encoded by influenza-specific peripheral B cells [75, 88]. Second, 
the serological repertoire is highly polarized, and on average, the top 6% of the most 
abundant clonotypes after vaccination account for more than 60% of the entire repertoire 
(Table 2.3). This polarization effect is also evident in the pre-vaccination serum IgG 
repertoires (top 12% antibody clonotypes constituting >60% of the repertoire). Third, the 
number of antibody clonotypes in the serum repertoire specific for a particular IIV1 
correlates with the respective serum titer (Spearman correlation = 0.82, P < 0.0001; 
Figure 2.8 and Table 2.4). Fourth, the frequency of vaccine-elicited antibody clonotypes 
shows an inverse correlation to the serum titer before vaccination (Spearman correlation 
= –0.82, P = 0.0010; Figure 2.9). In other words, individuals with a lower serum titer 
before vaccination, and therefore a repertoire comprising fewer antibody clonotypes, 
produce a greater number of vaccine-elicited antibody clonotypes. These data are 
consistent with a model (Figure 2.10) in which the greater the number of pre-existing 
clonotypes (reflected as a higher pre-vaccination serum titer), the greater the number of 
antigenic epitopes that are bound by circulating antibodies resulting in a blockade of 
antigenic sites (or possibly, more effective clearance due to formation of HA immune 
complexes decorated with a larger number of antibodies), thereby reducing the magnitude 
and diversification of the B cell response [83, 113]. 
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Table 2.2: Size of each IIV1 serological repertoire analyzed. Number of unique 
clonotypes in each repertoire is indicated. Total refers to the number of all 
the unique clonotypes that are identified for a particular donor and IIV1s. 
Donor Time point H1 A/CA09 H3 A/VI09 Vic B/BR08 
1 
Day 0 44 99 98 
Day 28 118 116 127 
Day 180 110 99 116 
Total 132 125 149 
2 
Day 0 32 49 20 
Day 28 55 92 57 
Day 180 65 98 57 
Total 80 121 62 
3 
Day 0 31 6 80 
Day 28 103 40 147 
Day 180 101 47 138 
Total 124 60 172 
4 
Day 0 29 14 25 
Day 28 95 68 112 
Day 180 50 80 112 
Total 97 95 134 
 
Table 2.3: D60 diversity indices. D60 diversity index refers to number of clonotypes 
that comprises the 60% (by abundance) of the serological repertoire. For 
each time point and IIV1 analyzed, D60 diversity index values were divided 
by the total number of clonotypes detected to determine the frequency of 
clonotypes that constitute D60 diversity indices. 
Donor Time point H1 A/CA09 H3 A/VI09 Vic B/BR08 
1 
Day 0 6/44  (14%) 8/99 (8.1%) 8/98 (8.2%) 
Day 28 8/118 (6.8%) 9/116 (7.8%) 2/127 (1.6%) 
Day 180 8/110 (7.3%) 10/99 (10%) 2/116 (1.7%) 
2 
Day 0 1/32 (3.1%) 3/49 (6.1) 4/20 (20%) 
Day 28 3/55 (5.5%) 8/92 (8.7%) 3/57 (5.3%) 
Day 180 5/65 (7.7%) 6/98 (6.1%) 3/57 (5.3%) 
3 
Day 0 3/31 (9.7%) 1/6 (17%) 1/80 (1.3%) 
Day 28 6/103 (5.8%) 3/40 (7.5%) 6/147 (4.1%) 
Day 180 4/101 (4.0%) 3/47 (6.4%) 5/138 (3.6%) 
4 
Day 0 4/29 (14%) 2/14 (14%) 7/25 (2.8%) 
Day 28 8/95 (8.4%) 4/68 (5.9%) 3/112 (2.7%) 
Day 180 7/50 (14%) 8/80 (10%) 4/112 (3.6%) 
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Figure 2.8: Correlation between ELISA serum titer to IIV1 with the number of 
clonotypes in the respective serum repertoires. Each data point corresponds 
to titers and the number of clonotypes in serological repertoire specific to an 
IIV1 for a donor at each time point (n = 36). Statistical analyses were 
performed using two-sided nonparametric Spearman rank correlation test. 
 
Table 2.4: Serum binding titers to each IIV1 in each collected sera measured by ELISA, 
with EC50 values representing titers. Averages are calculated as mean with 
error-bars indicating s.d., repeated in triplicate. 
Donor Time point H1 A/CA09 H3 A/VI09 Vic B/BR08 
1 
Day 0 70 ± 6 131 ± 7 96 ± 5 
Day 28 178 ± 3 285 ± 4 671 ± 19 
Day 180 96 ± 5 163 ± 8 346 ± 9 
2 
Day 0 46 ± 9 38 ± 2 54 ± 2 
Day 28 76 ± 3 201 ± 8 168 ± 14 
Day 180 57 ± 0.6 184 ± 8 167 ± 0.5 
3 
Day 0 45 ± 16 32 ± 9 71 ± 4 
Day 28 289 ± 33 210 ± 0.5 414 ± 22 
Day 180 231 ± 2 146 ± 4 294 ± 4 
4 
Day 0 76 ± 15 36 ± 12 23 ± 0.8 
Day 28 169 ± 3 205 ± 12 686 ± 25 




Figure 2.9: Inverse correlation between pre-vaccination ELISA serum titers and the 
frequency of vaccine-elicited clonotypes at day 28. Frequency is calculated 
as the number of vaccine-elicited clonotypes divided by the total number of 
unique clonotypes at day 28 (n = 12). Statistical analyses were performed 
using two-sided nonparametric Spearman rank correlation test. 
 
 
Figure 2.10: A model depicting the effect of high pre-vaccination serum titer on the 
number of antibody clonotypes elicited in the serological repertoire post-
vaccination. As shown in Figure 2.8, serum titer correlates with size of 
serum repertoire and thus, a higher titer reflects a more diverse antibodies 
circulating in serum. This likely results in a greater epitope coverage of the 
antigen HA, leading to a lower B cell stimulations. 
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Prevalence of Cross-reactive Serum Antibodies 
Comparing the repertoires specific to each IIV1, we noticed that a unexpectedly 
high number of the same antibody clonotypes were detected in both the H1 A/CA09 and 
H3 A/VI09 affinity chromatography eluates (Appendix A). We considered the possibility 
that these antibody clonotypes may have been isolated because they bound to constituents 
in the vaccine other than HA, or because of nonspecific binding. However, when we 
proteomically analyzed the affinity chromatography eluate from donor 1 day 28 serum 
using recombinant HA (rHA) of A/California/07/2009 X-181, >70% (by abundance) of 
all of the antibody clonotypes found in the eluate from affinity chromatography with 
immobilized H1 A/CA09 (IIV1) were also detected in the eluate from affinity 
chromatography with the rHA (Figure 2.11). In addition, the abundance of the H3 
A/VI09–specific antibody that was also detected in the anti–H1 A/CA09 serological 
repertoire, on the basis of the proteomic analysis, was in excellent agreement with 
biochemical estimates of the abundance of H3 A/VI09–binding antibodies found in the 
eluate from H1 A/CA09 affinity purification (Figure 2.12). These data suggest that the 
antibodies found in the H1 A/CA09 and in the H3 A/VI09 affinity chromatography 
eluates overwhelmingly recognize both of the respective HAs and are not directed to 




Figure 2.11: Proteomic and biochemical detection of H1 + H3 cross-reactive serum 
antibodies. (a) Comparison between anti-H1 A/CA09 (vaccine HA, vHA) 
and anti- A/California/7/2009 X-181 (recombinantly-expressed HA, rHA) 
serological antibody repertoires from the donor 1 day 28 serum. Antibodies 
clonotypes detected in LC-MS/MS following affinity chromatography with 
rHA constituted 74%, based on abundance, of the antibodies identified when 
affinity chromatography was carried out with IIV1 (H1 A/CA09). Antibody 
clonotypes comprising the remaining 26% were only detected in the eluate 
from the affinity chromatography with H1 A/CA09. Since the clonotypes 
detected only in the anti-H1 A/CA09 (26%) do not bind to rHA, such 
antibody clonotypes are specific to the IIV1 (vHA-specific). In the eluates 
from affinity chromatography with rHA, 94% of the antibody clonotypes, by 
abundance, were also found in the anti-H1 A/CA09. The antibodies that 
bind to both vHA and rHA (vHA + rHA) are directed to epitopes present in 
rHA that are also found in the IIV1, and these data suggest that the majority 
of the antibodies binding to IIV1 also binds to rHA. (b) Serum anti-
influenza vaccine antibodies overwhelmingly react with rHA. In accordance 
with the data in a above, the ELISA signal against rHA was 75% of the 
signal against IIV1 (EC50 of 133 vs. 178). A very low titer to neuraminidase 
(NA) or to gelatin, present in the vaccine as a stabilizer, was detected. 
verages are calculated as mean with error-bars indicating s.d., repeated in 
triplicate. (c) Correlation between the amounts of H1 + H3 cross-reactive 
clonotypes detected by affinity chromatography with either H1 A/CA09 or 
H3 A/VI09. Each dot represents one H1 + H3 cross-reactive clonotype with 
x axis and y axis indicating amounts of each clonotype in the H1 A/CA09 
and H3 A/VI09 affinity chromatography eluate, respectively. Amounts were 
calculated as described in Figure 2.6. Data points from all of the H1 + H3 
cross-reactive clonotypes at day 28 in all four donors are shown. Statistical 




Figure 2.12: Biochemical detection of H1 + H3 cross-reactive antibodies in the eluate 
from the affinity chromatography with H1 A/CA09. Donor 1 day 180 serum. 
IgGs were enriched by affinity chromatography with H1 A/CA09, and the 
eluates were collected. Then, the binding signals of the IgGs in the eluate to 
H3 A/VI09 and Vic B/BR08 were determined by ELISA. The EC50 value of 
the antibodies in the eluate binding to H3 A/VI09 was ~60% of the EC50 
value with H1 A/CA09 (EC50 of 40 vs. 24). In agreement with this 
biochemical analysis, the abundance, based on the LC-MS/MS analysis, of 
all anti-H1 A/CA09 antibody clonotypes that were also found in the anti-H3 
A/VI09 repertoire comprised 56%. Averages are calculated as mean with 
error-bars indicating s.d., repeated in triplicate. 
 
We designated the clonotypes detected in separate affinity chromatography 
eluates with H1 A/CA09 and H3 A/VI09 as ‘H1 + H3 cross-reactive’ (Figure 2.13). 
Notably, several highly abundant clonotypes were H1 + H3 cross-reactive, which was 
unexpected because previous reports on the HA specificity of antibodies isolated by 
single B cell cloning from IIV3 vaccines recipients had suggested that clones capable of 
binding to both group 1 and group 2 strains are rare [72, 79]. In the serum samples from 
the four donors we analyzed, the average fractions of H1 + H3 cross-reactive antibodies 
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among total IIV1-binding repertoire were 43.9%, 32.7% and 39.0% on days 0, 28 and 
180, respectively (Figure 2.14). Also, across all donors, 63.1% of H1 + H3 cross-reactive 
clonotypes were pre-existing, and a higher amount of H1 + H3 cross-reactive antibodies 
in serum at day 0 correlated with a lower frequency of newly elicited H1 + H3 cross-
reactive clonotypes at day 28 (Spearman correlation = –0.86, P = 0.0107; Figure 2.15), in 
agreement with the model in Figure 2.10. Comparison of the molecular features of H1 + 
H3 cross-reactive antibodies with those of antibodies detected only in the anti–H1 
A/CA09 or anti–H3 A/VI09 repertoires (assigned as ‘H1-specific’ and ‘H3-specific’, 
respectively) showed no significant differences in immunoglobulin heavy chain variable 
(IGHV) gene usage, CDR-H3 length, hydrophobicity or charge, suggesting that there are 
no specific B cell evolutionary trajectories or germline features that predispose antibodies 
toward H1 + H3 cross-reactivity (Figure 2.16). 
 
 
Figure 2.13: Representative histogram from donor 1, day 28 anti-influenza A serological 
repertoire. The fraction of each antibody clonotype in the anti–H1 A/CA09 




Figure 2.14: Relative abundance of H1 + H3 CR antibody clonotypes in the serum 
repertoires. Averages are calculated as the mean, with error-bars indicating 
s.e.m. (n = 8 for each group). 
 
 
Figure 2.15: Inverse correlation between pre-vaccination amount of H1 + H3 CR 
antibodies and the frequency of vaccine-elicited CR antibodies at day 28. y 
axis indicates the amount of H1 + H3 CR antibodies in sera at day 0, and x 
axis indicates the frequency of vaccine-elicited CR antibodies, calculated as 
the number of vaccine-elicited cross-reactive clonotypes divided by the total 
number of cross-reactive clonotypes at day 28. Amounts were calculated as 
described in Figure 2.6, and statistical analyses were performed using a two-




Figure 2.16: Analysis of antibody germline usage, CDR-H3 length, hydrophobicity and 
charge in H1+H3 cross-reactive vs. H1- or H3-specific antibodies. (a) 
Distribution of IGHV gene usage for H1- or H3-specific and H1 + H3 cross-
reactive antibodies. The frequencies of IGHV gene usage are calculated for 
each individual. The center-lines represent the mean value of the frequencies 





and the whiskers indicating min to max. Fisher exact tests were performed 
to identify differences in IGHV gene usage between H1- or H3-specific and 
H1 + H3 cross-reactive antibodies, and there was no statistically significant 
gene consistently found across the donors. (b) Box plot for the mean of 
CDR-H3 lengths, hydrophobicity indices and charge. For hydrophobicity 
index, Eisenberg scale was calculated using the “Peptides” package (version 
1.0.4) in R. No significant difference was found between H1- or H3-specific 
(Spec.) and H1 + H3 cross-reactive (CR) antibodies as the length, 
hydrophobicity and charge P-values (Mann-Whitney U test) were 0.1143, 1 





with the whiskers indicating min to max. 
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H1- or H3-specific Antibody Repertoire Analysis 
Analysis of H1- or H3-specific antibodies revealed that vaccine-elicited antibody 
clonotypes (as opposed to pre-existing antibodies detected at day 0) in sera were 
overwhelmingly either H1 specific or H3 specific (Figure 2.17a). The total amount of 
these H1- or H3-specific antibody clonotypes correlated with the HAI titer (Spearman 
correlation = 0.85, P < 0.0001; Figure 2.17b and Table 2.5). Because a large fraction of 
the serum repertoire comprises pre-existing antibodies that bind to conserved epitopes in 
HA (Figure 2.14), the response to the vaccine appears to become focused on new 
epitopes in the head domain, the region of HA that experiences the highest degree of 




Figure 2.17: Analysis of H1- or H3-specific, and influenza B–specific, serological 
repertoire. (a) Quantification of H1- or H3-specific antibodies in the 
vaccine-elicited antibody repertoire at day 28. Averages were calculated as 
mean, with error-bars indicating s.e.m. (n = 4 for each group). (b) HAI 
serum titers before and after vaccination as a function of the amount of H1- 
or H3-specific antibodies in serum before and after vaccination. Amounts 
were calculated as described in Figure 2.6, and statistical analyses were 
performed using a two-sided nonparametric Spearman rank correlation test.  
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Table 2.5: Hemagglutination inhibition (HAI) titers against each viral strain included 
the 2011-2012 IIV3. The reciprocal dilutions of the sera containing non-
agglutinated RBCs are used as HAI titers. 








Day 0 1 40 10 
Day 28 10 160 20 
2 
Day 0 10 10 10 
Day 28 20 80 80 
3 
Day 0 10 20 10 
Day 28 320 160 40 
4 
Day 0 10 20 10 
Day 28 80 160 40 
 
Anti-influenza B Antibody Repertoire Analysis 
Influenza B is antigenically distinct from influenza A strains. Globally, 
quadrivalent inactivated influenza vaccines (IIV4) that include both Yamagata and 
Victoria lineage HAs are gradually replacing the trivalent vaccine (IIV3), which contains 
one B lineage strain. Whether the IIV4 offers increased protection over IIV3 is actively 
debated [105, 106]. We evaluated the degree to which antibodies comprising the 
influenza B serum repertoires elicited by IIV3 containing a Victoria lineage strain (‘Vic 
B/BR08’ in Figure 2.1) also bound to a Yamagata lineage strain, specifically the 
influenza B component from the 2012–2013 IIV3 (B/Texas/6/2011, abbreviated as 
‘Yama B/TX11’). The fraction of antibody clonotypes detected in the eluate from Vic 
B/BR08 enrichment and also in the eluate with immobilized Yama B/TX11, designated 
as ‘Vic + Yama cross-reactive’, comprised 95.8%, 86.6% and 83.9% of the anti-influenza 
B serum repertoires at days 0, 28 and 180, respectively (Figure 2.18). Our data show that 
most of the serum antibodies elicited by vaccination with Vic B/BR08 also bind to Yama 
B/TX11. This finding raises the question of whether vaccination with the new IIV4 can 




Figure 2.18: Prevalence of Vic + Yama CR antibodies in serum. Average was calculated 
as the mean, with bars indicating s.e.m. (n = 3 for each group).   
 
DISCUSSION 
We used LC–MS/MS proteomic spectrotyping of antigen-specific antibodies (Ig-
seq) in combination with high-throughput sequencing of B cell transcripts (BCR-seq), to 
characterize, in a quantitative fashion, the serological repertoire to each of the 
monovalent components of the IIV3 influenza vaccine and how the serological repertoire 
changes before and after immunization. Although we analyzed a relatively small cohort 
because of limitations imposed by the labor involved and the LC–MS/MS instrument 
time requirements, our data reveal a number of findings that could not have been inferred 
from classical serology assays (i.e., ELISA and HAI titers) or from peripheral B cell 
cloning or sequencing. This is because bulk serological analysis cannot provide 
information on the properties or the persistence of the constituent individual antibodies. 
Similarly, the peripheral B cell repertoire cannot be used to infer the serological antibody 
repertoire because: (i) the former is much more diverse than the latter; (ii) at steady-state, 
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serological memory arises from antibodies produced by bone marrow plasma cells and 
not by peripheral B cells; (iii) blood samples capture a tiny fraction of the diversity of the 
peripheral B cell repertoire; and finally (iv) a clear negative correlation has been 
demonstrated between pre-existing serum antibody levels and the breadth of the B cell 
response, which is further correlated with age (or immune history) [114], an 
‘immunologic paradox’ recognized a half-century ago [115]. 
It has been known for many years that influenza-specific antibody response after 
vaccination is shaped by pre-exposure history [83, 92, 113, 116]. However, what could 
not be evaluated from bulk serological studies is the relative contribution of pre-existing 
circulating antibodies that are boosted by vaccination relative to that of the new, vaccine-
elicited antibodies. We now show that a substantial portion (on average ~60% across all 
IIV1 repertories in our cohorts as shown in Figure 2.7) of the serum response to influenza 
is due to the boosting effect of pre-existing antibody clonotypes. The fraction of the 
serum response that arises from the boosting of pre-existing antibodies and, conversely, 
the clonotypic diversity of ‘new’, or vaccine-elicited, antibodies are strongly correlated 
with the serum titer before vaccination. In other words, high serum titer before 
vaccination results in a more dominant boost effect of pre-existing antibodies and the 
emergence of fewer vaccine-elicited antibodies, and vice versa. 
In the analysis of the serological repertoire to the group 1 and 2 monovalent 
vaccine strains in IIV3, we found an unexpectedly high prevalence of antibody 
clonotypes that were detected in both of the respective affinity chromatography eluates. 
The unexpectedly large fraction of H1 + H3 cross-reactive antibodies that was detected 
by LC–MS/MS could not have been inferred by classical serology metrics. Similarly, a 
high frequency of H1 + H3 antibodies had not been noted in previous analyses of 
peripheral B cells. There are several possible explanations for this. Single-cell cloning 
 59 
typically involves the analysis of small samples of peripheral B cells, and therefore, 
plasmablasts or memory B cells that bind to H1 + H3 could have been missed. 
Additionally, the emphasis of B cell analysis studies has been on neutralization, which 
means that H1 + H3 cross-reactive antibodies that show little or no potency in 
neutralization assays could have been overlooked. An additional reason may be the 
kinetics of expansion of the memory B cells encoding these antibodies. 
Finally, a very large fraction of the serum antibody repertoire elicited by 
immunization with a Victoria strain reacts with the following year’s Yamagata strain. 
The data underscore the need for further serological and epidemiological studies to define 
the efficacy benefit that might be expected as the current IIV3 is being replaced with 
IIV4. 
In summary, clonal-level analysis of the serological antibody repertoire revealed a 
wealth of unanticipated aspects of the response to the seasonal influenza vaccine. 
Because humans are repeatedly exposed to influenza, the serological repertoire becomes 
skewed towards antibodies that target epitopes conserved among vaccine strains, and 
these cross-reactive antibodies likely continue to be boosted every time the same 
conserved epitopes are encountered in the seasonal vaccine. A key to the universal 
influenza vaccine will be the design of immunogens that can elicit broadly protective 
antibodies that bind to a variety of different strains and subtypes and also provide long-
term protection. Characterization of representative antibodies identified from sera would 
enhance our understanding of the serum response to the vaccination, which in turn could 
help engineer better immunogens. 
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Chapter 3: Recombinant Characterization of Abundant Antibodies 
Identified in Sera of Young Adults Following Influenza Vaccination 
 
This chapter is reproduced with some modifications from its initial publication: 
Lee, J. Boutz, D.R., Chromikova, V., Joyce, M.G., Vollmers, C., Leung, K., Horton, A.P., 
DeKosky, B.J., Lee, C.-H., Lavinder, J.J., Murrin, E.M., Chrysostomou, C., Hoi, K.H., 
Tsybovsky, Y., Thomas, P.V., Druz, A., Zhang, B., Zhang, Y., Wang, L., Kong, W.-P., 
Park, D., Popova, L.I., Dekker, C.L., Davis, M.M., Carter, C.E., Ross, T.M., Ellington, 
A.D., Wilson, P.C., Marcotte, E.M., Mascola, J.R., Ippolito, G.C., Krammer, F., Quake, 
S.R., Kwong, P.D., and Georgiou, G. Molecular-level analysis of the serum antibody 
repertoire in young adults before and after seasonal influenza vaccination. Nat. Med. 
http://dx.doi.org/10.1038/ nm.4224 (2016). 
 
INTRODUCTION 
Influenza is a respiratory disease which causes over 5 million cases of severe 
illness and approximately half a million deaths globally [4]. While the most effective 
means currently available for controlling infection is vaccination, its efficacy remains 
limited even after almost eight decades of being in use [3, 27]. Vaccine-induced 
protection against influenza is conferred mainly through the adaptive immune system, 
which relies on the stimulation of B cells to produce a diverse repertoire of antibodies 
specific for hemagglutinin (HA) for an extended period of time. There are two groups of 
influenza A virus, groups 1 and 2, comprised of 18 different HA subtypes, and two 
lineages of influenza B virus, Victoria and Yamagata. In order to develop the next 
generation of influenza vaccines with higher and broader protective efficacy, 
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understanding the detailed features of the antibody response to the flu vaccine is of 
paramount significance.  
Over the last couple of decades, studies involving cloning and characterization of 
antibodies from peripheral B cells has expanded our knowledge of key mechanisms for 
antibody-mediated neutralization of the virus [70, 72, 73, 81, 88, 90, 108]. Early studies 
focused on antibodies that can disrupt binding between the receptor-binding site (RBS) of 
HA and its target cell receptor. Hemagglutination inhibition (HAI) assay measures this 
ability of antibodies, and discovery of several RBS-targeting antibodies capable of 
neutralizing multiple strains of influenza A viruses belonging to group 1 or group 2, such 
as CH65 [73] and C05 [74], led to interest in developing vaccines that will elicit such 
antibodies that target the conserved receptor-binding regions. Later, several studies 
discovered that influenza can also be neutralized by other mechanisms by binding to the 
conserved stem region of HA [43, 81, 91], and notably one antibody, FI6 [70], 
neutralized virus by interfering with fusion between the virus and the host endosomal 
membranes after endocytosis of the virus. Because the stem regions are highly conserved 
across both groups 1 and 2, such stem-binding antibodies can target both group 1 and 2 
influenza A viruses, making them broadly neutralizing antibodies (bNAbs). Recent 
studies examining peripheral B cells have shown that stem-binding bNAbs are rarely 
elicited following seasonal vaccination [72, 79, 117], although they have been detected at 
increased frequencies in individuals who were infected or vaccinated with divergent 
strains, such as H5N1 or the 2009 pandemic H1N1 strain [75, 91, 118-120]. For that 
reason, vaccination strategies aimed at increasing anti-stem, neutralizing responses are 
currently at the forefront of the quest for a universal influenza vaccine [84-86]. 
In the previous chapter, we directly analyzed the sera of four young adults 
following seasonal vaccination and determined the identities of influenza-specific 
 62 
antibodies and their relative abundances. In order to better understand the serum response, 
it is essential to characterize the functions of constituent antibodies. Of the four donors 
analyzed in Chapter 2, donors 1 and 2 were selected for further analysis where we 
recombinantly expressed highly prevalent antibodies in sera and examined the functions 
of the antibodies.   
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MATERIALS AND METHODS 
 
Reagents 
Individual IIV1s comprising the 2011–2012 FluZone IIV3 (H1N1 
A/California/07/2009 X-179A, H3N2 A/Victoria/210/2009 X-187 and 
B/Brisbane/60/2008), as well as the influenza B component of the 2012–2013 FluZone 
IIV3 (B/Texas/6/2011), were obtained from Sanofi-Pasteur. The following reagents was 
obtained through BEI Resources, NIAID, NIH: H1 Hemagglutinin (HA) Protein with C-
Terminal Histidine Tag from Influenza Virus, A/Puerto Rico/8/1934 (H1N1), 
Recombinant from Baculovirus, NR-19240; H1 Hemagglutinin (HA) Protein from 
Influenza Virus, A/Brisbane/59/2007 (H1N1), Recombinant from Baculovirus, NR-
15267; H1 Hemagglutinin (HA) Protein with C-Terminal Histidine Tag from Influenza 
Virus, A/New York/18/2009, Recombinant from Baculovirus, NR-19441; H2 
Hemagglutinin (HA) Protein from Influenza Virus, A/Singapore/1/1957 (H2N2), 
Recombinant from Baculovirus, NR-2668; H5 Hemagglutinin (HA) Protein from 
Influenza Virus, A/Vietnam/1203/2004 (H5N1), Recombinant from Baculovirus, NR-
10510; H9 Hemagglutinin (HA) Protein from Influenza Virus, A/Hong Kong/1073/1999 
(H9N2), Recombinant from baculovirus, NR-654; H3 Hemagglutinin (HA) Protein with 
C-Terminal Histidine Tag from Influenza Virus, A/Perth/16/2009 (H3N2), Recombinant 
from Baculovirus, NR-42974; H3 Hemagglutinin (HA) Protein from Influenza Virus, 
A/New York/55/2004 (H3N2), Recombinant from Baculovirus, NR-19241; H3 
Hemagglutinin (HA) Protein from Influenza Virus, A/Wisconsin/67/2005 (H3N2), 
Recombinant from Baculovirus, NR-15171; H3 Hemagglutinin (HA) Protein from 
Influenza Virus, A/Brisbane/10/2007 (H3N2), Recombinant from Baculovirus, NR-
19238; H3 Hemagglutinin (HA) Protein from Influenza Virus, A/Uruguay/716/2007 
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(H3N2), Recombinant from Baculovirus, NR-15168; H7 Hemagglutinin (HA) Protein 
from Influenza Virus, A/Netherlands/219/2003 (H7N7), Recombinant from Baculovirus, 
NR-2633; H7 Hemagglutinin (HA) Protein from Influenza Virus, A/Anhui/1/2013 
(H7N9), Recombinant from Baculovirus, NR-45118; Hemagglutinin (HA) Protein from 
Influenza Virus, B/Brisbane/60/2008, Recombinant from Baculovirus, NR-19239; 
Hemagglutinin (HA) Protein from Influenza Virus, B/Malaysia/2506/2004, Recombinant 
from Baculovirus, NR-15172; Hemagglutinin (HA) Protein from Influenza Virus, 
B/Ohio/1/2005, Recombinant from Baculovirus, NR-19243; Hemagglutinin (HA) Protein 
from Influenza Virus, B/Jilin/20/2003, Recombinant from Baculovirus, NR-19242; 
Hemagglutinin (HA) Protein from Influenza Virus, B/Florida/4/2006, Recombinant from 
Baculovirus, NR-15169; N1 Neuraminidase (NA) Protein with N-Terminal Histidine Tag 
from Influenza Virus, A/California/04/2009 (H1N1)pdm09, Recombinant from 
Baculovirus, NR-19234. A/California/7/2009-X181 and A/Solomon Islands/3/2006 rHAs 
were provided by Dr. Stephen Harrison (Harvard Medical School). 
 
VH:VL Paired Sequencing 
Paired heavy and light chain sequencing of single B cells from donor 1 day 7 and 
donor 2 day 7 samples was carried out as previously described [94, 121]. Briefly, B cells 
were isolated as single cells inside emulsion droplets using a custom flow-focusing 
apparatus. Droplets contained lysis buffer and poly(dT)-conjugated magnetic beads, as 
well as lysis buffer to capture mRNAs generated by genes encoding heavy and light chain 
molecules. Magnetic beads were collected and emulsified to serve as template for 
emulsion overlap extension RT–PCR. A follow-up nested PCR generated 850-bp linked 
VH:VL amplicons that were sequenced using the Illumina MiSeq platform. VH and VL 
regions were amplified separately for full-length VH and VL analysis for the recombinant 
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expression of monoclonal antibodies using the Illumina MiSeq platform as previously 
described [42, 102]. 
 
Recombinant Antibody Synthesis, Expression and Purification 
Selection of antibody sequences for recombinant expression was based on the 
combination of VH:VL-paired databases and proteomics data. First, we identified antibody 
clonotypes identified in the proteomics analysis and searched for the same clonotype in 
the VH:VL-paired database. Full-length heavy- and light-chain-encoding sequences were 
then determined from the paired sequencing database. 
For two of the recombinantly expressed antibodies (D1 H1-1/H3-1 and D1 H1-
6/H3-2), their sequences were not found in the VH:VL paired database; thus their 
corresponding light chains were screened in phage as previously described [98]. Briefly, 
κ and  light chain libraries were constructed for each heavy chain by amplifying VL 
sequences from cDNA of day 7 PBMCs. Individual clones from the libraries were 
screened on Costar 96-well ELISA plates (Corning) coated with IIV1s, and wells with 
signals were sequenced to identify the light chain sequences. From each screening, 
multiple light chains were identified; they shared the same IGKV and IGKJ genes, and 
had homologous CDR-L3 sequences, indicating that they are likely similar to the 
endogenously paired VL. 
These genes were purchased as gBlocks (Integrated DNA Technologies) and 
cloned into the pcDNA3.4 vector (Invitrogen). Heavy- and light-chain-encoding plasmids 
for each monoclonal antibody were transfected into Expi293 cells (Invitrogen) at a 1:3 
ratio. After incubating for 5 d at 37 °C with 8% CO2, the supernatant containing the 
secreted antibodies was collected by centrifugation at 500g for 15 min at RT. The 
supernatant was passed over a column with 0.5 ml Protein A agarose resin (Thermo 
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Scientific) three times to ensure efficient capture. After washing the column with 20 cv of 
PBS, antibodies were eluted with 3 ml 100 mM glycine-HCl, pH 2.7, and immediately 
neutralized with 1 ml 1 M Tris-HCl, pH 8.0. Antibodies were buffer-exchanged into PBS 
using Amicon Ultra-30 centrifugal spin columns (Millipore). 
 
ELISAs 
EC50 values based on ELISA were used to determine the apparent affinities of the 
recombinant antibodies. First, costar 96-well ELISA plates (Corning) were coated 
overnight at 4 °C with 4 μg/ml IIV1 or rHAs and washed and blocked with 2% milk in 
PBS for 2 h at RT. After blocking, serially diluted recombinant antibodies were bound to 
the plates for 1 h, followed by 1:5000-diluted goat anti-human-IgG Fc horseradish 
peroxidase (HRP)-conjugated secondary antibodies (Jackson ImmunoResearch; 109-035-
008) for 1 h. For detection, 50 μl TMB-ultra substrate (Thermo Scientific) was added 
before quenching with 50 μl 1 M H2SO4. Absorbance was measured at 450 nm using a 
Tecan M200 plate reader. Data were analyzed and fitted for EC50 using a 4-parameter 
logistic nonlinear regression model in the GraphPad Prism software. All ELISA assays 
were performed in triplicate. 
 
Surface Plasmon Resonance 
To determine the affinities of the influenza-specific recombinant antibodies 
toward the rHAs, Biacore 3000 instrument (GE Healthcare) was used. Bovine serum 
albumin (BSA) was immobilized in reference channels of the CM5 sensor chip to 
subtract buffer effect and non-specific binding signal, and the rHAs were immobilized in 
separate channels by amine-coupling at pH 5.5. All SPR measurements were performed 
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in HBS-EP running buffer (10 mM HEPES, pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% 
v/v surfactant P20; GE Healthcare). The serial diluted antibodies (400–12.5 nM) were 
injected in triplicates at 30 μl/min for 2 min, followed by a dissociation time of 10 min. 
The chip was regenerated after each binding event with 10 mM NaOH or 50 mM Tris, 
pH 11, with a contact time of 1 min. The resulting sensorgrams were fit with a bivalent 
model using Biaevaluation 3.0 software and the kinetic parameters were reported as the 
average of the three technical replicates.  
In order to compare the binding epitopes of monoclonal antibodies, the antibodies 
in Na-acetate, pH 5.0 were immobilized on the CM5 sensor chips surface to a surface 
density of ~1,000 Response Units (RUs) by amine coupling. rHA at 100 μg/ml in HBS-
EP were flowed over the immobilized-antibody surface at a flow rate of 30 μl/min for 2 
min and, without the dissociation phase, each monoclonal antibody (at 100 μg/ml in 
HBS-EP) tested was immediately injected over the surface at 30 μl/min for 2 min. 
Between cycles, the flow cells were regenerated with 10 mM NaOH with a contact time 
of 1 min. 
 
Binding Studies Using Biolayer Interferometry 
A fortéBio Octet Red384 instrument was used to measure binding of H1+H3 CR 
antibodies (D1 H1-3/H3-3 and D1 H1-17/H3-18) to Influenza HA (full-length, RBD 
domain constructs, stem-only constructs). All the assays were performed with agitation 
set to 1,000 rpm in PBS buffer supplemented with 1% bovine serum albumin (BSA) in 
order to minimize nonspecific interactions. The final volume for all the solutions was 100 
μl/well. Assays were performed at 30 °C in solid black 96-well plates (Geiger Bio-One). 
HA molecules (35 μg/ml) in PBS buffer was used to load anti-penta His probes for 300 s. 
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Typical capture levels were ~1 nm, and variability within a row of eight tips did not 
exceed 0.1 nm. Antibody binding was allowed to proceed for 300 s and normalized to a 
control antibody (5J8 for RBD, 39.29 for HA stem and full-length HA). Measurements 
were carried out in triplicate.  
Antibody competition assays were carried out by first loading the HA molecule 
onto the probe for 300 s, followed by binding the competing antibodies (39.29, 5J8, or 
F005-126) for 300s. These loaded HA-IgG complexes were then allowed to bind to 
H1+H3 CR antibodies (D1 H1-3/H3-3 and D1 H1-17/H3-18) for 300 s. Competition was 
determined by comparison of H1+H3 CR antibody binding to uncomplexed HA 
molecules. Data analysis was carried out using Octet software, version 8.0.  
 
Hemagglutination Inhibition Assay 
Recombinantly expressed monoclonal antibodies were two-fold serially diluted in 
v-bottom microtiter plates. An equal volume of each influenza virus strains 
(A/California/07/2009, A/Perth/16/2009 and B/Brisbane/60/2008), adjusted to 
approximately 8 HAU/50 μl, was added to each well. The plates were covered and 
incubated at RT for 20 min followed by the addition of 1% turkey erythrocytes (RBC; 
Lampire Biologicals, Pipersville, PA, USA) in PBS. Red blood cells were stored at 4 °C 
and used within 72 h of preparation. The plates were mixed by agitation, covered, and the 
RBCs were allowed to settle for 1 h at RT. The HAI titer was determined by the 
reciprocal dilution of the last well that contained non-agglutinated RBC. Positive and 
negative serum controls were included for each plate. 
 
 69 
Production of Pseudotyped Lentiviral Vectors and Measurement of Neutralizing 
Activity of Immune Sera and Monoclonal Antibodies 
Influenza pseudotyped lentiviral vectors expressing a luciferase reporter gene 
were produced as described [122]. Briefly, the following plasmids: 17.5 g of 
pCMV∆R8.2, 17.5 g of pHRCMV-Luc, 60 ng of pCMV Sport/h TMPRSS2, 1 g 
CMV/R-HA and 0.125 g of corresponding CMV/R-NA of a given strain of influenza 
virus, were transiently cotransfected into 293T cells by use of Fugene6 (Promega). Cells 
were transfected overnight and replenished with fresh medium. 48 h later, supernatants 
were harvested, filtered through a 0.45-m PES membrane filter, aliquoted, and frozen at 
–80 °C. 
For neutralization assays, recombinantly expressed monoclonal antibodies at 
various dilutions were mixed with 50 l of pseudoviruses and then added to 293A cells in 
96-well plates (10,000 cells per well). 48 h later, cells were lysed in cell culture lysis 
buffer (Promega, Madison, WI) before mixing with luciferase assay reagent (Promega). 
Light intensity was quantified with a Perkin Elmer microplate reader, and antibody 
neutralization resulted in lower light intensity. 
 
Plaque Reduction Assay 
Monolayers of MDCK cells in 6-well plates were infected with 100 pfu of 
influenza virus in 100 μl of DMEM in presence or without tested monoclonal antibodies 
and incubated for 1 h at 37 °C. The inoculum was removed from the cells and cells were 
washed with PBS buffer. DMEM supplemented with 1% agar and 1 μg/ml TPCK-trypsin 
was added to each well. After 48 h of incubation at 37 °C cells were fixed with 4% 
formaldehyde, the agar plugs removed and the cells stained with 0.1% crystal violet to 
estimate the titer of virus in presence and without neutralizing antibodies. Concentration 
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of tested antibodies with fifty percent of viral titer reduction is considered as IC50 (μg/ml) 
and performed in three independent experiments. 
 
Testing of Binding of H1 + H3 Cross-reactive Antibodies to Infected Cells Using 
Flow Cytometry 
MDCK cells plated in 6-well plate format (approx. 9×10
5
 cells/well) were 
infected with pandemic H1N1 strain A/Netherlands/602/09 (NL09) at MOI of 1. They 
were incubated for 17 h at 37 °C before being trypsinized and fixed with 70% EtOH. 
Tested monoclonal antibodies were added at 5 μg/ml, incubated for 1 hr and detected 
with 1:1000-diluted goat anti-human IgG-Alexa-488 (Life Technologies; A11013) using 
flow cytometry. 50,000 events/sample were collected. 
 
IgG Passive Transfer and Protection to Influenza Virus Challenge in Mouse Model 
For passive transfer experiments, mice were randomized into groups of 5, and 
animal groups were not blinded to the investigators. Sample size was based on previous 
experience with similar experimental set-ups for antibody passive transfer influenza virus 
challenge experiments that used the same virus strains and challenge doses. Female 6- to 
8-week-old BALB/c mice (n = 5 per group) were intraperitoneally injected with 
monoclonal antibodies diluted in PBS. Two hours post transfer mice were anesthetized 
with a ketamin/xylazine mixture (0.15 mg/kg and 0.03 mg/kg) and intranasally infected 
with ten murine lethal doses of the respective challenge virus in 50 l of PBS. Weight 
loss and survival were monitored over a period of 14 d, and animals that crossed the 
humane end point of 75% of the initial body weight were euthanized. Initially, 
monoclonal antibodies D1 H1-1/H3-1, D1 H1-9/H3-7, D1 H1-3/H3-3, D1 H1-17/H3-18 
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and D2 H1-1/H3-1 were tested at 5 mg/kg for protection against the pandemic H1N1 
strain A/Netherlands/602/09 (NL09). D1 H1-3/H3-3, D1 H1-17/H3-18 and D2 H1-1/H3-
1 were also tested at lower doses (1 mg/kg and 0.5 mg/kg) against NL09. The protective 
breadth of these three mAbs was tested at 5 mg/kg against H3N2 strain X-31 (HA and 
NA from A/Hong Kong/1/68 and backbone of A/PR/8/34). The lung viral titers of mice 
(n = 3 per group) that were prophylactically treated with D1 H1-3/H3-3 and D1 H1-
17/H3-18 2 h before an infection with NL09 were analyzed. Lungs were harvested on day 
3 and day 6 after infection, homogenized and used for plaque assays. 
In therapeutic-setting protection experiments, female 6- to 8-week-old BALB/c 
mice (n = 10 per group) were challenged first with NL09 and then received D1 H1-3/H3-
3 and D1 H1-17/H3-18 monoclonal antibodies diluted in PBS, 24 and 48 h post infection 
(h.p.i.) at 5 mg/kg. 
In all cases, irrelevant human IgG1 was used as negative control and bNAb 
CR9114 served as positive control. All animal experiments complied with the guidelines 
and protocols approved by the Icahn School of Medicine at Mount Sinai Institutional 
Animal Care and Use Committee. 
 
Electron Microscopy and Single Particle Analysis 
For the initial analysis and screening of HA/Fab mixtures, protein samples diluted 
to approximately 0.05 mg/ml were adsorbed to glow-discharged carbon-coated copper 
grids, washed with several drops of buffer containing 20 mM HEPES, pH 7.0, and 150 
mM NaCl, and negatively stained with 0.75% uranyl formate, pH 5.0. Micrographs were 
recorded at a magnification of 100,000 on a FEI Tecnai T20 microscope operated at 200 
kV and equipped with a 2k×2k Eagle CCD camera. The pixel size was 2.22 Å/px. 
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SerialEM [123] was used for data collection. Particles were picked using EMAN2.1 [124] 
automatically or manually. Particle alignment and reference-free classification were 
carried out in EMAN2 and SPIDER [125]. 
The initial analysis revealed that a subset of HA/Fab combinations contained 
highly heterogeneous mixtures of aggregates, free HA trimers and Fab fragments, 
partially unfolded HA trimers and dimers with varying numbers of Fab fragments bound, 
HA dimers and monomers, and, as a major component, the complex between a monomer 
of HA and a single Fab fragment (Figure 3.12a). Analysis of a dataset containing 
approximately 12,000 particles revealed that the latter complex was represented by about 
50% of all particles and had a strong preferential orientation, with well-defined Fab 
fragments and head moieties of the HA and less well-defined membrane proximal regions 
(“tails”). The random conical tilt (RCT) approach [126] was utilized to obtain the three-
dimensional map of the complex. Grids were prepared as described above, except that the 
sample was supplemented with tobacco mosaic virus to simplify alignment of untilted 
and tilted micrographs. To accelerate data collection, 5×5 to 7×7 montages of untilted 
and 45°-tilted images from same areas of the grid were obtained using SerialEM. All 
further analyses were performed with SPIDER. Montages were aligned automatically and 
pairs of untilted/tilted images were formed using a custom written script. 4,843 pairs of 
particles consistent in size with the HA monomer/single Fab complex were picked and 
centered manually with JWeb [125]. Reference-free classification of the particles from 
untilted micrographs windowed into 128×128 boxes into 20 classes revealed that at least 
3,351 of them (9 classes) represented the complex (Figure 3.12b). The tilted particles 
corresponding to each 2D class were grouped, rotationally aligned, and used to compute 
three-dimensional reconstructions, which were then inspected in USCF Chimera [127], 
aligned, and merged. The resulting map was subjected to translational refinement, 
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yielding the RCT map of the complex (Figure 3.12c). This map was then used as the 
initial model for three-dimensional reconstruction and refinement using reference 
projections [128]. Particles from both the untilted and tilted micrographs were used for 
the refinement. No contrast transfer function (CTF) correction was performed. The 
“resolution” (level of self-consistency) of the final map was 22 Å when a Fourier shell 
correlation (FSC) threshold of 0.5 was used. Forward projections of the map 
corresponded well to two-dimensional classes (Figure 3.12d). The level of the map was 
chosen based on fitting a Fab domain into the corresponding density. The map was 






Recombinant Expression of Serum Antibodies 
The proteomics-based identification of serum antibodies in Chapter 2 only 
determines the heavy chain (VH) sequences. In order to acquire the endogenous light 
chain (VL) information for the identified heavy chains, we used day 7 peripheral B cells 
from donors 1 and 2 to pair the transcripts of VH and VL from a single cell, and 
subsequently perform high-throughput sequencing. Using the proteomics data and the 
paired VH:VL sequence database, we recombinantly expressed 16 monoclonal antibodies 
for further biochemical and functional characterizations (Figure 3.1). Additionally, for 
two H1 + H3 cross-reactive antibodies for which the VL sequence was not found in the 
paired VH:VL database, cognate light chains were identified by screening antigen-binding 
fragment (Fab)-encoding libraries constructed using the proteomically identified VH 
combinatorially paired with VL-encoding cDNA from day 7 B cells. For both VH libraries, 
we isolated multiple VL sequences with very similar CDR-L3 sequences with the same 
immunoglobulin kappa light chain variable and junctional genes (IGKV and IGKJ), 
suggesting that screening had converged onto a light chain that is likely to be clonally 




Figure 3.1: Experimental design. Day 7 peripheral B cells were used for sequencing the 
paired heavy and light chain (VH:VL) repertoire. Proteomics data and the 
VH:VL database were used to determine the full-length antibody sequences 
for recombinant expression, and these antibodies were characterized further.  
 
Functional Characterization of H1 + H3 Cross-reactive Antibodies 
We selected seven H1 + H3 cross-reactive antibodies (including some of the most 
abundant ones) from donors 1 and 2 for recombinant expression and subsequent 
characterization (Table 3.1). Seven of seven H1 + H3 cross-reactive antibodies we 
identified proteomically bound to both IIV1s. Furthermore, five of seven H1 + H3 cross-
reactive antibodies had exceptional binding breadth toward a diverse panel of 
recombinantly expressed HAs (rHAs) from influenza groups 1 and 2, with 50% effective 
concentration (EC50) values <100 nM, as assessed by ELISA (and apparent KD values 
between 2.5 pM and 160 nM, on the basis of surface plasmon resonance analysis (Figures 
3.2 and 3.3, and Table 3.2). One additional antibody isolated from donor 1 (D1 H3-11), 
which was originally identified only in the H3 A/VI09 eluate, also bound to rHAs from 
groups 1 and 2; however, because it bound to H1 A/CA09 (IIV1) with such low affinity, 
it was not detected in the H1 A/CA09 eluate. 
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Table 3.1: CDR-3 sequences, lengths, somatic hypermutation rates (SHM) and gene 
usages of the recombinantly expressed H1 + H3 cross-reactive serum 
antibodies. For each antibodies, heavy (VH) and light (VL) chain information 














 AKEDSSGYPTRRPVDY 16 4.5% IGHV3-9, IGHJ4 
V
L






 ARHFQERLGAARAGAFDV 18 5.4% IGHV4-34, IGHJ3 
V
L






 ARDFFEKLTGEDLNAFDV 18 1.7% IGHV4-61, IGHJ3 
V
L






 ARPSYTSGFAFDP 13 22.3% IGHV1-69, IGHJ5 
V
L






 ARASIRSRPQFFDF 14 3.5% IGHV5-51, IGHJ4 
V
L






 ARDFFEKLIADDLNAFDI 18 7.9% IGHV4-61, IGHJ3 
V
L






 ARRFVELLGGRSKPYDALDV 20 5.6% IGHV3-7, IGHJ3 
V
L






 ARELPGNWFDT 11 6.2% IGHV4-30, IGHJ5 
V
L






Figure 3.2: Biochemical and functional analysis of the recombinantly expressed H1 + 
H3 CR serum antibodies. Recombinant monoclonal antibody ID (rmAb ID) 
indicates the donor information, as well as the abundance rankings of the 
antibody at day 28 in respective repertoire (i.e., D1 H1-1/H3-1 indicates that 
this antibody is from donor 1 and ranked first in abundance in the anti–H1 
A/CA09 repertoire and first in the anti–H3 A/VI09 repertoire). EC50 values, 
as determined by ELISA, for each recombinant antibody tested against 
IIV1s or rHAs as listed are shown according to the color scheme included. 
A/California/7/2009 (CA09) and A/Perth/16/2009 (PE09) strains were used 




Figure 3.3: Surface plasmon resonance data for recombinant IgG binding to rHAs. 
Recombinant HAs were immobilized on CM5 sensor chips. Various 
concentrations of the recombinant monoclonal antibodies were tested (400, 
200, 100, 50, 25, and 12.5 nM). H1, rHA from A/California/07/2009 X-181; 
H3, rHA from A/Perth/16/2009. 
 
Table 3.2: Kd values (nM) of monoclonal antibodies to rHAs measured by surface 
plasmon resonance. Averages are calculated as mean with error-bars 
indicating s.d., replicated in triplicate. H1, rHA from A/California/07/2009 
X-181; H3, rHA from A/Perth/16/2009. 
Donor rmAb ID H1 H3 Vic 
1 H3-11 0.62 ± 0.09 56 ± 2 >200 
1 H1-1/H3-1 0.79 ± 0.08 79 ± 10 >200 
1 H1-3/H3-3 0.028 ± 0.004 0.098 ± 0.01 >200 
1 H1-17/H3-18 0.54 ± 0.07 0.75 ± 0.09 >200 
2 H1-1/H3-1 3.8 ± 1 160 ± 3 >200 
2 H1-27/H3-42 0.0025 ± 0.0009 24 ± 14 >200 
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Two antibodies, D1 H1-6/H3-2 and D1 H1-9/H3-7, bound only to the H1 A/CA09 
and H3 A/VI09 monovalent vaccines, but not to the respective rHAs. Consistent with this 
finding, these two antibodies were detected in the proteomic analysis of the affinity 
chromatography eluate with H1 A/CA09 but not with rHA A/California/07/2009 X-181 
(previously described in Chapter 2). These antibodies did not bind to neuraminidase, 
gelatin or other constituents of the monovalent vaccines. Notably, D1 H1-9/H3-7 
neutralized group 1 and group 2 strains in pseudotyped particle-entry inhibition (PVN) 
assays with pandemic influenza A/California/07/2009 (H1N1) and A/Perth/16/2009 
(H3N2) strains, and it bound to HA on the surface of infected Madin-Darby canine 
kidney (MDCK) cells (Figures 3.3, 3.4 and 3.5). We concluded that D1 H1-9/H3-7 
recognizes an epitope that is present in the conformation HA assumes on the surface of 
infected cells but is inaccessible in purified rHA. 
 
 
Figure 3.4: Binding of H1 + H3 CR antibodies to the HAs on the surface of the MDCKs 
infected with the 2009 pandemic H1N1 strain (A/Netherlands/602/09; 
NL09), as analyzed by FACS. 50,000 events/sample were collected. 
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Figure 3.5: FACS analysis of monoclonal antibodies binding to influenza infected 
MDCKs. First, a relatively homogeneous cell population was selected in 
Gate 1. Gate 1 was applied to the second dot plot, where the Gate 2 was 
created to select for singlets and this was then applied to third dot blot, 
where the x axis represents the mean fluorescence intensity (MFI) after 




Although none of the eight H1 + H3 cross-reactive antibodies showed HAI 
activity, four of eight antibodies showed neutralization activity in PVN assays (Figure 3.2, 
top panel). Two of these (D1 H1-1/H3-1 and D1 H3-11) competed with the stem-binding 
bNAb FI6 [70] (Figure 3.6). One of these stem-binding H1 + H3 cross-reactive 
antibodies was prevalent in the serum of donor 1 as D1 H1-1/H3-1 accounted for 14.2% 
and 14.9% of the H1 A/CA09 and H3 A/VI09 repertoires at day 28, respectively. D1 H1-
1/H3-1 in particular neutralized numerous influenza virus strains in PVN assays (Table 
3.3). However, both antibodies had very weak or no activity in the more physiologically 
relevant plaque reduction assays (Table 3.4) and, notably, did not confer protection 
against infection with the H1N1 virus strain in lethal-challenge experiments in mice when 
administered at 5 mg per kg body weight (mg/kg) (Figure 3.7a). 
 
 
Figure 3.6: Epitope-blocking assay for the neutralizing H1 + H3 cross-reactive 
antibodies. FI6 was immobilized on a CM5 sensor chip, and recombinant 
H1 (A/California/7/2009 X-181) was bound to the immobilized FI6 before 
testing for binding of the monoclonal antibodies. Head-targeting antibody, 
D1 H1-12, and H1-only were used as controls. D1 H1-1/H3-1 and D1 H3-11 
antibodies showed competition for binding epitope with FI6. The 
experiments were repeated in triplicate. 
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Table 3.3: IC50 (μg/ml) of the D1 H1-1/H3-1 on PVN assays against the listed 
influenza strains. 1: A/South Carolina/1/1918, 2: A/Puerto Rico/8/1934, 3: 
A/New Caledonia/20/1999, 4: A/Singapore/1/1957, 5: A/Canada/720/2005, 
6: A/Vietnam/1203/2004, 7: A/Indonesia/05/2005, 8: A/Hong 
Kong/1073/1999, 9: A/Hong Kong/1/1968, 10: A/Netherlands/219/2003, 11: 
A/Anhui/1/2013). 
Group 1 Group 2 
H1 H2 H5 H9 H3 H7 
1 2 3 4 5 6 7 8 9 10 11 
3.00 4.25 1.88 >50 >50 0.435 3.59 0.465 5.90 5.08 0.917 
 
Table 3.4: IC50 (μg/ml) of recombinant monoclonal antibodies with H1N1 
A/California/07/09 and H3N2 A/Perth/16/09 viruses determined from 
plaque reduction assays performed in three independent experiments. 
 Virus strains 
Antibodies tested H1N1 A/California/07/09 H3N2 A/Perth/16/09 
D1 H1-1/H3-1 >100 >100 
D1 H1-9/H3-7 100 >100 
D1 H3-11 >100 100 
D1 H1-3/H3-3 >100 >100 
D1 H1-6/H3-2 >100 N/A 
D1 H1-17/H3-18 >100 >100 




Figure 3.7: Protective efficacy of the H1 + H3 cross-reactive antibodies in mice. (a) 
Survival data (Kaplan–Meier plots) (top) and weight loss data (bottom) for 
BALB/c mice (n = 5 per group) after passive immunization (5 mg/kg) with 
H1 + H3 CR antibodies followed by challenge with NL09. (b) Survival (top) 
and weight loss (bottom) data for BALB/c mice (n = 5 per group) after 
passive immunization (5 mg/kg) with the protective antibodies from a 
followed by challenge with H3N2 strain X-31 (A/Hong Kong/1/68 in the 
backbone of A/PR/8/34). (c) Survival (top) and weight loss (bottom) data 
for BALB/c mice (n = 10 per group) challenged with NL09, followed by 
therapeutic administration of with antibodies (5 mg/kg) at 48 h.p.i. For a–c, 
averages were calculated as mean, with error-bars indicating s.d. 
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The remaining four of eight H1 + H3 cross-reactive antibodies showed no 
neutralization activity in HAI, PVN or plaque reduction assays (Figure 3.2, bottom and 
Table 3.4). Three of these (D1 H1-3/H3-3, D1 H1-17/H3-18 and D2 H1-1/H3-1), which 
were highly abundant in both donors, competed with each other for binding to HA 
(Figure 3.8), indicating that they target either the same or overlapping epitopes. Of note, 
administration of these three antibodies at 5 mg/kg, and even at lower doses (1.0 and 0.5 
mg/kg), conferred excellent protection in mice that were challenged with the H1N1 strain 
(Figures 3.7a and 3.9) Furthermore, D1 H1-3/H3-3 and D1 H1-17/H3-18 also conferred 
100% protection (although transient weight loss was observed) in challenge experiments 
with the H3N2 strain (Figure 3.7b). Finally, treatment with D1 H1-3/H3-3 and D2 H1-
1/H3-1 both led to a reduction in viral titers in the lower lung, following H1N1 challenge, 
and also conferred protection when administered therapeutically 24 and 48 hours after 
infection with the H1N1 strain (Figures 3.7c and 3.10).  
 
 
Figure 3.8: Epitope-blocking assay for the non-neutralizing H1 + H3 cross-reactive 
antibodies. D1 H1-3/H3-3 was immobilized on a CM5 sensor chip, and H1 
was bound to the immobilized D1 H1-3/H3-3. Stem-biding antibody, FI6, 
and H1-only were used as controls. D1 H1-17/H3-18 and D2 H1-1/H3-1 
antibodies showed competition for binding epitope with D1 H1-3/H3-3. The 
experiments were repeated in triplicate. 
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Figure 3.9: Protection in mice challenged with H1N1 live influenza following passive 
immunization with low dose of select H1 + H3 cross-reactive, non-
neutralizing antibodies. Survival data for BALB/c mice (n = 5 per group) 
after passive immunization (intraperitoneally) followed by challenge with 
2009 pandemic H1N1 (A/Netherlands/602/09) 2 hours later and 
corresponding weight loss for (a) D1 H1-3/H3-3, (b) D1 H1-17/H3-18 and 
(c) D2 H1-1/H3-1. Each antibody was tested at 1 mg/kg and 0.5 mg/kg, and 
survival (left) and body weight loss (right) were monitored for 14 days. 




Figure 3.10: (a) Lung viral titers in mice (n = 3 per group) that had been passively 
immunized with monoclonal antibodies (5 mg/kg) followed by challenge 
with NL09. Lungs were harvested at days 3 and 6 after passive 
immunization. Lung viral titers were measured by plaque assay. (b) Post-
infection (therapeutic treatment) survival data. Survival and weight loss data 
for BALB/c mice (n = 10 per group) challenged with NL09 with antibody (5 
mg/kg) administered 24 h.p.i. Average calculated as mean, bars indicate s.d. 
 
Structural Characterization of H1 + H3 Cross-protective Antibodies 
To identify the epitope targeted by the three non-neutralizing yet in-vivo-
protective antibodies (D1 H1-3/H3-3, D1 H1-17/H3-18 and D2 H1-1/H3-1), we used 
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negative-staining electron microscopy (EM). We first tested the binding of these 
antibodies to multiple rHA proteins, as well as to smaller rHA domains, and although no 
binding was observed to a trimeric rHA stem molecule[84], strong binding was observed 
to the rHA RBS [129]. The antibodies bound to the full-length rHA molecule (A/Hong 
Kong/1-4-MA21-1/1968) but not to a disulfide-bonded covalent trimer version of the 
rHA (A/Hong Kong/1-4-MA21-1/1968 212Cys-216Cys) [130] (Figure 3.11a). When we 
mixed Fab fragments with the trimeric, full-length rHA molecules (A/Hong Kong/1-4-
MA21-1/1968), we observed dissociation of the rHA trimer molecule with ~50% of the 
mixture, forming a 1:1 complex of one HA protomer with one Fab molecule as shown by 
negative-stain EM (Figures 3.11b and 3.12). To visualize the epitope on the HA protomer, 
a three-dimensional negative-stain EM map at ~22-Å resolution was determined by using 
random conical tilt. A single HA protomer and an Fab molecule could be fit to the EM 
map (Figure 3.11c,d), indicating that the antibody’s mode of binding was incompatible 
with an intact HA trimer molecule due to steric clashes. Competition assays with the 
F005-126 antibody [80] (Figure 3.13) and analysis of the Fab contact site on the HA 
molecule indicated that the antibodies Asn171, Arg208, Pro239, Gly240 and Asp241, 
which is occluded in the intact HA trimer (Figure 3.11e). These residues are highly 
conserved in the HA sequence database of over 4,468 sequences from human-infecting 




Figure 3.11: Structural analysis of H1 + H3 CR antibodies. (a) Binding characteristics to 
head versus stem HA, as determined by biolayer interferometry, repeated in 
triplicate. (b) Analysis of HA–Fab complexes by negative-stain EM shows 
that the antibody binds to a HA monomer. Scale bar, 100 Å. (c) EM 
structure of D1 H1-3/H3-3 in complex with HA, determined to 22 Å using 
the random conical-tilt method. (d) Combine electron-density map of a 
single HA protomer and antibody Fab that were docked separately. (e) The 
fitted HA protomer–Fab complex was overlaid with an intact HA trimer 
(colored red-to-white indicating influenza HA conservation for one 
protomer; light blue for the remaining two protomers) showing that major 
overlap occurs between the Fab and an adjacent protomer molecule, which 
precludes binding of the antibodies to intact trimers. A set of highly 
conserved residues are located in this region (inset), which likely form part 
of this antibody epitope. 
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Figure 3.12: Negative-stain electron microscopy and single particle analysis for D1 H1-
3/H3-3 in complex with HA. (a) A representative micrograph illustrating 
high compositional and structural heterogeneity of the antibody/HA mixture. 
Examples of L-shaped 1:1 complexes between the Fab fragment and the HA 
monomer are enclosed in white squares. (b) Results of reference-free 
classification of untilted particles. The classes used for random conical tilt 
(RCT) structural analysis are enclosed in green squares. (c) Angular views 
of the final RCT map, which was used as the initial model for three-
dimensional reconstruction and refinement using reference projections 
(Figure 3.11c). (d) Examples of forward projections of the final map (Figure 




Figure 3.13: Binding-competition assay using stem or head directed antibodies. Biolayer 
Interferometry showed that the binding of D1 H1-3/H3-3 and D1 H1-17/H3-
18 to HA can be fully blocked by F005-126 antibody, indicating that they 
compete for overlapping binding epitope (but not with 39.29 [117] or 5J8 
[78]). Averages are calculated as mean with error-bars indicating s.d., 
repeated in duplicate. 
 
Functional Characterization of H1- or H3-specific Antibodies 
We selected four H1-specific and one H3-specific antibodies from donor 1 for 
recombinant expression and subsequent characterization (Table 3.5). As expected, 
recombinant antibodies identified exclusively in the eluate from H1 affinity 
chromatography bound only to H1 A/CA09 and not to the H3 strains, and vice versa 
(Figures 3.14 and 3.15, and Table 3.6). All of the H1-specific antibodies competed for the 
same epitope as the RBS-targeting antibody C05 [74] (Figure 3.16), and most of them 
showed activity in HAI assays, indicating that they target the RBS. One antibody, D1 H3-
9, neutralized the A/Perth/16/2009 (H3N2) strain in PVN assays and also bound with 
high affinity to a number of recent historical group 2 rHAs (Figure 3.14). 
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Table 3.5: CDR-3 sequences, lengths, SHM and gene usages of the recombinantly 
expressed H1- and H3-specific serum antibodies. For each antibodies, heavy 
(VH) and light (VL) chain information is shown with SHM measured by 














 AREYRILDERSNYFDA 16 5.9% IGHV4-38, IGHJ5 
V
L




 ARLYMVRGELWGFYFDH 17 3.9% IGHV4-59, IGHJ4 
V
L




 ARDDTSGELPRGLDY 15 4.5% IGHV4-38, IGHJ4 
V
L




 ARGERFGESPYYSYHMDV 18 4.6% IGHV4-59, IGHJ6 
V
L




 TTGDHYNDPTTPAHRNW 17 6.9% IGHV1-69, IGHJ5 
V
L





Figure 3.14: Biochemical and functional analysis of the recombinantly expressed H1- or 
H3-specific serum antibodies. EC50 values, as determined by ELISA, for 
each recombinant antibody tested against IIV1s or rHAs are shown 
according to the list of hemagglutinins and color scheme included in Figure 
3.2. A/California/7/2009 (CA09) and A/Perth/16/2009 (PE09) strains were 




Figure 3.15: Surface plasmon resonance data for recombinant IgG binding to rHAs. 
Recombinant HAs were immobilized on CM5 sensor chips. Various 
concentrations of the recombinant monoclonal antibodies were tested (400, 
200, 100, 50, 25, and 12.5 nM). H1, rHA from A/California/07/2009 X-181; 
H3, rHA from A/Perth/16/2009. 
 
Table 3.6: Kd values (nM) of monoclonal antibodies to rHAs measured by surface 
plasmon resonance. Averages are calculated as mean with error-bars 
indicating s.d., replicated in triplicate. H1, rHA from A/California/07/2009 
X-181; H3, rHA from A/Perth/16/2009. 
Donor rmAb ID H1 H3 Vic 
1 H1-2 0.013 ± 0.0003 >200 >200 
1 H1-12 4.3 ± 0.5 >200 >200 
1 H1-53 5.0 ± 0.3 >200 >200 
1 H3-9 >200 4.9 ± 0.4 >200 
 
 
Figure 3.16: Epitope-blocking assay for the H1-specific antibodies. C05 was 
immobilized on a CM5 sensor chip, and H1 was bound. Stem-biding 
antibody, D1 H1-1/H3-1, and H1-only were used as controls. D1 H1-2, D1 
H1-12 and D1 H1-53 antibodies showed competition for binding with C05 
while not competing for binding with the head-binding cross-reactive 
antibody, D1 H1-3/H3-3. The experiments were repeated in triplicate. 
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Functional Characterization of Influenza B-specific Antibodies 
Five antibodies that were identified as Vic + Yama cross-reactive from donor 1, 
including one antibody that constituted ~40% of the anti-Vic B/BR08 repertoire, were 
recombinantly expressed (Table 3.7), and their binding affinities to a panel of Victoria 
and Yamagata rHA proteins and their HAI titers to the vaccine strain were determined 
(Figures 3.17 and 3.18, and Table 3.8). Four of five antibodies bound with high affinity to 
all influenza B rHAs tested, whereas one antibody bound only to both Vic B/BR08 and 
Yama B/TX11 IIV1s but not to the respective rHAs. Our data show that most of the 
serum antibodies elicited by vaccination with Vic B/BR08 also bind to Yama B/TX11. 
This finding raises the question of whether vaccination with the new IIV4 can offer 
significant additional protection benefit over that with IIV3. 
 
Table 3.7: CDR-3 sequences, lengths, SHM and gene usages of the recombinantly 
expressed influenza B-specific serum antibodies. For each antibodies, heavy 
(VH) and light (VL) chain information is shown with SHM measured by 
mutation rates in IGHV gene. 












 KCLLTTFPEKWFDP 14 7.1% IGHV3-15, IGHJ5 
V
L






 ATNLDYYDRSGYYVRDAFDI 20 3.1% IGHV5-51, IGHJ3 
V
L






 AKDNYGGNLSGWFDP 15 2.1% IGHV3-23, IGHJ5 
V
L






 ARDLKYYGSVRMGWFGP 17 10.9% IGHV4-59, IGHJ5 
V
L






 ARVSPGGIGTGYGDY 15 5.9% IGHV4-38, IGHJ4 
V
L




Figure 3.17: Biochemical and functional analysis of the recombinantly expressed 
influenza B-specific serum antibodies. EC50 values, as determined by 
ELISA, for each recombinant antibody tested against IIV1s or rHAs is listed. 
HAI assays were performed with B/Brisbane/60/2008 (BR08). All assays 
were repeated in triplicate. 
 
 
Figure 3.18: Surface plasmon resonance data for recombinant IgG binding to rHAs. 
Recombinant HAs were immobilized on CM5 sensor chips. Various 
concentrations of the recombinant monoclonal antibodies were tested (400, 
200, 100, 50, 25, and 12.5 nM). Vic, B/Brisbane/60/2008). 
 
Table 3.8: Kd values (nM) of monoclonal antibodies to rHAs measured by surface 
plasmon resonance. Averages are calculated as mean with error-bars 
indicating s.d., replicated in triplicate. H1, rHA from A/California/07/2009 
X-181; H3, rHA from A/Perth/16/2009. 
Donor rmAb ID H1 H3 Vic 
1 Vic-1/Yama-1 >200 >200 0.0086 ± 0.001 
1 Vic-4/Yama-3 >200 >200 0.14 ± 0.01 
1 Vic-8/Yama-20 >200 >200 1.4 ± 0.2 
1 Vic-9/Yama-5 >200 >200 0.21 ± 0.01 
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DISCUSSION 
We used the proteomics data with the VH:VL-paired databases to recombinantly 
express and characterize the functions of the representative antibodies identified from 
sera of two donors following IIV3 vaccination. Recombinant expression of a set of H1 + 
H3 cross-reactive antibodies show a remarkable breadth of binding, recognizing not only 
historical H1 and H3 strains but also binding to H2, H5, H7 and H9. The unexpectedly 
large fraction of H1 + H3 cross-reactive antibodies that was detected by LC–MS/MS 
could not have been inferred by classical serology metrics. Similarly, a high frequency of 
H1 + H3 antibodies had not been noted in previous analyses of peripheral B cells. There 
are several possible explanations for this. Single-cell cloning typically involves the 
analysis of small samples of peripheral B cells, and therefore, plasmablasts or memory B 
cells that bind to H1 + H3 could have been missed. Additionally, the emphasis of B cell 
analysis studies has been on neutralization, which means that H1 + H3 cross-reactive 
antibodies that show little or no potency in neutralization assays could have been 
overlooked. An additional reason may be the kinetics of expansion of the memory B cells 
encoding these antibodies. 
We distinguished two classes of H1 + H3 cross-reactive antibodies on the basis of 
their epitope specificity. One class recognized H2, H5, H7 and H9 with good to moderate 
affinity (in addition to H1 and H3), and these antibodies were found to compete with the 
stem-binding bNAb FI6. Because these antibodies are present at high levels at day 0 and 
bind to epitope(s) that overlap those recognized by antibodies such as FI6, their existence 
could be interfering with the recognition of the critical protective epitopes in the stem and 
the elicitation of high-potency broadly protective antibodies. The second class of H1 + 
H3 cross-reactive antibodies, identified in multiple donors, were all shown to bind to a 
highly conserved epitope on monomeric HA and to confer prophylactic and therapeutic 
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protection against challenge by both group 1 and group 2 strains despite their complete 
lack of neutralization activity in vitro. Such antibodies have not been previously 
described. Given that they bind to the HA molecules on the surface of infected cells 
(Figure 3.4) but lack any detectable in vitro neutralization activity, the ability of these 
antibodies to confer protection in vivo is probably dependent on effector functions 
mediated by crystallizable fragment (Fc), namely complement activation and/or antibody-
dependent cellular cytotoxicity and phagocytosis [131, 132]. Studies to determine the 
precise mechanism for protection are under investigation. 
Our data on the existence of broadly protective, non-neutralizing antibodies, 
which are present in relatively high amounts in serum, raise interesting questions in terms 
of their role in the prevention of influenza infections and whether it might be desirable to 
design universal influenza immunogens that stimulate the production or boosting of this 
class of antibodies, perhaps in addition to the elicitation of neutralizing antibodies. 
  
 97 
Chapter 4: Longitudinal Analysis of Serum Antibody repertoires after 
Repeated Exposures to Influenza 
 
INTRODUCTION 
Influenza is a rapidly evolving, enveloped virus globally infecting over a billion 
people every year, approximately 500,000 of which resulting in death [4, 5]. Among the 
three types, influenza A virus especially poses a global threat as it accounts for 
pandemics and the majority of seasonal outbreaks [9, 14]. There are two groups of 
influenza A virus, group 1 and group 2, and they are differentiated based on the antigenic 
properties of two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA) [9]. 
HA, in particular, is the major target of humoral response due to its high antigenicity and 
abundant presence on the surface [133, 134].  
HA consists of two domains, head and stem, and they mediate attachment to host 
cells via the receptor-binding site (RBS) and fusion with the host cell upon infection [10]. 
HA-targeting antibodies are known to confer protective immunity, but the influenza virus 
is equipped with an ability to rapidly evolve and evade the host’s immune system through 
a process called ‘antigenic drift’ [85, 104, 135]. Because of the necessity for the virus to 
maintain its cell-binding capability and assemble into the infective viral structure, 
however, not every amino acid residue is equally inclined to mutate. For instance, the 
stem region and RBS tend to be conserved while the residues around the RBS diverge 
substantially across different strains of virus [20].  
There are two main classes of HA-targeting antibodies that confer protection 
against influenza. First class of antibodies neutralize virus by binding to the RBS and 
preventing the viral attachment to host cells [73, 108, 129, 136]. Due to the 
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aforementioned high variability in the areas around the RBS, these antibodies tend to 
neutralize a narrow range of homologous strains. On the other hand, another group of 
antibodies neutralize infectivity of the virus by targeting conserved sites on the stem of 
HA [70, 75, 76, 81, 91, 118, 137] and interfering with the membrane fusion required for 
infection. Because those antibodies bind to highly conserved epitopes, they neutralize a 
wide range of influenza strains, including viruses within group 1 [75, 77, 91], group 2 [74, 
138, 139], and across group 1 and group 2 [70, 81, 117, 140]. Currently, the stem-binding 
broadly-neutralizing antibodies (bNAbs) have garnered the most interest as therapeutics 
[26], and development of vaccination strategies aimed at increasing the elicitation of such 
anti-stem bNAbs are at the forefront of the quest for a universal influenza vaccine [84-86]. 
Because influenza is a widespread virus, most individuals develop antibodies 
against influenza at an early age, and the pre-existing repertoire of influenza-specific 
antibodies affects the succeeding exposure to influenza. Over five decades ago, Thomas 
Francis first recognized this phenomenon and reported that sera from patients collected 
after being infected with an H1N1 strain showed higher neutralizing potency against a 
drifted variant that had circulated during their childhood than the strain responsible for 
the existing infection [92, 141]. The observation, which was termed ‘original antigenic 
sin’ (OAS), suggested that a sequential exposure to closely-related viral strains 
diminished antibody response to the unique antigenic determinants in the subsequent 
virus. In other words, the antibody response elicited from the first influenza infection or 
vaccination in childhood governed the future immunity against influenza. Subsequent 
studies examined the extent of the OAS effect in humans and other animals [142-144], 
using bulk serologic metrics, such as ELISA and neutralization titers. These assays 
measure the amounts of antibodies in serum that can bind to or neutralize the virus, 
respectively. The data available so far suggest that recurring exposures to influenza 
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preferentially induce antibodies targeting conserved regions [114, 116, 138, 145, 146], 
including the stem [146]. However, a molecular-level analysis of the serum antibodies is 
required to identify the constituent individual antibodies and determine their persistence 
in order to deconvolute the polyclonal nature of such aggregate metrics.  
To address the question above, the HA-specific serum antibody repertoire was 
determined across a period of 6 years in a donor from whom analysis of peripheral B 
cells had yielded seminal insights on the emergence of broadly neutralizing antibodies 
active against both group 1 and group 2 viral strains [70, 137, 140, 147, 148]. 
Specifically, we determine the extent of variation in the clonotypic identity, 
diversity, and abundance of the antibodies in the sera, identify antibodies that persist for 
many years as well as others that are produced transiently, and compare the persistence of 
head- and stem-binding antibodies in serum. Insights gained from this study could help 
understand the determining factors for persistence in serum, which is critical for 




MATERIALS AND METHODS 
 
Purification of Total IgG from Serum and Subsequent Digestion into F(ab’)2 
Each serum samples analyzed in this study was passed through a 1 ml Protein G 
Plus agarose (Pierce) affinity column in gravity mode. Serum flow-through was collected 
and passed through the column three times. The column was washed with 15 cv of PBS 
prior to elution with 5 cv of 100 mM glycine-HCl, pH 2.7. The eluate, containing total 
IgG from serum, was immediately neutralized with 2 ml of 1 M Tris-HCl, pH 8.0.  
Purified IgG was digested into F(ab’)2 with 10 μg of IdeS protease (Genovis) per 1 mg of 
IgG in PBS for 4 h on inverter at 37 °C.  
 
Antigen-enrichment of F(ab’)2 and Mass Spectrometry Sample Preparation 
CA09pdm (A/California/07/2009pdm) rHA provided by Dr. Stephen Harrison 
(Harvard Medical School) was immobilized on N-hydroxysuccinimide (NHS)–activated 
agarose resins (Pierce) by overnight rotation at 4 °C. The coupled agarose resins were 
washed with PBS, and unreacted NHS groups were blocked with 1 M ethanolamine, pH 
8.3 for 30 min at RT. The beads were further washed with PBS, and packed into a 0.5 ml 
chromatography column (Clontech). The column was equilibrated with 10 cv of PBS.  
For each sample, F(ab’)2 was applied to the individual antigen affinity columns in 
gravity mode. Flow-through was collected and reapplied to the column three times, and 
the column was washed with 10 cv of PBS and 10 cv of diluted PBS (1:2 in ddH20). 
Antigen-enriched F(ab’)2 was eluted with 2% (v/v) formic acid in 0.5 ml fractions. 20 μl 
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from each elution fraction, neutralized with NaOH/Tris, and flow-through were assayed 
by indirect ELISA with the rHA. Depletion of ELISA signal in each flow-through sample 
was checked. Elution fractions showing an ELISA signal were pooled and concentrated 
under vacuum to a volume of ∼3 μl before neutralizing with NaOH/Tris. The neutralized 
elution samples were concentrated to 50 μl under vacuum.  
For each enrichment, elution and flow-through samples were denatured in 50% 
(v/v) 2,2,2-trifluoroethanol (TFE), 50 mM ammonium bicarbonate, and 10 mM 
dithiothreitol (DTT) at 60 °C for 1 hr, then alkylated by incubation with 32 mM 
iodoacetamide (Sigma) for 1 hr at RT in the dark. Alkylation was quenched by the 
addition of 20 mM DTT. Samples were diluted 10-fold with 50 mM ammonium 
bicarbonate and digested with trypsin (1:30 trypsin/protein) for 16 hr at 37 °C. Formic 
acid was added to 1% (v/v) to quench the digestion, and the sample volume was reduced 
to ∼100 μl under vacuum. Peptides were then bound to a C18 Hypersep SpinTip 
(Thermo Scientific), washed three times with 0.1% formic acid, and eluted with 60% 
acetonitrile, 0.1% formic acid. C18 eluate was dried under vacuum centrifugation and 
resuspended in 50 μl in 5% acetonitrile, 0.1% formic acid.  
 
LC-MS/MS Analysis 
Samples were analyzed by liquid chromatography-tandem mass spectrometry on a 
Dionex Ultimate 3000 RSLCnano uHPLC system (Thermo Scientific) coupled to an LTQ 
Orbitrap Velos Pro mass spectrometer (Thermo Scientific). Peptides were first loaded 
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onto an Acclaim PepMap RSLC NanoTrap column (Dionex; Thermo Scientific) prior to 
separation on a 75 μm×15 cm Acclaim PepMap RSLC C18 column (Dionex; Thermo 
Scientific) using a 5–40% (v/v) acetonitrile gradient over 250 min at 300 nl/min. Eluting 
peptides were injected directly into the mass spectrometer using a nano-electrospray 
source. The LTQ Orbitrap Velos Pro was operated in data-dependent mode with parent 
ion scans (MS1) collected at 60,000 resolutions. Monoisotopic precursor selection and 
charge state screening were enabled. Ions with charge ≥+2 were selected for collision-
induced dissociation fragmentation spectrum acquisition (MS2) in the ion trap, with a 
maximum of 20 MS2 scans per MS1. Dynamic exclusion was active with a 45-s 
exclusion time for ions selected more than twice in a 30-s window. Each sample was run 
three times to generate technical replicate datasets.  
 
MS/MS Data Analysis 
Protein sequence databases were constructed using the VH sequences obtained 
from the donor. Specifically, HA-specific antibody sequences obtained across 7 years [70, 
137] were combined with high-throughput sequencing of VH transcripts from 2014 days 7, 
14 and 21 post-vaccination B-cells with ≥2 reads. These sets of VH sequences were 
concatenated to a database of background proteins comprising non-donor derived VL 
sequences (HD1 [98]), a consensus human protein database (Ensembl 73, longest 
sequence/gene), and a list of common protein contaminants (MaxQuant). Spectra were 
searched against the database using SEQUEST (Proteome Discoverer 1.4; Thermo 
Scientific). Searches considered fully-tryptic peptides only, allowing up to two missed 
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cleavages. A precursor mass tolerance of 5 ppm and fragment mass tolerance of 0.5 Da 
were used. Modifications of carbamidomethyl cysteine (static) and oxidized methionine 
(dynamic) were selected. High-confidence peptide-spectrum matches (PSMs) were 
filtered at a false discovery rate of <1% as calculated by Percolator (q-value <0.01, 
Proteome Discoverer 1.4; Thermo Scientific).  
Iso/Leu sequence variants were collapsed into single peptide groups. For each 
scan, PSMs were ranked first by posterior error probability (PEP), then q-value, and 
finally XCorr. Only unambiguous top-ranked PSMs were kept; scans with multiple top-
ranked PSMs (equivalent PEP, q-value, and XCorr) were designated ambiguous 
identifications and removed. Observed precursor masses were recalibrated according to 
the previous method [109], and the average mass deviation (AMD) for each peptide was 
calculated as described [97] using data from elutions only. Peptides with an AMD >1.5 
ppm were removed. Additionally, only peptides identified in ≥2 replicate injections for at 
least one elution sample were kept as high-confidence identifications.  
Peptide abundance was calculated from the extracted-ion chromatogram (XIC) 
peak area, as described [98], using peak area values generated by the Precursor Ions Area 
Detector node in Proteome Discoverer. For each peptide, a total XIC area was calculated 
as the sum of all unique XIC areas of associated precursor ions, and the average XIC area 
across replicate injections was calculated for each sample. For each antigen dataset, the 
eluate and flow-through abundances were compared and peptides with ≥10-fold higher 
signal in the elution sample were considered to be antigen-specific.  
 
 104 
Clonotype Indexing and Peptide-to-clonotype Mapping 
VH sequences were grouped into clonotypes based on single-linkage hierarchical 
clustering as described [98]. Cluster membership required ≥90% identity across the CDR-
H3 amino sequence as measured by edit distance. High-confidence peptides identified by 
MS/MS analysis were mapped to clonotype clusters, and peptides uniquely mapping to a 
single clonotype were considered “informative”. Abundance of each antibody clonotype 
was calculated by summing the XIC areas of the informative peptides mapping to ≥4 
amino acids of the CDR-H3 region.  
 
Quantitating Abundances of Individual Antibody Clonotypes  
For each serological repertoire, relative abundance of a clonotype was calculated 
by dividing the XIC area for a particular clonotype by the sum of the XIC areas for all 
clonotypes. Fraction of serological repertoire refers to this relative abundance based on 
XIC.  
ELISAs 
EC50 values based on ELISA were used to determine the binding titers of 
CA09pdm-specific antibodies in the serum samples. First, costar 96-well ELISA plates 
(Corning) were coated overnight at 4 °C with 4 μg/ml CA09pdm HA and washed and 
blocked with 2% milk in PBS for 2 hr at RT. After blocking, serially diluted recombinant 
antibodies or serum samples bound to the plates for 1 h, followed by 1:5000 diluted goat 
anti-human IgG Fc HRP-conjugated secondary antibodies (Jackson ImmunoResearch; 
109-035-008) for 1 h. For detection, 50 μl TMB-ultra substrate (Thermo Scientific) was 
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added before quenching with 50 μl 1 M H2SO4. Absorbance was measured at 450 nm 
using a Tecan M200 plate reader. Data were analyzed and fitted for EC50 using a 4-
parameter logistic nonlinear regression model in the GraphPad Prism software. All 
ELISA assays were performed in triplicate. 
 
Statistical Analysis 
Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad 
Software, Inc., San Diego, CA), unless specifically noted otherwise in the figure legends. 
All the statistical tests performed are described in the figure legends, and correlations 






Blood samples were collected from the donor during each encounter with 
influenza through infection or vaccination (Table 4.1). Peripheral B cells were isolated 
from the collected blood, immortalized with Epstein Barr Virus [69] and individually 
cultured, secreting antibodies to media which were subsequently screened for binding to 
HA. B cells encoding HA-binding antibodies were sequenced and recombinantly 
expressed to characterize their biochemical and functional properties. It should be noted 
that the donor was repeatedly exposed to pandemic A/California/04/2009 (CA09pdm) 
viral strain as summarized in Table 4.1. ~500 CA09pdm HA-binding monoclonal 
antibodies were discovered of which ~200 of the antibodies targeted the stem region, and 
several of them showed remarkably broad neutralization activities. One of the antibodies, 
named FI6, is a pan-influenza A neutralizing antibody currently under clinical trials as 
therapeutics for influenza [70]. Additionally, ~300 antibodies that bound to the HA-head 
were also identified. The exhaustive analysis of HA-specific antibodies from the donor 
across a decade also led to details regarding the developmental pathways of CA09pdm 




Table 4.1:  List of the collected samples and the encountered viral strains. IIV1, 
monovalent inactivated influenza vaccine; IIV3, trivalent inactivated 
influenza vaccine; CA09pdm, A/California/04/2009pdm; VI09, 
A/Victoria/210/2009; BR08, B/Brisbane/60/2008; VI11, 
A/Victoria/361/2011; WI10, B/Wisconsin/1/2010; TX12, A/Texas/50/2012; 
MA12, B/Massachusetts/02/2012. 
Exposure history Viral strains encountered Sera analyzed (collection dates) 
2009 infection CA09pdm 21 d post-exposure (Dec. 1, 2009) 
2010 vaccination 1 IIV1 (CA09pdm) 14 d post-exposure (May 6, 2010) 
2010 vaccination 2 IIV3 (CA09pdm, VI09, BR08) 
Pre-exposure (Dec. 6, 2010)  
14 d post-exposure (Dec. 20, 2010) 
2011 vaccination IIV3 (CA09pdm, VI09, BR08) 
Pre-exposure (Nov. 11, 2011) 
17 d post-exposure (Nov. 28, 2011) 
2012 vaccination IIV3 (CA09pdm, VI11, WI10) Pre-exposure (Nov. 14, 2012) 
2013 vaccination IIV3 (CA09pdm, VI11, MA12) 
Pre-exposure (Dec. 3, 2013) 
16 d post-exposure (Dec. 19, 2013) 
2014 vaccination IIV3 (CA09pdm, TX12, MA12) 14 d post-exposure (Dec. 10, 2014) 
 
It is important to note, however, that the investigation of the peripheral B cells 
does not provide information regarding the individual antibodies’ relative abundances in 
serum. In previous studies directly analyzing serum antibodies, we have observed that the 
presence of B cells in the periphery is not always an indication for the corresponding 
immunoglobulin molecules circulating in serum [98]. Furthermore, the steady-state 
serum antibody response, referring to antibodies that persist for many months or years 
after they were elicited as a result of infection or vaccination, is maintained by long-lived 
plasma cells (LL-PCs) in the bone marrow [65, 66]. Given the difficulties and limitations 
associated with analyzing LL-PCs isolated from bone marrow, a direct analysis of the 
antibodies in serum at steady-state can provide valuable information regarding the 
antibody repertoire formed by the subset of B cells in the bone marrow. Such information 
is imperative for a longitudinal study to investigate the OAS effects at a molecular level 
and understand how the serological antibody repertoire is shaped by repeated exposures 
to influenza.  
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Using our previously developed proteomics-based method [98, 99], we delineated 
the composition and relative abundances of the antibody clonotypes comprising the 
serum IgG repertoire specific to CA09pdm in each of the collected serum samples. To 
briefly summarize, we sequenced B cells isolated from the donor 7, 14 and 21 days after 
the vaccination in 2014 and combined the high throughput sequencing data with the 
aforementioned ~500 CA09pdm-HA-specific antibody sequences to compile a list of 
antibodies encoded by the B cells from the donor. Then, the immunoglobulin molecules 
specific to CA09pdm HA were isolated from each serum sample through two separate 
affinity chromatography steps, first using protein G resins to capture the total IgG and 
second using agarose resins with immobilized CA09pdm HA. The eluates from the final 
purification were analyzed by high-resolution liquid chromatography coupled to tandem 
mass spectrometry (LC–MS/MS) (Figure 4.1). We identified complementarity-
determining region 3 (CDR-H3) peptides and used the corresponding LC peak intensities 
to determine the relative abundance of each CDR-H3 peptide. Antibodies that have high 
similarity in the CDR-H3 were grouped together into a clonotype. Accordingly, we 
delineated the longitudinal landscape of the anti-CA09pdm serum antibody repertoire in 




Figure 4.1:  Experiment design. For sequencing of B cell receptor (BCR) transcripts 
(BCR-seq), we used peripheral B cells isolated 7, 14 and 21 days after the 
vaccination in 2014 to sequence the heavy chain variable (VH) regions. 
These sequences were added the VH sequences of the ~500 antibodies 
obtained from the longitudinal B cell analysis for constructing custom 
database for the heavy-chain peptide identification. From each serum 
sample, antibodies with binding affinities to CA09pdm were isolated 
through column purification and the eluates were subsequently analyzed 
proteomically (Ig-seq).  
 
Longitudinal Analysis of the Serological Repertoire to CA09pdm 
For each sample analyzed, the clonotypic antibody composition and relative 
abundances were plotted as a histogram, with each bar indicating an individual clonotype 
and the y axis displaying its relative abundance (Figure 4.2, left). To compare the 
serological repertoires from different time points, each histogram was represented as a 
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subdivided bar graph with individual divisions representing the relative quantities of 
antibody clonotypes (Figure 4.2, right). Individual subdivided bar graphs were combined 
together, and the same colors were used for the same clonotypes across the time points to 
illustrate the longitudinal changes of the individual antibody clonotypes (Figure 4.3). We 
determined the total amounts of CA09pdm-binding IgG in each serum sample by 
measuring ELISA serum titers (Table 4.2), and dashed lines were used to indicate the 
total quantities of the CA09pdm-specific antibody in the sera. Lastly, the subdivided bar 
graphs were scaled accordingly to the corresponding serum titer values. Therefore, the 
height of each bar indicates the total amounts of antibodies specific to CA09pdm with the 
divisions representing the relative abundance of each antibody clonotype comprising the 
serological repertoire.  
 
 
Figure 4.2: Representative serological repertoire (2009 infection, 21 d post-exposure). 
Each bar represents a unique clonotype and the y axis indicates the relative 
abundance (fraction) determined by the proteomic analysis. Based on the 
histogram, a subdivided bar graph was generated where individual divisions 
represent the top-20 most abundant unique clonotypes and their relative 
abundances. Different colors were used for different antibody clonotypes, 
and the black division at the bottom indicates the fraction of the rest of the 
antibody clonotypes.  
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Figure 4.3:  Longitudinal landscape of the serological repertoires across 6 years. For 
each time point, a subdivided bar graph was used to represent the relative 
abundance of individual antibody clonotypes as described in Figure 4.2. The 
top-20 most abundant antibody clonotypes are individually colored with the 
black shade indicating the abundances of the rest of the antibodies. The 
same colors are used for the same antibody clonotypes across the time 
points. Dashed lines represent serum titers to CA09pdm, with ‘*’ indicating 
predicted titers based on the exposure history of the donor. 
 
Table 4.2:  ELISA titer to CA09pdm for each serum sample. 
Exposure history Serum samples Serum titer (EC50) 
2009 infection 21 d post-exposure 135 
2010 vaccination 1 14 d post-exposure 59 
2010 vaccination 2 
Pre-exposure 





17 d post-exposure 
118 
281 
2012 vaccination Pre-exposure 102 
2013 vaccination 
Pre-exposure 
16 d post-exposure 
58 
252 
2014 vaccination 14 d post-exposure 112 
 
Examination of the longitudinal serum samples revealed some general features of 
the serum antibody repertoire to influenza. First, the number of unique antibody 
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clonotypes in each serum analyzed ranged from 19 to 115 (Table 4.3), agreeing with our 
earlier observation that the influenza-specific serological repertoire is restricted and 
oligoclonal. In addition, we observed a high degree of polarization as the top-10 most 
abundant clonotypes accounted for on average ~73% of the antibody response by 
abundance. These results indicate that the protection mediated by serum antibodies is 
conferred by a limited number of serum antibody clonotypes. Interestingly, ~50% of the 
antibody repertoires was comprised of the antibodies that had been identified through the 
B cell immortalization. 
 
Table 4.3: Size and fraction of the top-10 most abundant clonotypes of each serological 
repertoire analyzed. Number of unique clonotypes in each repertoire is 
indicated, and the abundances of the top 10 antibody clonotypes were added 
to determine the % fraction of the top-10 clonotypes. 
Exposure history Serum samples 
Number of antibody 
clonotypes  
Relative abundance of 
top-10 clonotypes (%) 
2009 infection 21 d post-exposure 40 75.1 
2010 vaccination 1 14 d post-exposure 44 66.8 
2010 vaccination 2 
Pre-exposure 












2012 vaccination Pre-exposure 27 81.4 
2013 vaccination 
Pre-exposure 





2014 vaccination 14 d post-exposure 73 76.1 
 
Persistent and Intermittent Antibody Clonotypes 
To analyze the antibodies persisting in circulation, we identified the antibody 
clonotypes that are detected in serum samples collected before encountering influenza 
(pre-exposure serum samples). These antibodies circulating in serum prior to exposure 
events represent the steady-state antibodies since the peak response generated by the 
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previous encounter with influenza has waned, and they are likely being secreted by the 
LL-PCs in the bone marrow [65]. Based on the proteomic analysis of the four pre-
vaccination serum samples (2010 vaccination 2, 2011 vaccination, 2012 vaccination and 
2013 vaccination), we defined the antibody clonotypes detected in all four samples as 
‘persistent’, and the rest as ‘intermittent’ antibody clonotypes. It should be noted that 
these definitions are strictly based on the detection in our LC-MS/MS data, and it is 
possible that some of these clonotypes were present at low quantities in serum but not 
detected.  
Overall, we identified 15 persistent antibody clonotypes across all the time points 
(Table 4.4). Two persistent antibody clonotypes, clonotype-633 and clonotype-324, were 
of particular interest. As shown in Table 4.5, clonotype-633 antibodies comprised 
substantial fraction of the serological repertoire in each serum sample, indicating how the 
serological repertoire can be constantly dominated by one antibody clonotype during the 
6 years of repeated exposure to CA09pdm. In contrast, while clonotype-324 is a 
persistent clonotype, it comprised one of the major clonotypes only in 2 of the 10 serum 
samples analyzed (i.e. present as one of the top 10 antibody clonotypes). However, it is 
important to note that one of the antibodies belonging to clonotype-324 is the 
aforementioned pan-influenza A neutralizing antibody, FI6. Our data suggest that while 
FI6 persisted in circulation, it did not constitute one of the dominant components of the 
antibody response to CA09pdm, further highlighting the importance of analyzing the 





Table 4.4: Size and fraction of the persistent antibody clonotypes in each serological 
repertoire analyzed.  
Exposure history Serum samples 
Number of persistent 
clonotypes detected 
Fraction of the  
persistent clonotypes (%) 
2009 infection 21 d post-exposure 13 66.4 
2010 vaccination 1 14 d post-exposure 15 62.0 
2010 vaccination 2 
Pre-exposure 












2012 vaccination Pre-exposure 15 50.2 
2013 vaccination 
Pre-exposure 





2014 vaccination 14 d post-exposure 10 56.8 
 
Table 4.5: Fraction of clonotype-633 and clonotype-324 in each serological repertoire 
analyzed.  
Exposure history Serum samples 
Fraction of  
Clonotype-633 (%) 
Fraction of  
Clonotype-324 (%) 
2009 infection 21 d post-exposure 19.3 Not detected 
2010 vaccination 1 14 d post-exposure 23.1 1.0 
2010 vaccination 2 
Pre-exposure 












2012 vaccination Pre-exposure 10.8 12.1 
2013 vaccination 
Pre-exposure 





2014 vaccination 14 d post-exposure 45.8 Not detected 
 
On average, these 15 persistent antibody clonotypes comprised 53.1% of the 
CA09pdm HA-binding antibodies in serum, and this surprisingly high abundance 
indicates that during the repeated exposure to CA09pdm, approximately half of the serum 
antibodies did not change, and the variation in different serum samples resulted from the 
elicitation of the intermittent antibody clonotypes. The high fraction of antibody response 
comprised by the persistent antibody clonotypes reveal the high degree of the OAS effect 
observed in serum at a molecular-level.  
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Next, we quantitatively determined the extent of overlap between the antibody 
repertoires. For the analysis, we separated the serum samples into two groups. The pre-
exposure group contained the four serum samples collected before each exposure (2010 
vaccination-2 pre-exposure, 2011 pre-exposure, 2012 pre-exposure, and 2013 pre-
exposure), and the post-exposure group consisted of the six serum samples collected after 
(2009 post-exposure, 2010 vaccination-1 post-exposure, 2010 vaccination-2 post-
exposure, 2011 post-exposure, 2013 post-exposure, and 2014 post-exposure). We 
determined the fraction of antibody clonotypes that is overlapping between all the 
samples in the same group. As illustrated in Figure 4.4, the overlap between the pre-
exposure serum samples was on average 78.2% of the antibody repertoires. The degree of 
overlap between the post-exposure samples was significantly lower than the pre-exposure 
samples, at 61.5% on average. Considering that the 15 persistent antibody clonotypes 
comprised about half of the serological repertoire, this data suggest that the intermittent 
antibody clonotypes changed greatly between the post-exposure samples as those 
antibody clonotypes were elicited and quickly decayed. However, the steady-state 
repertoires existing prior to each exposure to CA09pdm are much similar to one another. 
In other words, the immediate antibody response varied for each instance of being 
exposed to influenza, but the serum antibody repertoire returns back to its pre-exposure 
state. This finding strongly support the notion that the antibody repertoires generated 
from previous exposures govern the future antibody response to influenza, again 





Figure 4.4:  Fraction of overlapping antibody clonotypes between the pre- and post-
exposure serum samples. For each serum sample analyzed, the abundances 
of the antibodies overlapping between each sample in the group were 
determined. The center-lines represent the mean value of the overlapping 





 percentiles and the whiskers indicating min to max. Unpaired t test with 
Welch’s correction was performed to identify the differences in the degree 
of overlap between the two groups. 
 
The Persistent Antibody Clonotypes Are Likely to be Stem-binding 
As mentioned earlier, the longitudinal investigation of the donor’s B cell receptors 
and subsequent characterization of the recombinant antibodies enabled us to determine 
the binding specificity of some of the antibody clonotypes detected from the serum 
samples. We focused on these antibody clonotypes with the knowledge about whether 
they are stem-binding or head-binding to investigate the differential persistence of the 
antibodies in serum based on their binding specificities. It is important to note that due to 
the variation in the head resulting from antigenic drift, antibodies that target the HA-head 
are likely to react with narrow range of viral strains while stem-binding antibodies tend to 
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have broad recognition due to the high degree of conservation in the HA-stem, including 
across group 1 and group 2. From our proteomics data, we identified 20 stem-binding 
antibody clonotypes and 10 head-binding antibody clonotypes. The fraction of head- and 
stem-specific antibodies in each serological repertoire is summarized in Table 4.6. 
 
Table 4.6: Fraction of the head- and stem-binding antibody clonotypes in each 
serological repertoire analyzed.  
Exposure history Serum samples 
% of head-binding 
antibody clonotypes 
% of stem-binding 
antibody clonotypes 
2009 infection 21 d post-exposure 0.4 48.0 
2010 vaccination 1 14 d post-exposure 2.0 52.6 
2010 vaccination 2 
Pre-exposure 












2012 vaccination Pre-exposure 7.7 31.3 
2013 vaccination 
Pre-exposure 





2014 vaccination 14 d post-exposure 11.2 54.0 
 
It is important to note, the donor was infected with the CA09pdm viral strain in 
2009. The HA-head of this strain diverged considerably from the viral strains that 
circulated previously, and this was the reason for the pandemic that followed because 
most of the population had not been exposed to a similar strain in the past, lacking pre-
existing immunity. It is established that because of its divergent head domain, exposure 
to CA09pdm boosted the antibodies with binding specificity toward the stalk domain 
[149]. In agreement with these observations, the abundance of head-binding antibody 
clonotypes in serum 21 days post-infection was very low. The fraction of the repertoire 
resulting from head-specific antibody clonotypes did not substantially increase until the 
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second vaccination in 2010. In contrast, the stem-binding clonotypes dominated the post-
infection repertoire to CA09pdm in 2009. 
The relative abundances of the head-binding and stem-binding antibody 
clonotypes in the pre-exposure samples and the post-exposure samples are presented in 
Figure 4.5. Our data showed that the stem-binding antibodies consistently dominated the 
pre-vaccination over the head-specific antibody clonotypes (Figure 4.5a). This indicates 
that the persistent antibody clonotypes are likely to be stem-binding antibodies. When we 
analyzed the post-exposure sera, the head-specific antibodies significantly increased 
following the vaccination in 2010 and 2011, but their relative abundances waned and the 
stem-binding antibody clonotypes’ abundances increased. Addition to the fact that 6 
clonotypes are stem-binding while 2 clonotypes are head-binding, our data illustrate that 
the stem-binding antibody clonotypes are likely to be persistent in serum while the head-
binding antibodies are intermittent.  
 
 
Figure 4.5:  Fractions of head- and stem-binding antibody clonotypes in the pre-
exposure and post-exposure serum samples. Antibody clonotypes with 
known binding specificities are indicated and the rest is of antibody 




We have performed a longitudinal analysis of the serum antibodies at the 
molecular-level to analyze the persistence and decay of CA09pdm-specific serum 
antibodies across 6 years. Our analysis identified 15 persistent antibody clonotypes that 
dominated the pre-exposure serological repertoires and on average comprised 
approximately half of the identified antibody repertoire to CA09pdm. Our analysis 
illustrate that the serum repertoire changes after each exposure to CA09pdm resulting 
from the elicitation of the intermittent antibody clonotypes. But after a period of time, the 
serum antibody repertoire returns back to the steady-state that existed prior to the 
exposure. Given that half of the antibody repertoire stays the same and that the 
serological repertoire returns back to its pre-existing state, our study clearly illustrates the 
extent of the OAS effects in serum. It also highlights the importance of vaccination in 
childhood as the antibodies elicited during the early exposure to influenza will likely 
dominate the future antibody responses.  
The general understanding of the OAS is that it is a ‘sin’ because it is unfavorable; 
however if repeated exposure could lead to the persistence of neutralizing antibodies 
targeting conserved regions, such as the stem, this phenomenon could be beneficial and 
should be exploited by vaccines. Our finding showed that through the multiple exposures 
to CA09pdm, the immune system selectively promoted the persistence of the stem-
binding antibody clonotypes. It is worth noting that the majority of studies illustrating the 
detrimental effect of the OAS relied on the aggregate serologic metrics, like the HAI titer. 
However, the HAI assay does not measure the neutralizing activity of the stem-binding 
antibodies since the assay quantifies only the antibodies neutralizing the infection 
through binding to the head region. If the repeated exposure promoted the antibodies 
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targeting the conserved stem domains, it could have decreased the HAI activity without 
compromising the level of protection conferred by the antibodies in serum.  
A key to the universal influenza vaccine will be the design of immunogens that 
can elicit broadly-protective antibodies to handle a variety of different strains and also to 
provide long-term protection. It is important to note that just elicitation of broadly 
neutralizing antibodies is not the end point. Given how polarized serological repertoire is, 
the objective of a universal vaccine might need to focus on promoting the generation of 
antibodies with desired functions so they constitute a major fraction of the serum 
antibodies. For instance, we observed FI6 in the sera of the donor across many years, but 
it was not one of the abundant antibody clonotypes. The next step in the field should be 
focused on understanding what are the determining factors for certain antibody 
clonotypes becoming one of the most abundant antibody clonotypes. With the stem-
binding antibodies showing a tendency to persist in serum at a detectable level across 
multiple years, the repeated exposure to influenza promotes longevity and increase of 
such antibodies. The differential longevity of stem-binding and head-specific antibodies 




Chapter 5: Future Directions and Perspectives 
Vaccine-induced protection against influenza is conferred mainly through the 
stimulation of B cells to produce a diverse repertoire of antigen-specific immunoglobulin 
molecules. These antibodies circulate in serum and afford immunity by binding and 
neutralizing the virus, and characterizing them is the essence of understanding serological 
immunity. Until recently, serological studies relied on the aggregate metrics, but the 
inability to deconvolute the polyclonal nature of serum antibody has restricted the depth 
of information obtainable from such studies. The recent rapid advancement of novel 
technologies for analyzing functional antibody repertoires has enabled high-through and 
deeper characterizations of humoral immune responses. In particular, with the 
combination of the high-throughput sequencing of B cell receptor-encoding transcripts 
(BCR-seq) and the high-resolution proteomics analysis of immunoglobulin molecules 
(Ig-seq), we are now entering a new era of serologic studies as the technical 
advancements have enabled us to directly interrogate the serum antibodies at an 
unprecedented high resolution.  
In this dissertation, we used the proteomics-based serum antibody repertoire 
analysis pipeline to identify and delineate, in a quantitative fashion, the monoclonal 
antibodies comprising the human serum response to influenza. We first interrogated the 
influenza HA-specific IgG molecules circulating in sera of four young adults before and 
after seasonal vaccination. Our study led to several new findings including the dominance 
of pre-existing antibodies in the vaccine response and the higher than expected 
abundance of cross-reactive antibodies in serum. Subsequent recombinant analysis led to 
the discovery of non-neutralizing but protective cross-reactive antibodies targeting a 
newly identified conserved epitope in the HA-head. We also examined the serum 
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antibodies from one individual across 6 years to show the degree of change, or the lack 
thereof, in the antibody repertoire through the repeated exposure to influenza. Our 
analysis also illustrated the likelihood of the stem-binding antibodies persisting over the 
head-binding antibodies. These findings provide important data to help describe the 
immunological mechanisms underlying cross-reactivity and persistence, which have 
direct implication for the evaluation and design of future vaccine for influenza. 
As we utilize these new technologies to better understand serological immunity to 
influenza at the molecular-level, there are numerous questions waiting to be answered. 
We so far have investigated a small number of young adults. There is a need to explore a 
cohort in different age groups, in particular the elderly since the majority of the 
influenza-related death occurs in people over the age of 65. A comparison of the 
serological repertoire specific to influenza between different age groups could provide 
useful information.   
In addition to IgG, it is known that IgA also plays a role in protection against 
influenza. The relationship between the IgG repertoire and IgA repertoire remains to be 
explored. For example, to what degree are the influenza specific IgG and IgA repertoires 
clonally relate to each other? Characterization of the antibodies that are found in serum as 
IgA and IgG isotypes could elucidate about the relationship between class switching and 
serum immunity.  
Furthermore, these approaches are not only applicable for studying the vaccine-
elicited antibody repertoires. The analytic tools can be extended to other infectious 
disease as well as autoimmunity and cancer. In infectious diseases, pathogen-specific 
antibodies could be directly isolated from serum and further developed as therapeutics. 
Also, new epitopes being targeted by abundant serum antibodies could be identified, 
which would be valuable for developing vaccines. In autoimmune diseases and cancer, 
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characterization of the serological repertoire would enable the identification of novel 
biomarkers, as well as therapeutic or diagnostic antibodies. Such studies could provide 
insights into the underlying mechanisms of disease. There are many directions we could 
take as the new technologies for the direct analysis of serum antibodies has resulted in an 







Anti-H1 A/CA09 serological repertoire clonotypic antibodies 















ARHFQERLVAARAGAFDV 557 57 248 252 1.63E+07 3.55E+08 6.91E+08 
ARDFFEKVTGDDVNAFDI 368 48 135 185 1.77E+07 2.33E+08 4.97E+08 

















KCLLTTFAESWFDP 129 7 75 47 8.47E+05 4.89E+07 6.66E+07 
ARDLAIPIDSLTYYLRAFDS 105 33 34 38 1.04E+07 4.08E+07 3.23E+07 
ARDRRDLLTGYDQNH 92 24 44 24 9.83E+06 8.99E+07 1.39E+08 
ARDFFEKLIADNLNAFDI 86 11 37 38 1.42E+06 2.20E+07 4.45E+07 
AKDLAQWPPGAGALDY 76 16 25 35 1.40E+05 4.43E+05 8.38E+05 
ARDVAMGGFDS 71 19 23 29 1.26E+07 5.10E+07 9.89E+07 
ASGPGGLLRLGELLFEY 66 18 27 21 2.17E+06 1.56E+07 1.59E+07 
ARPSYTSGFAFDP 65 14 20 31 6.86E+06 1.30E+08 1.97E+08 






ATNLEYYDRSGYYIRDAFGI 51 18 11 22 4.42E+06 1.62E+07 3.41E+07 
ARAACSLCPLDY 48 8 22 18 1.53E+06 4.57E+07 4.45E+07 
VRKGLCDY 44 21 13 10 3.45E+06 8.89E+06 2.32E+07 












TREFQSTFDP 30 8 11 11 4.90E+06 2.73E+07 4.23E+07 
ITSLGTYYRARVDY 29 7 8 14 4.24E+06 1.16E+07 4.85E+07 











ARGRGSYPIRGAFDI 27 12 6 9 2.88E+06 5.57E+06 8.95E+06 






























ARTERGYYYYHDGMDV 21 6 7 8 5.66E+05 2.63E+06 9.83E+06 
ARHFLERLGAARVGAFDI 21 3 12 6 8.73E+05 4.18E+06 5.54E+06 






ARSSRLYYHGLDV 20 3 8 9 1.99E+05 1.22E+06 2.40E+06 
TSGVGKTDVDY 20 7 6 7 3.90E+05 2.67E+05 2.79E+06 




































































































































































































































































































































































































































        
Anti-H3 A/VI09 serological repertoire clonotypic antibodies 















ARHFQERLGAAPVGAFDV 400 45 208 147 3.48E+07 3.60E+08 5.10E+08 
ARDFFETLTGDDLNAFDV 365 70 142 153 9.44E+07 2.32E+08 4.30E+08 
ARVPPYSSGWLRPMDV 167 65 53 49 1.15E+08 1.56E+08 3.21E+08 
ARACSSSCHYYYAMDV 150 43 34 73 6.01E+07 7.82E+07 1.31E+08 
ARLVATARDYFGLDV 130 28 33 69 3.55E+07 3.31E+07 6.80E+07 
KCQLTTFAERWFDP 119 25 47 47 2.54E+07 4.03E+07 8.81E+07 
ARASIRSRPQFFDF 88 32 30 26 5.40E+07 8.55E+07 1.59E+08 
ARKGLGDF 83 35 23 25 1.78E+07 1.48E+07 4.45E+07 
ARDLAIPIDSLTYYLRAFDS 76 24 30 22 2.15E+07 3.24E+07 2.39E+07 






ARDPSRGDYFPYYSCYMDV 69 23 15 31 8.77E+07 1.09E+08 1.60E+08 
ARPSYTSGFALDP 68 17 22 29 1.31E+08 2.35E+08 3.54E+08 
ARDVAMGGFDA 64 24 14 26 5.13E+07 6.27E+07 1.36E+08 
ARAVALSGYYGSGTPYNWFDP 52 13 20 19 8.67E+07 1.71E+08 2.24E+08 
TRLRGYNILTGDLTAAEFDP 51 23 23 5 4.43E+06 6.45E+06 5.96E+05 
ARLNMVRGEFWGYYVDD 49 23 15 11 1.71E+07 2.48E+07 6.69E+07 
AGGRGWSYYMDV 45 20 20 5 1.01E+07 2.42E+07 1.69E+06 
ARGGGRKPFDP 43 12 12 19 1.13E+07 2.13E+07 1.51E+08 






ARAACSLCPLDY 39 14 10 15 1.98E+07 2.03E+07 2.43E+07 
ARDFFEKLGGEDHNAFDI 39 7 13 19 6.81E+06 1.35E+07 3.16E+07 
TLLRWGAVAGRDWFDP 34 10 8 16 1.55E+06 2.46E+06 8.48E+06 
TRQRQNQPGATDY 33 10 8 15 6.04E+06 6.18E+06 2.63E+07 
ARVCSSSCHYFYAMDV 33 12 12 9 7.80E+06 1.06E+07 4.68E+06 
ARDLGGGELLDS 31 7 14 10 2.48E+06 7.38E+06 6.44E+06 
AKEDRSGYPTRRPIEY 30 4 15 11 1.19E+06 3.99E+07 4.69E+07 
ARDYLGSGREFDP 30 1 19 10 4.78E+05 1.52E+07 2.69E+07 
ARGRFDIVVVPGAMPGPYMDV 29 2 13 14 1.04E+06 2.14E+07 5.44E+07 
TREFQSTFDP 28 7 7 14 1.89E+07 4.18E+07 8.19E+07 
STRGIVRRTNYDY 28 10 9 9 6.66E+06 7.60E+06 3.09E+07 
ARNRPGGDYYQYGMDV 28 7 11 10 5.60E+06 1.82E+07 1.73E+07 
ARDEKRVRGVGRMALDP 25 8 9 8 3.21E+06 4.16E+06 1.10E+07 
ARDFFEKLTNEDHNAFDV 24 8 9 7 3.61E+06 1.72E+07 2.54E+07 
VKDAVWFGDSLTHNYFDP 24 7 13 4 2.62E+06 1.96E+07 1.22E+07 
ARDFFEKLIGEDLNAFDI 23 8 7 8 3.12E+06 1.63E+07 1.30E+07 
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ARVSLRYCSGGSCANWFDP 23 8 8 7 8.40E+06 9.20E+06 1.01E+07 




AKGLVRFGESHENWFGP 22 2 3 17 6.40E+05 1.65E+06 2.18E+07 
ARVRSSLHIDGFDM 22 6 6 10 3.59E+06 4.08E+06 9.18E+06 


















AREPGDYLSVYRGYEGYSGFDV 20 6 12 2 5.23E+05 3.56E+06 1.33E+06 
ATNLEYYDRSGYYIRDAFGI 19 8 6 5 2.67E+06 4.12E+06 8.71E+06 
ARDGAGDGYLATNAFDI 19 7 9 3 5.43E+05 7.42E+05 7.94E+05 
ARDSGHSSGPRERAGFDY 19 7 6 6 2.19E+06 2.29E+06 4.16E+06 
ARGPEYVRGYYGMDV 19 7 8 4 3.82E+06 3.48E+06 4.09E+06 
AIEVKLSLRDMDTRSWFDP 18 9 7 2 7.00E+06 1.04E+07 4.51E+06 
VNSRDYYDNSGYRD 18 3 6 9 2.10E+06 2.13E+07 4.47E+07 
ARDGKFSGFDWNFDY 18 6 6 6 3.56E+06 7.41E+06 2.81E+07 
TSDAEGDVVVPASMRDDLDYYYYMDV 18 7 5 6 1.63E+06 2.88E+06 1.68E+07 
AKDWSYYYFKGIFDS 18 7 6 5 3.01E+06 3.11E+06 1.30E+07 
ARDNTAWSVDF 18 9 5 4 2.45E+06 3.71E+06 2.09E+06 
ITSLGTYYRARVDY 17 2 5 10 8.52E+06 1.16E+07 3.54E+07 
AREREWVQFLFDY 17 5 4 8 1.51E+06 2.29E+06 5.73E+06 
LGVGAIGISDI 16 8 6 2 4.53E+06 5.37E+06 1.45E+07 











ARGGDTAEIPNGMDV 15 5 6 4 3.95E+06 8.52E+06 1.30E+07 
ARLSGTNGWYPDY 15 7 4 4 1.61E+06 1.07E+06 4.95E+04 
ARVLGRPYSYGMDV 14 2 10 2 1.65E+06 1.11E+07 5.14E+06 






ARTERGYYYYHDGMDV 13 5 5 3 1.57E+06 1.81E+06 6.55E+06 
ARAEGYIDYHYGMDV 13 2 7 4 9.43E+06 9.65E+06 9.80E+06 





























ARDSVAAPRVFDS 10 2 1 7 5.83E+03 4.84E+06 3.86E+07 





STFDGVSGWH 10 1 4 5 1.26E+06 2.32E+06 7.80E+06 
ARPMVRGVFYMDV 10 4 4 2 1.70E+06 1.85E+06 2.83E+06 
ARPEGEWWLRPFDY 9 6 2 1 2.09E+06 1.53E+06 5.63E+06 











ARDFFERLSGEDHNAFDI 8 3 4 1 1.99E+06 1.36E+07 1.51E+07 









ARAIGAAGAF 8 3 1 4 1.19E+06 1.66E+07 1.89E+07 
















































TRARPGSYVDY 6 1 2 3 4.26E+06 5.32E+06 6.97E+06 
ARPIASSGYYGSGTPYNWLDP 6 2 3 1 1.26E+06 1.73E+06 3.24E+06 
































































































        
Anti-Vic B/BR08 serological repertoire clonotypic antibodies 
 130 



























ARINQWEDGYYSDPAKYFDY 426 4 263 159 1.09E+06 2.26E+09 1.22E+09 






VRASMGSYPDS 156 39 51 66 3.22E+08 4.16E+08 6.30E+08 
AKDNYGGNLSGWFDP 115 54 25 36 3.09E+08 8.56E+08 5.01E+08 







ARDLKYYGSLRMGWFDP 106 24 43 39 6.19E+07 9.42E+08 9.36E+08 
ARVGDDSGAYDKGYYYYPMDV 104 29 37 38 4.59E+07 2.24E+08 2.33E+08 
ARDNFGGNLSGWFDP 104 20 41 43 4.42E+07 2.20E+08 1.68E+08 






AKDLAKWLVTPYFDS 86 40 22 24 1.21E+08 2.27E+08 3.14E+08 
ARGLVTTGPTSQF 82 29 25 28 1.33E+08 2.42E+08 2.80E+08 
ARDERLYYYGLGSTQPRT 77 27 22 28 5.39E+07 1.17E+08 1.71E+08 
ARASSTSWDFDH 69 19 24 26 1.47E+08 4.10E+08 4.19E+08 
ARAAAEGLILTNWLDP 61 1 36 24 2.40E+03 1.58E+07 7.24E+06 
ARLKRVRGELWGYHFDY 60 26 19 15 5.43E+07 1.05E+08 1.73E+08 
ARDVAMGGFDA 57 50 1 6 1.29E+08 1.14E+05 7.14E+07 
ARMRFGECLDY 56 25 14 17 2.00E+07 2.25E+07 1.61E+07 
AQDRGGGNFWGWFDP 49 7 22 20 3.70E+06 2.98E+08 2.02E+08 
ARDMGYYGSVRMGWFGP 47 13 17 17 1.28E+07 3.11E+08 3.80E+08 
ARGVVTTGPTSYD 47 18 9 20 4.75E+07 3.59E+07 6.73E+07 
ARSPGGMNWFDP 46 20 12 14 6.86E+07 1.22E+08 1.79E+08 
TRQMQNQPGATDY 45 7 20 18 6.50E+06 4.32E+07 5.60E+07 
ARHGVWTLRYFDW 45 26 7 12 2.92E+07 1.55E+07 1.94E+07 
ARAEGGSYLLTRAFEI 43 28 8 7 2.75E+07 2.31E+07 2.43E+07 
KFLVTTMMEKWIDP 42 2 29 11 1.79E+06 7.18E+07 2.42E+06 
ARVSPGGIGTGYGDY 41 7 17 17 1.72E+07 1.33E+08 1.01E+08 
STFYGGRGGH 37 15 9 13 9.87E+06 1.68E+07 2.94E+07 
ARRGNYYRALDY 36 22 8 6 1.59E+07 4.22E+07 1.64E+07 
ARHSGYHFRVNWFDP 34 12 7 15 1.39E+07 3.16E+07 5.23E+07 
ARRGGYTFDYAY 29 6 13 10 1.69E+07 7.76E+07 3.89E+07 
ARGHVTGMAPHNGMDV 28 10 6 12 1.33E+07 3.30E+07 2.50E+07 
ARGLISTGPTSEY 28 8 6 14 9.86E+06 1.61E+07 2.56E+07 

















ARDSVTAPRVFDA 23 12 5 6 6.18E+06 6.59E+06 3.37E+06 
ARPFDSAQRGGFHV 22 5 6 11 4.00E+06 1.05E+07 1.82E+07 
VRVELDGDSPLVSRGYYYYPMDV 21 3 9 9 3.38E+06 2.56E+07 3.03E+07 
ARDGSGGSTGWGYDH 20 7 5 8 6.54E+06 4.18E+07 7.28E+07 
ARDLVGRTMVRGVPNDY 20 2 3 15 1.71E+06 9.84E+06 1.16E+07 
VKDHHRPYRYAKNGLDV 20 10 4 6 3.26E+06 1.88E+06 1.11E+06 
AKDLSEDNLRGFDFWSGYVF 19 7 6 6 1.60E+07 4.33E+07 6.29E+07 
ARQDGLVAAPIDY 19 2 2 15 1.23E+06 5.44E+06 4.94E+07 
ARAACTLGPLEY 19 8 2 9 7.91E+06 2.15E+07 2.61E+07 























AKEPLTYRVLDV 16 5 5 6 1.69E+06 4.43E+06 5.96E+06 















GRVPTGYYRNDY 14 8 3 3 4.41E+06 6.39E+06 9.33E+06 





ARDPFPTSISFGYFDP 14 6 2 6 3.96E+05 4.29E+06 8.21E+06 






ARRSYDY 13 6 1 6 7.24E+05 3.28E+06 4.25E+06 





TRKIGEY 12 4 4 4 3.99E+06 2.20E+07 1.43E+07 





ARHGAWELRSFDY 12 4 6 2 4.56E+06 1.65E+06 8.60E+03 




































ARDHLLDERSCDL 10 2 2 6 1.10E+06 6.02E+06 8.64E+06 















ARAMYSSSLGGLTTSHPDY 9 3 1 5 1.09E+06 6.77E+06 1.16E+07 






ARDFGLPTITPFDY 9 1 3 5 3.24E+03 5.60E+06 8.07E+06 


































































ARDDTSGELPRGLDF 7 4 1 2 5.02E+06 1.82E+07 6.08E+04 










































































































ARPWSRALDV 5 2 1 2 8.86E+05 2.36E+04 3.36E+06 
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Anti-Yama B/TX11 serological repertoire clonotypic antibodies 















KSLLTTFPEKGFDP 1635 161 714 760 4.26E+08 1.95E+10 2.74E+09 
ARIKTRGYEGSGSVVDAFDL 739 238 44 457 1.38E+08 4.14E+07 9.61E+07 
ATNLDYYDSSGYYVRDAFDV 465 3 253 209 1.95E+07 1.50E+09 1.40E+09 
ARDPSRGDYFPYYSYYMDV 163 32 99 32 9.41E+07 1.34E+09 4.40E+07 
VRASMGSYPDS 154 66 68 20 6.36E+08 5.91E+08 8.74E+07 
ARDLKYYGSLRMGWFDP 135 25 58 52 6.49E+07 1.28E+09 2.94E+08 
AKDNYGGNLSGWFDP 119 38 32 49 3.63E+08 7.24E+07 3.21E+08 
ARDNFGGNLSGWFDP 110 37 38 35 5.56E+07 6.65E+07 9.52E+07 






ARVGDDSSAYDKGYYYYPMDV 71 29 30 12 1.17E+08 1.58E+08 3.10E+07 
AQDRGGGNFWGWFDP 59 22 18 19 9.89E+07 2.19E+08 3.10E+07 
AKDLAKWLVTPYFDS 59 24 20 15 2.62E+08 2.03E+08 3.07E+07 
ARASSTSWDFDH 59 27 17 15 4.74E+08 4.48E+08 4.42E+07 
ARLYRVRGELWGFNFDY 53 23 9 21 1.60E+08 7.43E+07 3.89E+07 
LGVGAIGISDI 52 1 2 49 6.05E+06 1.94E+07 3.27E+06 
AKGLVIFGESHEDWFDP 50 1 38 11 2.43E+07 4.12E+06 4.64E+07 
ARDLAIPVDSLTYYLRAFDS 46 12 19 15 1.04E+07 7.93E+07 5.99E+06 
TRAWFQFFDS 45 13 18 14 2.64E+07 7.04E+07 1.93E+07 
ARSPGGMNWFDP 42 17 13 12 1.39E+08 1.79E+08 2.05E+07 












ARPFDSAQRGGFYV 34 18 11 5 3.24E+07 2.12E+07 7.37E+05 
TRQMQNQPGATDY 34 12 7 15 2.35E+07 7.20E+06 1.09E+07 
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VRVELDGDSPLVSRGYYYYPMDV 28 10 10 8 4.46E+07 6.02E+07 9.34E+06 




ARVSPGGIGTGFGDY 27 4 12 11 1.16E+07 1.16E+08 1.58E+07 
ARGHVTGMAPHNGMDV 26 13 4 9 1.52E+07 6.36E+06 7.72E+06 
ARDGSGGSTGWGYDH 25 10 9 6 1.54E+07 3.10E+07 1.06E+07 
ARAACTLGPLEY 25 9 7 9 5.18E+07 5.87E+07 1.50E+07 
AREWAAADLFHAFDI 23 2 11 10 9.12E+04 1.14E+07 5.98E+06 




ARDERLYYYELGSTQPRT 21 12 6 3 3.87E+07 2.30E+07 7.75E+06 
AREYRILDERSNYVDA 21 4 9 8 2.88E+06 4.31E+07 7.67E+06 
ARDSVAAPRVFDS 20 4 9 7 3.44E+06 7.04E+07 8.10E+06 
ASPGRDYGDRGGFYFYGMDV 19 2 8 9 4.01E+06 1.28E+07 5.54E+06 






















TLLRWGAVAGRDWFDP 15 5 3 7 1.90E+07 5.20E+06 4.94E+06 



















ARDNGIAVPRSPQGLFDY 14 1 12 1 
 
4.40E+05 1.67E+03 
ARSQKYYGSGTHNWFDP 14 6 4 4 4.16E+04 9.12E+05 1.93E+05 











ARLTGYSGYHERIGDYYYYYMDV 12 5 1 6 1.71E+07 1.20E+07 2.03E+07 

















ARDERMYYYGLGSTQPRN 11 3 2 6 1.74E+06 1.97E+05 2.80E+06 
ARGFGLGEIFYYMDV 11 7 2 2 5.74E+06 1.70E+07 1.66E+05 
ARSYSIGNSFDI 11 4 1 6 3.84E+07 2.34E+07 3.33E+07 



















ARGVASGWFDYFDY 10 2 1 7 7.19E+04 2.55E+05 1.22E+06 









ARGLVTTGPTSQY 10 2 2 6 9.32E+07 1.26E+08 2.59E+07 
 135 
























AKDRLRYFDWALNY 9 1 3 5 3.93E+06 8.44E+05 3.82E+06 
































ARDDTSGELPRGLDY 7 1 2 4 5.48E+04 9.07E+07 1.07E+07 
























































ARTYSSSSPFDY 5 3 1 1 5.45E+05 
 
8.24E+05 
























































Anti-H1 A/CA09 serological repertoire clonotypic antibodies 















ARRFVELLGGRSKPYDALDV 208 63 75 70 8.39E+08 1.18E+09 4.02E+08 
 136 
ARDKGYSVSNNCLDP 198 15 116 67 1.56E+07 8.29E+08 2.13E+08 























































ARELGELLGYRLFDA 31 11 9 11 1.56E+07 4.85E+07 3.79E+07 
VRDSGEGLDP 30 11 13 6 2.44E+06 5.51E+06 1.72E+06 












AGQGEGRLVDELSNWFDP 24 6 14 4 1.52E+06 1.37E+07 1.38E+06 
ARHVREVLVATPLDSFDT 24 7 11 6 2.05E+06 1.03E+07 1.81E+06 
ARAEYYYGRYYYMGV 23 5 11 7 2.16E+06 5.19E+06 4.55E+06 
VRLFNTGVGGRGYFDP 21 2 8 11 6.29E+05 3.93E+06 5.47E+07 
ATAGLTKYCVGDGHV 20 6 6 8 2.81E+06 5.87E+06 3.68E+06 
AKFEGELRAFEV 18 6 7 5 1.33E+07 5.94E+07 3.44E+07 
ARSYTSGWSGPFFDP 17 6 4 7 1.57E+06 9.93E+05 2.05E+06 
AKKLSSKVPYSGYLDS 15 1 8 6 2.78E+05 4.13E+06 3.89E+06 




















ARRGVYMGDAFDL 13 5 3 5 4.49E+06 2.40E+06 4.78E+06 
























































































































































































































        
Anti-H3 A/VI09 serological repertoire clonotypic antibodies 


























AREALLWFEELTPNYMDV 127 42 39 46 4.46E+06 2.41E+06 7.19E+06 
AKHFPEWLLRANDY 125 3 7 115 6.97E+05 1.42E+06 2.00E+08 
ARAQRKYDDGAYRAEYPFYYSTDV 107 38 41 28 6.27E+07 5.84E+07 2.33E+07 
AATRRPLRGDLVTNAFDL 78 33 27 18 1.05E+07 1.46E+07 6.89E+06 
 138 







































AGQGEGRLVDELSNWFDP 28 5 11 12 3.43E+06 5.46E+06 1.18E+07 
















































VREYYDVMTGDSEPGP 18 6 5 7 6.40E+06 4.34E+06 4.22E+06 
LSGTLKGFDY 18 6 6 6 2.56E+06 1.13E+06 1.91E+06 











AARRRGGTLVRADYYLDG 18 5 7 6 4.41E+07 4.09E+07 3.64E+07 

















ARVSGNYLERNYYYYYMDV 16 6 6 4 1.28E+06 2.34E+06 2.17E+06 










ARAEYYYGRDYDMGV 15 2 8 5 1.36E+06 4.29E+06 2.56E+06 
SQQLGGRRDDVWSCDSRYFDA 15 3 3 9 9.37E+05 8.93E+05 5.08E+06 






ATDRRLGVEAYYFYYMAV 14 7 6 1 8.22E+05 5.57E+05 6.22E+05 
ARFYRSDYMDV 13 4 4 5 1.39E+07 8.31E+06 1.45E+07 
 139 






















































ARESAGWKNYLDN 10 4 2 4 2.19E+07 8.21E+06 1.11E+07 











ARDKGYRVSKNCLDP 9 4 2 3 2.42E+06 7.65E+05 1.63E+06 































































































































































































































































        
Anti-Vic B/BR08 serological repertoire clonotypic antibodies 































ATFKGDYGDSSTNY 163 15 85 63 8.42E+05 8.69E+07 1.11E+08 

















ARMGQTE 42 13 14 15 6.02E+05 5.02E+06 6.30E+06 
















AREPGDWAPAGQDWFDP 24 6 10 8 3.62E+05 5.59E+06 3.09E+06 
ARELGELLGYRLFDA 23 6 9 8 3.04E+05 6.78E+06 1.27E+07 
 141 





















AKFEGELRAFEV 19 6 5 8 6.16E+05 6.31E+06 1.27E+07 













































































































































































        
Anti-Yama B/TX11 serological repertoire clonotypic antibodies 















AREDLEMGTGTAGAPFDY 973 196 439 338 1.55E+08 5.51E+08 5.43E+08 
ARDGEPNTSMDYFYHYYLDV 344 60 114 170 1.63E+07 2.65E+08 2.45E+08 
ARWEYNDRSGYFQLYDY 156 54 52 50 2.48E+07 9.54E+07 1.25E+08 
AREWGEDNYAPPFDY 149 42 57 50 1.26E+07 6.83E+07 4.84E+07 
ARAFPGTSGGWYYFDY 135 50 43 42 5.72E+07 1.11E+08 1.01E+08 
ARSYTSGGSGPLFDP 130 76 25 29 4.43E+06 6.08E+06 1.49E+07 
ALGGLGELPSGFGY 121 51 34 36 2.37E+07 5.07E+07 9.52E+07 
ARGGGDGYTFGFAPCFDA 119 55 18 46 2.40E+07 2.93E+07 1.48E+08 
ARNWARLDD 115 34 49 32 3.45E+06 1.25E+07 1.26E+07 
ARQDGELEGYNWFDP 97 7 44 46 2.34E+06 4.39E+07 4.31E+07 
ARAYRSFSSVHFDF 97 27 37 33 3.70E+07 2.57E+08 2.70E+08 
ARGNVDAVMDYYSFYSLDV 95 23 20 52 4.33E+06 1.10E+07 3.31E+07 
AAFKGDYGDASTNF 91 34 27 30 1.34E+08 1.88E+08 2.49E+08 
AVPGSFREVLYYYHYMDA 88 19 28 41 3.82E+06 8.03E+06 2.30E+07 
AREFPDFSEFYFDS 84 38 27 19 6.34E+07 1.91E+08 1.30E+08 
ARKYWGTEPSSFYMDA 76 27 24 25 8.31E+06 3.18E+07 3.27E+07 
ARDQTVAGPRTVDY 73 12 31 30 3.18E+06 6.10E+07 8.97E+07 
ARRSHDTLD 70 21 23 26 2.72E+06 7.67E+06 1.15E+07 
ARYRASGYVPCDF 65 30 10 25 2.95E+06 1.59E+06 7.32E+06 
ARSTWGELLLRSGGYFDL 64 20 25 19 7.26E+06 2.01E+07 2.05E+07 
ARGNLDSLMDYYYYDYMDV 63 18 23 22 2.68E+06 1.15E+07 9.64E+06 
ARGTRERFFDC 58 18 18 22 7.46E+06 3.21E+07 7.23E+07 
ARHLGSSGFRGMDG 55 16 18 21 2.22E+07 2.12E+07 2.00E+07 
TAQWELRFPKRVMDY 54 23 14 17 9.39E+07 1.92E+08 1.48E+08 
ARRGVYMGDAFDL 53 11 25 17 2.92E+06 8.65E+06 1.53E+07 
ARDRLGEYQMMYQWAY 52 12 20 20 1.98E+06 2.12E+07 2.24E+07 
SRHHGDYSSTPPPLDY 48 11 18 19 1.22E+06 3.13E+07 2.94E+07 
AGRGNVADDQGSDHHMDV 47 7 14 26 1.07E+06 1.36E+08 2.19E+08 
AREEMYYLDSSGSFDY 45 16 14 15 7.65E+06 2.21E+07 1.64E+07 
ARFYRSDYMDV 43 1 9 33 3.13E+07 6.37E+06 5.51E+07 
ARELPENWFDN 43 13 15 15 3.79E+06 6.24E+06 5.96E+06 
ARDKGYSSSNNWRDP 40 6 14 20 6.32E+05 1.10E+08 2.20E+08 






ATDSRWRFASLGPNYSYYMDV 39 14 14 11 8.22E+06 1.27E+07 2.45E+07 
ARDCGESSDEPPFLY 38 4 16 18 1.45E+06 1.19E+07 4.02E+07 
AHRRTPGPDGTFDY 36 12 12 12 5.05E+06 1.25E+07 2.02E+07 






ARDVWGGTLAFDV 33 9 15 9 7.03E+06 1.33E+07 1.56E+07 
ARDWTKLVEVPPLGPFDP 32 4 16 12 2.60E+05 1.07E+07 1.09E+07 
 143 
ARHHEEVGLPEGGFAY 32 4 18 10 3.08E+06 1.18E+08 7.11E+07 
ARDLGKGLAVLPASMKARGTGDFDF 31 5 9 17 7.49E+05 1.70E+07 1.47E+07 
ARAPGQWLTGRESYFDY 30 18 6 6 3.20E+07 8.23E+07 1.18E+08 
AKDPEGAYYYDSGLDY 30 7 15 8 2.14E+06 7.88E+06 6.29E+06 






VSGDYFGH 28 14 6 8 2.84E+07 4.78E+06 1.45E+07 
ARCSWFGDSERLLDCDLYYYDRDV 27 5 8 14 1.06E+06 7.68E+06 3.54E+06 
ARDWGEYLYEPPFDS 27 2 18 7 7.54E+05 2.97E+07 3.82E+06 






ARDSVTTLTHDAFDV 25 9 12 4 7.94E+05 5.05E+06 3.48E+06 
ARDRGTTGGAFDL 25 3 11 11 2.28E+05 6.84E+06 5.10E+06 
ARDNSQSPRFFQH 25 10 8 7 2.31E+05 1.27E+06 8.96E+05 
AKEGGSSGTDRYHLDD 23 6 4 13 1.64E+07 3.49E+07 2.93E+07 
ARGRSFYYDSSGFSWWFDP 23 11 6 6 1.26E+06 1.95E+06 2.74E+06 
ARRRDYYDSSGSDTAVHL 22 2 13 7 5.99E+02 7.72E+06 1.38E+06 






TRDRLFYDFWNAQFAL 21 11 8 2 7.44E+05 9.12E+04 1.40E+03 
GRRDYDLLTACEGAFDV 20 6 4 10 1.21E+06 9.46E+06 9.87E+06 
AKDKGMQVWLQCYFEH 20 10 2 8 1.73E+05 3.62E+05 8.28E+05 
AKDRARNVLCSLYSCPTDAFDM 20 1 11 8 2.25E+05 1.21E+07 1.60E+07 
AKFEWELRAFDV 20 7 6 7 5.08E+04 5.29E+06 4.56E+06 



























ARDLLLRRGSSYLHYYMDV 18 1 11 6 1.01E+05 2.85E+06 1.71E+06 











ARAAGVLECLSYYSDS 17 7 2 8 1.74E+05 6.84E+05 2.80E+06 

















ARDPRGYGEGYDWFDP 15 1 7 7 2.46E+05 7.21E+06 8.86E+06 













EREDGATVDGPSHYFDY 14 6 5 3 3.04E+05 1.42E+06 6.26E+05 
VKAARFCSGSGSYFDY 14 7 2 5 1.90E+06 9.33E+05 7.84E+05 
AGGFSYAVPYYYMDV 14 6 2 6 4.78E+06 1.67E+07 8.05E+06 











AKRGNYTGGALDY 14 1 6 7 3.35E+03 1.98E+06 5.45E+06 



























ATAPLGTRNTVVVPAARSGYYMYV 11 2 8 1 2.38E+05 7.58E+05 2.72E+05 
VHRPSGMNSATVLGRFDG 11 1 1 9 1.86E+05 1.20E+06 3.91E+06 
ASFAVTSDRPTYLDYMDG 11 5 4 2 5.84E+06 1.29E+07 4.16E+06 
















VRRRLDMDGAFDL 11 6 4 1 5.45E+05 6.96E+06 1.10E+06 
ASKGTYALGWRY 11 5 3 3 4.19E+06 4.16E+05 5.95E+06 
LSGTLKGFDY 11 6 1 4 2.37E+06 4.56E+06 1.72E+07 
ARDMWSGYSGYNVFY 10 2 6 2 5.32E+06 3.64E+06 1.23E+07 



























ARERGDFWSGYTALGV 9 2 5 2 2.91E+05 4.32E+06 4.75E+06 



















































































































































Anti-H1 A/CA09 serological repertoire clonotypic antibodies 






























AHARLANRGYDFFDY 288 87 99 102 1.48E+08 4.14E+08 5.88E+08 






















ARVRQSYYIDY 68 23 20 25 9.86E+06 4.78E+07 3.98E+07 























































ARLKDYVWGS 28 9 10 9 8.69E+06 2.06E+07 1.16E+07 











TTVVVGGTSYRHY 26 4 2 20 1.52E+06 2.68E+06 1.52E+06 











































AKEKGGVDY 19 17 1 1 3.76E+07 2.91E+07 1.03E+07 
















































































































































ARSGGYNHGRGFDL 9 1 1 7 7.74E+05 2.52E+06 2.07E+06 
























































































































































































































































        
Anti-H3 A/VI09 serological repertoire clonotypic antibodies 
























































AKEKGGVDY 31 20 2 9 1.57E+06 2.38E+06 6.84E+06 




























































































































































































































































        
Anti-Vic B/BR08 serological repertoire clonotypic antibodies 















AKSLQQLADPEFDY 1626 65 784 777 9.53E+07 1.72E+09 1.65E+09 
AKLIVLRFSEWSYDL 881 8 349 524 3.97E+07 6.66E+08 1.89E+09 
ARGYASYNFDY 697 72 225 400 8.48E+07 4.91E+08 7.00E+08 
AGDPSRGYGQEPPHAPFDF 364 1 202 161 4.24E+04 6.04E+08 7.67E+08 
VKEVGDDHGYYIGAFDI 313 3 118 192 1.92E+06 9.31E+07 6.76E+07 
ARGLMGHYYDSSGSYD 249 32 106 111 8.84E+07 7.80E+08 1.09E+09 
VRQFSEYLSPPWNTPMACFDY 113 7 41 65 5.85E+06 1.81E+07 3.46E+07 
 150 
ARVTFPYGDNPNTWFDP 90 21 30 39 1.07E+07 8.14E+08 1.17E+09 
AKDSGSNIYYDFLGYYMNL 76 1 54 21 2.10E+04 2.28E+07 1.03E+07 






ARDLGAGHYTEGVPDY 69 6 38 25 1.07E+07 1.99E+08 5.01E+07 






ARSPSDLWNGYRLYFDY 56 9 27 20 8.03E+06 3.67E+07 2.85E+07 
ARDRTPDCYDCTPTFDY 54 7 18 29 2.02E+07 9.92E+07 1.14E+08 
ARSFASYGDVDS 50 6 10 34 1.19E+06 4.57E+06 1.74E+06 
AGRRAGTVD 44 4 23 17 1.10E+07 5.31E+07 3.16E+07 



























ARDWGSGSYNLDH 36 11 12 13 1.44E+07 4.28E+07 4.97E+07 
ARDKDGYTPGDY 35 8 16 11 4.99E+07 2.36E+08 2.23E+08 






ARGLNYYDYSDQGVRCDY 32 6 14 12 4.97E+06 9.65E+07 2.60E+07 
ARSTKDHLVRGIGSFDP 32 6 14 12 6.12E+06 2.04E+07 1.64E+07 
ARDFESYFMDV 31 7 10 14 1.06E+07 1.58E+07 1.86E+07 
AKGRSTVVTTAGNWFDP 30 9 12 9 7.43E+06 1.22E+07 2.31E+07 






VPLLARPLVEERMRD 28 1 6 21 1.90E+06 5.86E+07 1.61E+08 
ARGERRSSDFDF 28 11 11 6 3.41E+07 2.84E+07 2.53E+07 






ARGGVATTPPGMDV 26 8 2 16 4.25E+06 1.14E+07 1.46E+07 
VKDRLEWTLRGAFET 25 11 4 10 6.22E+07 2.78E+07 1.68E+08 
ARTDLSHSNYFDP 23 12 5 6 1.33E+07 3.11E+07 3.79E+07 






AGQRLSRVARCDS 22 2 12 8 1.19E+07 3.68E+07 2.34E+07 
ARVWPAANPGDY 21 8 6 7 8.53E+06 2.02E+07 3.72E+07 












ASLSAVQGGRGHNWLDP 18 6 6 6 1.18E+07 3.44E+07 4.37E+07 





























ARDFYGGNSLSLDS 17 8 8 1 2.72E+06 3.05E+06 2.09E+06 






















ARRTGDY 15 2 8 5 4.75E+06 8.18E+06 3.74E+06 
ATHSGDHYRSMYMDV 14 3 8 3 7.87E+06 3.38E+07 7.94E+06 

























ANDRGVVIGPRNDPFET 12 1 7 4 8.67E+05 4.05E+07 3.57E+07 



































ARGTKWALGRGVGWFDP 11 3 6 2 1.38E+06 1.68E+07 1.22E+07 









































































































ARDRHYYVSVFDH 7 1 2 4 
 
6.25E+07 2.26E+07 






ATKGQSSRWKSFDV 7 1 3 3 2.41E+06 8.89E+06 3.84E+06 











































ARGTYSTMWGSYRAFDF 6 1 4 1 5.36E+07 1.58E+07 9.34E+03 



















































































































































































































































        
Anti-Yama B/TX11 serological repertoire clonotypic antibodies 




















AKLMVLRVSEWSHDY 751 17 471 263 1.24E+08 5.00E+08 8.22E+08 
ARVFLSYSFDD 519 73 229 217 6.92E+07 3.93E+08 4.11E+08 
ARGLMGHYYDSSGSYD 267 47 116 104 1.75E+08 6.23E+08 7.81E+08 
ARDRTPDCYDCTPTFDY 106 21 45 40 8.17E+07 2.93E+08 3.55E+08 
ARVTFPYGDTPNNWFDP 95 14 40 41 2.82E+07 6.32E+08 6.93E+08 
ARAAWAYEADSGYSLGPLDH 93 10 48 35 7.54E+04 1.78E+08 8.29E+07 
ARDVAARPGALQH 73 30 10 33 4.90E+07 5.65E+06 6.70E+07 

















ARARRGFYERGGGFFDPFDF 50 10 21 19 1.70E+06 1.28E+07 8.97E+06 
TRDPFYYDTSGNPGGY 47 23 14 10 1.16E+08 9.73E+07 6.32E+07 
ARSPSDLWNGYRLYFDY 46 5 29 12 1.02E+07 3.41E+07 2.64E+07 






ARGLNYYDYSDQGVRCDY 41 5 14 22 9.20E+06 8.84E+07 1.98E+07 
ARGGGDTYDYRVYFDY 39 12 14 13 2.23E+07 2.23E+07 2.55E+07 
ARDKDGYTPGDY 36 8 17 11 7.13E+07 2.03E+08 1.19E+08 
VRAIVEMYSRAGTGDY 35 11 10 14 2.41E+07 4.35E+07 2.80E+07 
ARGRPTAVAGQMDV 35 18 12 5 1.55E+07 1.23E+07 1.61E+07 
ARSTKDHLVRGIGSFDP 35 13 15 7 6.12E+06 1.43E+07 8.12E+06 
ARDWGSGSYNLDH 34 13 10 11 4.24E+07 3.13E+07 2.18E+07 
ARGGVATTPPGMDV 34 10 11 13 1.82E+07 1.09E+07 2.08E+07 






ARVWPAANPGDY 31 8 17 6 1.94E+07 3.33E+07 2.27E+07 
ARSLQQLADPEFEY 30 8 15 7 1.48E+07 1.19E+08 5.09E+07 

















ARDLNHYHSSGFFYKGAHYFDD 25 12 6 7 8.19E+07 1.06E+08 1.14E+08 
AGQRLSRVARCDS 24 6 8 10 7.46E+06 2.42E+07 2.13E+07 
ARDDYYHSSGYHVH 24 13 2 9 1.58E+07 1.96E+06 1.94E+07 
ARAWGGSPAAKDNWFDP 24 10 7 7 8.22E+06 4.71E+06 5.34E+06 
VKDRLEWTLRGAFDT 23 4 7 12 2.59E+07 3.15E+07 1.31E+08 






ARGPGYNVGWSPVRWIY 23 2 9 12 9.45E+04 1.17E+07 1.07E+07 
VPLLARPLGEERMRD 21 1 10 10 4.91E+06 9.95E+07 6.61E+07 
















AGSLRGNWFGP 19 8 2 9 9.20E+06 5.82E+06 1.07E+07 
ARARGYTYVQERGGFDP 19 6 6 7 6.83E+06 4.75E+06 7.88E+06 
































AKDLSRPSLRYFDS 16 9 5 2 3.44E+07 2.75E+07 1.08E+07 
ARVNLGTTRGLEY 16 6 5 5 9.35E+06 7.28E+06 2.77E+06 

































































VKDHTNWNYGY 12 3 2 7 2.49E+06 2.76E+06 7.19E+06 





















AFSSSSSRRPFDS 10 1 4 5 3.54E+07 2.38E+07 1.49E+07 








































































































































ATHSGDHYRSMYMDV 6 2 3 1 1.10E+07 2.21E+07 9.17E+06 












































ARDLMADHYRYESSADHGMDG 5 3 1 1 4.15E+06 1.05E+07 3.89E+07 























































































































Anti-H1 A/CA09 serological repertoire clonotypic antibodies 

























ARDDYVDTDLKNWYPDI 96 25 33 38 2.56E+07 2.36E+08 1.38E+08 
AALIGVGVTSIRNRWRDWFDP 69 10 24 35 3.13E+06 9.47E+07 4.98E+07 

















ARRGGSSGDFLD 40 13 15 12 5.55E+06 2.29E+07 6.49E+06 
























AKDRITFTLRGAFDV 31 6 18 7 6.93E+05 2.26E+07 3.22E+06 
ARRMGATDLGYYFDY 29 1 20 8 2.92E+05 4.81E+07 8.31E+06 

































ARGTTGSYGID 18 2 7 9 6.86E+05 4.29E+06 1.90E+06 
ARNMDY 18 4 8 6 6.43E+05 2.56E+06 2.40E+06 



























































































ARGDSSGWDVDY 11 6 4 1 4.31E+05 3.23E+06 1.01E+06 



























































































































































































































































        
Anti-H3 A/VI09 serological repertoire clonotypic antibodies 















ARDGRQGVVMVDARRGLDS 152 32 54 66 
   
AGDWQEKLVSDLVNAFDF 142 16 22 104 
 
3.82E+08 1.54E+07 





32 43 4.81E+05 2.21E+08 2.19E+07 
SRDRGDYRYSPGSH 75 18 17 40 7.93E+06 3.01E+07 5.47E+07 
ARAHYEYGSSGYRGESPPGASFDY 52 3 6 43 
   
ARLTMSPPWLLDS 48 
 
17 31 1.55E+05 6.41E+07 5.62E+06 
ARQTNSGDQVDY 47 8 11 28 
   
AALIGVGVTSIRNRWRDWFDP 45 
 






ARIQTGGFDY 45 12 15 18 




   




















   




9 20 6.93E+05 2.26E+07 3.22E+06 














   


























   
ARDGDGIDY 21 8 11 2 
   































































AKDLDGNVPRGVDS 9 2 7 
 




































   
ARPYASDDY 7 
 




























































































    
ARGIGGSSWVDY 5 
 












































































        
Anti-Vic B/BR08 serological repertoire clonotypic antibodies 















ASFATSGSYYDIFSK 1195 15 414 766 6.01E+05 1.90E+09 5.05E+09 















































































































































































ARDDFALTPRVLDV 23 12 8 3 2.61E+06 5.19E+06 2.07E+07 










































































































































































































































































































































































































































































Anti-CA09pdm serological repertoire clonotypic antibodies. Values indicate the fraction (%) of the 
serological repertoire based on XIC. 
 































ARGQGYCLSASCPNYFDP 19.28 23.13 29.02 0.90 17.62 8.90 10.80 16.60 14.17 45.80 
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ARNNYFDSGYGMDV 
 
0.65 0.54 17.16 3.25 12.85 1.70 1.01 3.79 4.86 
ARTLLDQGEAFHL 0.44 1.32 0.82 2.66 1.44 11.43 0.61 2.54 4.20 
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